<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:91.2pt;left:60.7pt;line-height:13.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:13.0pt;color:#ffffff">REVIEW</span></p>
<p style="top:91.2pt;left:461.4pt;line-height:13.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:13.0pt;color:#ffffff">Open Access</span></p>
<img style="position:absolute;transform:matrix(.3209263,0,-0,.32492293,613.9001,118.568149)" src="data:image/jpeg;base64,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==">
<p style="top:120.9pt;left:56.7pt;line-height:23.4pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:23.4pt;color:#131313">The use of mesenchymal stem cells for</span></p>
<p style="top:146.9pt;left:56.7pt;line-height:23.4pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:23.4pt;color:#131313">cartilage repair and regeneration:</span></p>
<p style="top:172.8pt;left:56.7pt;line-height:23.4pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:23.4pt;color:#131313">a systematic review</span></p>
<p style="top:207.0pt;left:56.7pt;line-height:10.7pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">Andy Goldberg</span><sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">1</span></sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">, Katrina Mitchell</span><sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">1</span></sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">, Julian Soans</span><sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">1</span></sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">, Louise Kim</span><sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">2</span></sup><sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313"> </span></sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">and Razi Zaidi</span><sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">1*</span></sup></p>
<p style="top:245.9pt;left:63.2pt;line-height:10.3pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Abstract</span></p>
<p style="top:264.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Background:</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> The management of articular cartilage defects presents many clinical challenges due to its avascular,</span></p>
<p style="top:276.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">aneural and alymphatic nature. Bone marrow stimulation techniques, such as microfracture, are the most frequently</span></p>
<p style="top:288.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">used method in clinical practice however the resulting mixed fibrocartilage tissue which is inferior to native hyaline</span></p>
<p style="top:300.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">cartilage. Other methods have shown promise but are far from perfect. There is an unmet need and growing</span></p>
<p style="top:312.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">interest in regenerative medicine and tissue engineering to improve the outcome for patients requiring cartilage</span></p>
<p style="top:324.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">repair. Many published reviews on cartilage repair only list human clinical trials, underestimating the wealth of basic</span></p>
<p style="top:336.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">sciences and animal studies that are precursors to future research. We therefore set out to perform a systematic</span></p>
<p style="top:348.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">review of the literature to assess the translation of stem cell therapy to explore what research had been carried out</span></p>
<p style="top:360.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">at each of the stages of translation from bench-top (in vitro), animal (pre-clinical) and human studies (clinical) and</span></p>
<p style="top:372.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">assemble an evidence-based cascade for the responsible introduction of stem cell therapy for cartilage defects.</span></p>
<p style="top:387.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Main body of abstract:</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> This review was conducted in accordance to PRISMA guidelines using CINHAL, MEDLINE,</span></p>
<p style="top:399.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">EMBASE, Scopus and Web of Knowledge databases from 1st January 1900 to 30th June 2015. In total, there were</span></p>
<p style="top:411.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">2880 studies identified of which 252 studies were included for analysis (100 articles for in vitro studies, 111 studies</span></p>
<p style="top:423.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">for animal studies; and 31 studies for human studies). There was a huge variance in cell source in pre-clinical</span></p>
<p style="top:435.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">studies both of terms of animal used, location of harvest (fat, marrow, blood or synovium) and allogeneicity. The</span></p>
<p style="top:447.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">use of scaffolds, growth factors, number of cell passages and number of cells used was hugely heterogeneous.</span></p>
<p style="top:462.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Short conclusions:</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> This review offers a comprehensive assessment of the evidence behind the translation of</span></p>
<p style="top:474.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">basic science to the clinical practice of cartilage repair. It has revealed a lack of connectivity between the in vitro,</span></p>
<p style="top:486.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">pre-clinical and human data and a patchwork quilt of synergistic evidence. Drivers for progress in this space are</span></p>
<p style="top:498.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">largely driven by patient demand, surgeon inquisition and a regulatory framework that is learning at the same pace</span></p>
<p style="top:510.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">as new developments take place.</span></p>
<p style="top:527.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Keywords:</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> Matrix-induced autologous chondrocyte implantation, Autologous chondrocyte implantation,</span></p>
<p style="top:539.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">Mesenchymal stem cells</span></p>
<p style="top:569.3pt;left:56.7pt;line-height:10.3pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Background</span></p>
<p style="top:581.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Articular cartilage is a highly specialised tissue acting as</span></p>
<p style="top:593.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">a shock absorber, enabling synovial joints to articulate</span></p>
<p style="top:605.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with low frictional forces. Due to its avascular, aneural</span></p>
<p style="top:617.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and alymphatic state, it has a limited repair potential [1].</span></p>
<p style="top:629.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Surgical options to manage damaged articular cartilage</span></p>
<p style="top:641.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">include arthroscopic debridement [2</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">5], bone marrow</span></p>
<p style="top:569.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stimulation techniques [6</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">8], chondrocyte implantation</span></p>
<p style="top:581.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[9</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">13], osteochondral autografts (mosaicplasty) [2, 14, 15],</span></p>
<p style="top:593.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">osteochondral allograft [16</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">18] and, in the presence of</span></p>
<p style="top:605.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">osteoarthritis, joint replacement [19].</span></p>
<p style="top:617.7pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Bone marrow stimulation techniques, such as micro-</span></p>
<p style="top:629.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">fracture, are the most frequently used method in clinical</span></p>
<p style="top:641.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">practice for treating small symptomatic lesions of the</span></p>
<p style="top:653.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">articular cartilage [6</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">8]. However, the resulting tissue</span></p>
<p style="top:665.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">has shown to be a mixed fibrocartilage tissue [20</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">22]</span></p>
<p style="top:677.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with varying amounts of type II collagen [8, 21, 23, 24]</span></p>
<p style="top:689.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and inferior to native hyaline cartilage. Fibrocartilage is</span></p>
<p style="top:665.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">* Correspondence:</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> razizaidi@doctors.net.uk</span></p>
<p style="top:672.7pt;left:56.7pt;line-height:5.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:5.3pt">1</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">Institute of Orthopaedics and Musculoskeletal Science, Royal National</span></p>
<p style="top:683.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">Orthopaedic Hospital (RNOH), Brockley Hill Stanmore, London HA7 4LP, UK</span></p>
<p style="top:692.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">Full list of author information is available at the end of the article</span></p>
<img style="position:absolute;transform:matrix(.3199981,0,-0,.3200001,264.07008,1.9094162)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAArAAAAB+CAIAAABTW7UMAAAACXBIWXMAAA7EAAAO
xAGVKw4bAABJE0lEQVR4nO19iVsUx/b29//cRAFFBVdQWQQR96sh7goq7iIhuBEX
4r5E4xaJoBEVuYiKEve4RFxQhBAIijvxukWNRnPV+5vvZTq3OFPd0109MwxgzvvU
k8cw3dW1nvOeqlOn/p+DwWAwGAzG3x7/r6kLwGAwGAwGo+nBhIDBYDAYDAYTAgaD
wWAwGEwIGAwGg8FgOJgQMBgMBoPBcDAhYDAYDAaD4WBCwGAwGAwGw8GEgMFgMBgM
hoMJAYPBYDAYDAcTAgaDwWAwGA4mBAzGh4r7d+/k5mRrac93O169fNnUJTLD//33
v5dLSjavXzcnNSV53JipE5IWzpuzI2tr6YWSZl5yP+DH0z+Irjx55PumLg6jsXCt
tFR09KHCfZgUfi4AEwIG48NE8cH9bQNbaykkuM3NG9ebukRu8ejfDxbPnxsZ3i2o
1UcBH/9DJJQ8qnvYpMSx9+7caeoyNiWmJY8XXTkyYUhTF4fRWFiyIEN0dHyvqPfv
3/u5AEwIGIwPE0X7CoRmbRPQqvZ6TVOXyBjHig+HdQqlPEBKwYGtHz965P2HIF7B
PGqqqmCHnT9zuqKsDG3y7OlT73NubCSPGy1aI2HQgKYuDqOxsGBuuujo6B7hekLw
6uVLkIZhQwalzZh2/67vWTITAoYFig/sTx43BlYaUur0qa//+KOpS8RQwqHCfdTU
bp6E4MK5c9D3JmwAaXLSOG8+UV3506Z1axNHDovqHtaxfbBYhAh08qQuoR1giqVM
mVSQt7vZkgNMPdEanw4e2NTFYTQWFs2bIzo6JqKHnhDMnJwsHujXO+Y/f/7p2wIw
IWBYYNnihQ16JaDV82fPmrpEDCU0f0Lw5vXrXj27U93fNyZ6/aqV4KCF+XlfrVg2
ceyo8M4d8W/P8j9eXDxi6GBofXPCIVLXjiHz09Oa4fYEE4K/CcwJAYwx8Fc6YivL
r/m2AEwIGBZYs3ypGH8wsF48f97UJWIoofkTgt07cqh0g/Xz7u1b6ZlXL1/q/2gJ
KPWkUSMUeYCUOnVot3XDeh9V0TdgQvA3gTkhgOzF4KRj9eqli74tABMChgWYELRQ
NH9CAPNdlLBnty6+Wv88e/JEWGdjpwRtjyCqe1hcdGRkWFeIV8mNUaQp4xN9vh4r
YfasmUMH9k+dPtXSmZwJwd8E5oQA42RgfG/xQGi7tk8fP/ZtAZgQMCzAhKCFopkT
gt9fPKfrn5kZ832S7Q/Hj7VvEyhpd4jOKRMSC/bsqqmqwgDWlhyg7589fVpZfm1H
1tbRn37SVrezgD++ef3GJ6XS4+7tWxoXARNiQsDQYOlDUHqhJDayJ8Zq9y6d9uXt
8XkBmBAwLMCEoIWimRMCaOJAYp0fKTrofZ5VFRXQ/VSp4xNzUlNU3AIqyq7qdxmm
jE/0vlSGyM3epn0iNqIHEwKGBktC4HAS2dqaX17+/qIxCsCEgGEBJgQtFM2cEJw6
eqRBbX/8j/IrV7zMEIKyT3QkVecYrsUH9tvKZOPa1YGunCB7y2YvC2YIQT6YEDAE
VAhBo4IJAcMCTAhaKJo5ITjwr3xRvODA1rdqb3iZIR2oSO3bBP54+gcP8vlmw3pp
u8Hn5w7qt0tCOjAhYEhgQsBo7mBC0ELRzAlB8cH9onjtggJ+vX/Pm9weP3yIwUkV
eW72No9zm5Y8nmaVOn2qN2XTg66O9I6KsHyeCcHfBEwIGM0dnhGCd2/fXist3Zn9
7ZIFGZCnUyYkzp41E1nBLlS0t2A21VRVVVVUaMlWrLrnz56JF5GJfl49fPBA+7W6
slJ/qu16dfX2rG/mpaWi2GkzpqEKwn/ntydPRM56L/Saqp93b8/J/GL+zMnJUCrz
0matW7kcmu/Rvx+oF14A3zp/5nT2ls0owGfONkRhli78Ijcnu6LsqqVZ2UiEAN+t
KCtDNZctXqiVKj1l+qolX6KJbtfWKmaCpvt6zSq6QgBr/s7NmzTdqr3xx6tXihl+
tWIZVeHD/jnIw+o5gcFGz3e1bxNYd0/mK+/fvUN3ayNB/ysqCK2/eumXs6ZOEiNB
WwU5e/LEoL59ROaRYV0ry8vFoBKpuvInMcBMCMGb16/RdJvXrcVwnTohKWXKpIXz
5mzdsP7sqVMebzM/e/r0h+PHkGfG7M+1kZyRnob/xR8Vpz9mnJi8D+rqpF/v3r5V
kLd7ReYiSAaUeU5qyvpVK08c+d6zwFBoJXylYM8uiJe5n81Chijzgjnpm9atRRd4
FjcF5b966SKmHhpzxqSJSAvmpuN/r1y8iH73IEPM5WPFhzEGIAZRQkzkVUsyIQwl
Hrx4/lxzQoCRJkYI5oji19EFR4oOrl+9EoMEvYn2QYduXLu6+MB+KRMmBAwL2CUE
UH7LFy/s1bO7tBdLxeuIT4ZAXZnnA2XQJbRDoHODGQnqR73MWZs2iBeRiV4oQJNp
vwa1+ogG94AUGz96pD52Xq+e4ZoCxqQSOVM/uPxduZDy7mLgoN0mjh0FaaJSeJAV
iJ4RQwd3DmlvmFuA01cuvldUztYtJjaEzwkBhBoGAyzaQDdH9WDoQ12ZOD8jh8P7
C1OnTY4I60qHR6CTE+D1YJoCW+ft3KFSMDRCbGRPmptnmwUUIGG0aqAv0gMY5+hW
bSRI9wvs3pETG9FD3z5jR3yK9jHoTaMU1Prj2ppftAwNCQFGNXQqWtLdIAnrHDo/
PU1PVkwALQiFIbYz9KlrxxDMHZAV83yePn4MRqVVZPSnn4i/l5w9kzhyuP4YiJYw
VaEpFfUc5iP0PcYSGJW7s6Naniiwuu4EwQKTqB/kbjLET99sWK9+JBWfRqXcNWlI
cJvkcaNFOAEqbA0JweSkcWKEqASxhjWC9pc8bWnCROsbEw2JrUknJgQMC9giBLnZ
2yAy3A0+vXyEreAuKxACaqXBMlYvc9bGDeJFZKInBDBNxAOwe7Q/wshwN3OgzrVn
YMqIP8IsdjgvFaTn6U1S24BWeN2k2NCXsJZMeIA+QT24s6t8SwjQON27dFIs1fAh
g4UyEwB/slU1pJ3Z36qUrfzKFcpR+vWO8aamGm7euN6W8MKB8XHSAyAEkObar32i
I7U/Qp1AZNuqo7sEiW9ICDQ1gEEb6Z4K0NQ1tIPKCQ6UPD1lhmJUR2h0cBGTNSoQ
ArGDE90jXPsjpjBYjmXmmLB7vrMggru354AQqzcm8gQTtWyEC+fOxbn6pbpLUKKV
5eWWGaIiUighwwTJoAkTWALij4aEgI6EIf37mnwaRARUQL2JVny52MGEgGEJdUJA
b+aQpZsbCg8dU1F21TC3+hUCQqvtrhCIF5GJ4QqBeADGPf6Sm5PtziZAWjx/rvbi
+tUNhGDm5OTHDx8aymUTk0VvawrAmDOUyGg96B40vuGv0BCGsfx8SAggLOz2LPTQ
xR/P0Uy2bd6oLp60tOPbLJXiwaSjb2HEelxTCpAAkWe7oADJ1AYhEPRRiyWAXgAT
sltHk3S9ulr7FlUDyePGgA3oF7EwNqCnDccwel+wXkNAf9PKuvSv++IljhwGGuEu
Q6EI0UqYy3M/m6U+eJA2r19nUuDEkcMN30I34buGKxBohMslJSZ5gjHgdf2Lwc67
B/V/x4cunT9vkiGqYFhIqP9gow8tnDen+ECDY427FQLxwNCB/d19GkI1vHNH9ZE2
oE+sdhsqEwKGBRQJAei/NMigKTPS04r2FVy5eLGirOzsqVPgv0mjR0iToVvHEMOb
ef1GCKB1Ksuv0bg0sZE956XNQmnBEtatXD4tefzx4mLtRUoIekdFgKQ3vBXRA1O6
cG8exAQyhPTJ37UTpEHYkUIcVFdWuiv5jEkTaf4oRmF+HnL79f69x48e1VT9fOBf
+WNHfCo1Neqrz8pXhIBWWUugcZDvKFjphRL07I+nf9ie9Q0UlSSIMVrodgwUKkzV
o4eKkI4VH878Yj5tk9zsbUcPF2m/agkPKy53TxgzqkHHfPwPiYh4DLqhi1R80OUE
IyUE0A3/+fNPWNgNWiQoAPYZ5g5sWQykRfPmTJ2QhLmAOmIsjR89kjamaBaXdLhI
XCRGCcGgvn2ErAfvxFfAtM6fOY2xcbu2FpoAIwQjVpploCyvXr40rCa+An0gdTGU
DZgraET5lSvXSkvRXzBh+8fJj0ExG64TUEKAklA1FtYpFLMPpjPMcQweTBM0EQaP
nuJIDU6BIUcFCNonZ+sWzLtbtTfwaRjHeADdJ/mZovzuVjXqL9lybbH4XlEY+SVn
z9TW/AJmhgyXL16IZpRkl7shSmeflrp2DIF8OHX0CHoKEq+s9HLBnl0pUybRQoLc
C5LkMSHATO+mW6bVhAnmqXZRCDg0RFNcVIRmY+B/tXeZEDAsoEIIIL/o4MMggx51
Zz1ASWDc0+chj/Q2rt8IwZzUFCEQIa325n5nsjGv145as4BVuPM2qqmq6hsTTZ+H
FHCXPyQ7Cpw6bTK0msmSrOYkQWe7vsw+IQSQg3S1Ax+FWHTnrYaaSquUoFbuhgEd
M7DMHj986EHxHM69ZBp+wHCHyDOA29G6rF76Jf2VEgL8AwOeqMlh5rvs1EHB7imD
Bo0VEw015u4VKFppiwfKwPBJDDb6WERYV6h/d9nuy9vT1fV+HW2pWQIlBDTNS0v9
7ckTw5xBO6RpAt7jbjsMnQ7tDm6E2WrS3WDePbp2pnnCLNE/9vuL59QVAyoZQs9w
OkP6SSdQxgxLMKy+tHOaNGqEO8/ie3fuUIIokmeEAMWm4Y0DnFzwYEG+O2GCgQrm
J2gNEwKGBSwJASR+ZHg38UxQ64/BfM3zhPofOzyBjtqNa1dLz/iNEIj1wF49u1v6
yesJQUhwG/OVQ4fTz4DKR4hUd+YaRIDieQqqJKCzqyoqpAe8JwQQLnSnNlBtDV/a
RHfXcS5xCIIC1E8oSAA7oSGQxXa+94CKoqxrxqSJ9FdKCND+YjdH7C6ZYCE5XWY3
DoGW4qIjLXkPOCXdYzL0QQPho3WEXrRclYGWpQYohhZMXukZQ0KwInORec5Q/5Jn
gInnkGIY/+PFxbSChr2zYI7LXue2zRvN8wQJoM/D6JceoKcHkUYlDLXs4oljR0nN
5RkhoF4IAU5GbutALxMChgUsCQGUBB2CikHpwcopeYeOlHL2GyEQBVDRSXpCYLhc
rwc1CiGhSi+YbWeqoOTsGSrpCvJ2Sw94TwgK8/NoTdNTpqu89eb1mxjiYw+taWgb
+YoQgGzRxd7hQwZ7lo8eUI10U3nEJy5HCSghEOkztYgFXhICqHnFa+7ogg00tH7y
olI0W8XdlmPFh+nYg9EsPaAnBDDoVXKuLC+nvRnWOVT96Kk7UD9B6Gbp1wd1dR3a
BokHhPuwCTBW6e5Y4shh9Fc0MmWokJkqKhkySlpU8IAQYOrRpQ4U0mR30hBMCBgW
sCQE1B0JY1r99LMI564lKZKMnwlB4d48lZwlQtC9SyfFA0hXLl6kMnRv7nfq1THE
q5cvafvol1i8JwT09AS6Xn1V/2BBPm0lsUNJ4StCUFVRQX3XoTs9y0cPGKz0WMTA
+N70Vz0hiAzv5m5/RIKXhMBwmdoQO7K2irecJ2xdHOOvV1fTJQQoG8VsHa5UA4pH
CjagJwSWq4YC0tw08SRQRNqMaSK3ON0CEiYOnSb61Q5D0EX+kOA2dGpIO03qt3ZJ
J109IAQ02BfSonlzFD8twISAYQFzQlB/OovIlLmfzVLPGSqfrj1K5N2fhECS9SaQ
CAFkjeKLjx89ot5DhjrSLnpHRYgM9Vu5XhKChw8eUDNIbwWa4N3bt9T9yvB8lK8I
gcS0Zk5O9iwfPTACw8k2fP84l9OMekKQm5OtmLOXhGD3jhzFD104d46+KO2gb3Y9
nXH25AnFbB06tyGJzUuEAP9WDzpUVnqZnj6Yk5qiXipDUPeOXj3DpV8H94sXv6rH
s5KMmaOHi8RPGIHi7+BbNVVVinlKp2c9IASzpk7yZso7mBAwLGFOCPJ27qATw8Qd
yRBU0nVx3Vn3JyHI2bpFMWeJEKjbPahOWOdQz6rjDtSZbtWSTOlXLwkBPQEVYLQl
YQ5qlkkmlIZGIgTpKTM8y0cPHSFwWfSWCIGJX4ge3hCCNqanVCRUll9zp7ccrof3
wjqFKi5vaHj5+wu6fCJdCykRAvMT8xLev3tHj/Kqk3V3oNvqvXp2pz9hWNJDQKAO
inle/NGFaYn4IuhKukMRFxVh2bkCb16/oePNLiGo/zSxEBT3aCQwIWBYwJwQ0NgD
hhFezUGP6kpX3vmNEEDCigPflqCEwNYdfZjb1GhesiBDvTruQD2wfE4IaL8Htf5Y
3dDRAHOZSkx96EBfEYJ6g5J8yNZKhjmg4Olh7v6mKwRjh6su4zu8IwTdOoaoM4+K
sjLaCzQ8KAYkdfUYNsR2sOehA/o1aL7oSFoLiRCkTptsK+ek0Q33UIOpeOlGQK15
iRCcP3Oato/JqQ0Jv953CRkiljGePX1KFwLtjkbapHYJgTQgZ8+aaevTGpgQMCxg
TgjoEXAoPMMIOSaAyUInJI0m5jdCAMNdHPi2BCUEIEDq9+BBXFJ/HxVC8J8//4Qa
PlZ8eNvmjSsyF81PT0udPhUiJnnc6DHDEkYmDKFL+j4nBClTGpYfYf7+/sLepVYl
Z8/QntXHnvMVIZA2wsePHulZPnrQcHtIg/vF018l+au+VezwjhDgefUPSYSAzi9M
Clo7RY9RCrpA3bVjCJUMEiFYbnM9jHrpY2zcv2sxy6Ceodp378iBsIKJkp4yA9Nk
6oQksDTMlKjuYe4Iwe7tOeInLcoyXlRJiSOH0+X9KRP+WiCprqyko1GLP6iOKeMT
PSYEFWVXKTPeumG9rU9rYELAsIA5IaCUtl9sL7uZX710kQoselTab4QgRkEiC1BC
AJGn7menTghQ8cK9eZj5IFht1ULJNgYhoOGPonuE2714rabqZyoZ0W7SA74iBFDM
1EvcJHybXaBItP3RINJ3KSHQO3WawBtCYGuWmRCCu7dvUX9+w3AC5qBOcO1c1bZE
CMwjdutBnRsMj9RquHT+PFqyX+8YKfaXSZIIAY1E7k0SOyYoEv27YqhNARrP0S4h
oFdoIhXmK3lJS2BCwLCAOSGg97bZ2inUAAuYEu2sjQ1H+PxGCCAj1LUdJQRoDfVr
DFUIAZ7ZvH6dFEpFMfmcEIxKGCpe1/tmW+LenTt0AUOK6uPwHSF48/oNjcAD7qJO
78whrSdL3glNRQhAwdU/ZEIIKsvL6ekMuzoboPdVIisab1QiBOp78xqkw/T6OB8l
Z88MHzLYJKyyuyQRAhou05uUPG60luEPx4/Rv6v7GGmwvO3QhBBIbp7mwardgQkB
wwKNSgiuV1e7EIJNf19C8PjRI8NI+FCrUd3DEgYNgNBJnT4VNkRmxnx0CkpCZa7P
CcHIhIYT6h5E+4G9SAmB/n4BXxECh+sg7NA2SH/frmeQPMm/cV2DbSpCYOtmZ1NC
cI3GoPSAENArJEAItMudNfiWEEhb+xj5+ks9IEbCO3fsHxebOHLYzMnJaTOmoZGX
L16IfqE3TEqEgCrgQKe/QniXTrZT547z0v46XXXiyPe0VNo9KeqgeyW2CcFhJgSM
xoc5IaDB/Af0se3XKu170Rhh3hCCr1Ysa1mE4M3r19LtMm0DWkENQKnD1HanMGiG
vt8yIKEkbe2qaKit+YWutzcqIaAnGpAglD3OyiTb82dO01+bihCI649VYEII0OD0
+gAPboSCuqXDlV4x7CUhoLeVQtOjFuIn6ahkgPNyS1ATPOPOE4hubUiEgN7AgkFY
U/UzZiLysZtEMBJpVSl/105bFffhCoF0okQRTAgYFjAnBEmjGvyBI8O72d1pllbY
9uXtET95QwhWZC5qWYRgGZGtAc749pah6CCD6LEFnxMCes2SBwHjSi+UUKqnP9jp
Q0IgnX3NmP25x1kJoL8wMESenUPaS26VLZ0Q/PbkCS2/sHHVMSc1RbwO9U9jCUuE
IPMLGx6XDlcVTqlGdWUlvXiwTUCrrRvWW7YejUwsEQJ6yimo1UfmN1CooD6WAGlw
ugeqgoz0NI8JgcRFdm9XDVZBwYSAYQFzQkBHMOSLYhx+AWlVtuTsGfGTN4QgPWV6
CyIE0DQ01il0j8rhBRACunfuc0JArzyGKUntPxVIwQr1ASp8SAgk/zi0s2L4SBNc
On+eSvbEkcOlB1o6IXj/7l10j3Dxk61jkxposMKo7mH0NiCJEEjXQFiC1hfTQcgc
Oq+RNqtF9zIhBNIoLT7gbVTEunv36E7ZQpuxAqdM8PyUQU1VFd1JsXuyQwMTAoYF
zAnB7h0u53akZVVL0BtjO7QNevigQb+CENDIJ7bGN92Mb/6EQHIPNrnQhQIylyok
nxMC6f5WuyuQLrcbB7bW33DtQ0IADBsyiJbWMxdrCulSO7p2paGlEwKH665Q/fKe
m+s6DYGH6XiWwoxKhGBQ3z7qOaM1YkmAhD7/i3CASUoZDL6uOG1pV0qEoD7uNXGk
8D46CJgodQoGZ7L1Ot2BtUsIpMCv0qEYRTAhYFjAnBBIp8Btqe36mR/ZU7zbr3cM
lYxvXr+m41t9HRgvhnVqiAnY/AkB3TENcHNDqx6SCetzQvDrfRdbZ15aqq3XxY3S
7lrYt4RACiDfOyrCbkgMisrycro03b1LJ30UP58RgsieTUUIXI4J1G/VX1XP+eql
i9QdWDpFog9drH4ntXSUX8T2gbVAG1w95g+9VVkiBNK+W3xMtPdHVOh9UZBg6jFO
Xr18Sa+W9iB0MXWfRFYeBHRiQsCwgOXlRlT0g8KrC2Lp6lWJnmNm0khq6oT3zInj
NNvmTwjo9SpI1IXKBJkZLiemfE4IHK5md7iRUnQHqBZ6pM0waJpvCQFGHb3ZIcCj
m100YDDQYwsBuvMFGrwhBDS+Z32MByvTvJEIgRQrYsGcdPWcQRDFi5huZaWX6a/6
y43UV+Olo4AipNWdmzcpQ0UbquQm0QuJEDhcwyuhIpAeiuV0B3p1AtLRQ6pLaydd
Tyh4QAioM3WARzeoMSFgWMCSEEhnhNRjcQz7Z4O+cd4CIt8zRhWSeqx1GlGnRRAC
aYVAH+VXDwhc6nbQSISgYM8u+gl1nUddTSFkDR0kfUsIHLrLF5B2Zn/rQT70cpoA
ZwwGQ48EbwjBqiVfiheRyW9Pnpg/30iEwOE6BzGeFUOP3719i9a9f1ysZFjrCYHi
acnHDx/SjcJ6t6T/xf6SVggUb7GStn70hEC6/6l/XIxdz2gJ1ZU/UQqSMGiA4os0
YLNnhKC25hf66diIHnbXyZgQMCxgSQj+ePWKbptBEGBcWma7yfX40IQxBteQ01O5
Aa5xDN2hcG+eFK6k+RMC6dJSFfdJei1N4xECSBO6m9uhbZDKqjIYIS3YiKGDDR/z
OSFw6KR/oFFAJBNgnEj3CkK8Xi4pMXzYG0JAPW8CFPwzGo8QSP4rIz4ZYrlm/v7d
O0uPDT0hQMrbKYev1oNeK4wE8138hNFI5Uy9G6PVtN2Xt4fuaxgSAoeryxFS6vSp
luU0B703PEDNRoIQCHItqgeEwOEaSz7A5vWzDiYEDEtYEgKHc+LRUdizW5fSC8Zi
VAOkJ1Xb0DR6pzOH7iANvu5OOmsoyNtNo9i2FEIg7dbDQjK5lB3W5MSxo6Q6NhIh
AI4VH6ZfCescau7ikL1lM7VRggNbV5aXGz7ZGIQA3LRf7xipZYb073vyyPfmeu71
H3/s3p4TGd5NehfVcfeKN4QAepqO/4Hxvc1HYOMRAiB53Bj6DEaXyVXFGH6JI4fR
52H669vWkBCgl00i94FnzJ41kz7fLihAGrSStjOPnbAjaysNtGBCCGDT0wkY4LRP
LE/6oNZo3vnpaUX7CqSfILho/6IY5iELjxQdlK7S9pgQ1FRVtSMnbgKcB0rN11bR
p8eLi+/evuVgQsCwhAohcOiiuGAO4C8Xzp17+fsL8cyDujpY8AmDBkhDX3/zjQZM
OWk3F/oemg/6UiyF4RkoVCg/6jINRiImZPMnBICk48M6hebmZFO5jBJiqq9buVzc
v9c1tEP/uAbvjUYiBA7dOg30/czJyT+e/oGOBLQDlA11p9KSyTnsxiAEDue5rzhX
ZwIt4Y8Zsz8HZSwrvVxb8wtaA+158cdzudnbUqdNNgwXba7jvSEEUH70ktwApzs6
vdQY3Q2KLE72NyohgD7o1TOcPobWQHXQSsK5AdMNkw6Dn550DXA6zWmKRAIlBBgw
lBwkjRoB/UfPE6EAGAzUFUlLm3SnCqVgfIHOawalq0ofP3x4sCCfrmGAsgiSakgI
HLrzz9rsTk+ZAUJ85+bN3188f/USkuw5Knvl4kXIK3AXjCjNpqfh1AQkchPgvO8A
ZJreVImiIn8QMiGs6gXX/9YJPCMEDt0WpLPW4V+vWVVRdhX9olUEdAfGFfguvg5J
AiGphfNiQsCwgCIhwNilV3VRkdEnOrJfbC9MRT0LRvpqxTKTr5deKGmro/ltA1ph
5sTHRCPb6B7h0tUmg/vFg4gIp7YWQQigDAzXNmA7QpzBxoXxSgP/wQhAHeldbY1H
CIBU0lwiQY5Aq8Eih+Si9+a5q6OERiIEDqc2okfk9QktiQbRh78VCSNq9w6LuC7e
EAKHLpiS1ghoTNHd1J5uVELgcO49R5LBKcYMRmzfmGhMNMN7trqEdtDfMqBBIgSo
LHXm1+YO5h3mL4YQdRoQydBFAJNozLCEAF27QTfDzECCqJGGIpQ6FKDoKXeEwKFb
thSpfZvArh1DwNEx4KWFBC3pg245nOcXqH+GSMhHyEOpqOh3iDsxLD0mBA7XiIci
BTpXH+sr0jFEkjbgeZo3JRMChgUUCYEG6AATOSsljE6VbUVYdYbz0DBhkjx+9Aiz
UUy2FkEIHE6fOGmtz11CjY4XFztcr1ZrVELgcA4D/QKsuwT5ayglKRqPEGjYumF9
WOdQxQLTNDJhiLttDgovCQEwdUKSeUkw8rUnG5sQOJx3T9DbKywTqCpd0pAgbRmc
Onrk5o3rvY1WbgwT7H53Wzy/PXmiX0twl8RZWXHy0IQQOJxjUqzAqSd3vk1/vHol
+QmaJLCZZ0+fvnn9WrSbN4TA4YzxrChPApyOXyd5hYChAluEwOHUUmDx5vf2Ip+0
GdPUg99dKy0dlTCUnmTTJ5Dcr9es0hY5nXFn/1oFBZnQ74lS7zO8qE4IVi9t8A+H
lqUrn+ZAkbqSsAqGIczQdDQyiT6hBZJGjRCqHURHUCU9wyjMz6PvSiurHqD8yhUI
OHNaANs6ZcokFa9SaDv6oqETiZeAWlq/aiUMMsmzzF3J0bYnle9BQNe3Mb2swRIY
dbDkgt1LbUEIqA+prSA/6DKaIRSe+fO52dukvQx9wswC2TI/KikRAu24Byx11JeG
H9Wn+F5R+i15Ca9evpz72SxzIwGKn27bizjcmOzmmYPnLZo3R4VKQsT1j4sFEaQx
m/UAXdD7ptDUrWPIVyuWCcElHjaUS/T8Dr5uXpeqioop4xMtrSmM/NmzZmqMnAkB
wwJ2CYEGWA+gqBPGjOrXOyaqexhSbEQPaDuY5nk7d6jrUQpIt3Url0Mn9Y+Lie4R
jjxBogf3iwe32Je3Rwo1f/RwUdamDdlbNu/ekaM/Nnb+zGnt122bN+Jd9WgkMLm0
F+tz3p7z5vUbxRfxCUgofA4vIgeTqwp+OH4Mlg3oP2qHOqKmaEMIAtRd7+QPEY88
kSE4k/QT+Jb2OaQdWVupM4c3gLLP2rghedwYqRdSp01GgyieW3M4L9dpKN63WXRv
1bdwOn9dxVdmTZ2krSprrao17OhPP1kwNx3k6df7qiXXgK7PzcnWyo/2ryy/5lnx
aqqqwDJHfDIkLipCKxiMbxiCULriOCKGhDbq8F/1c+0AqLBWQu1dw/1+CVBCZ04c
z8yYP2LoYK1ISNDTKCHU+Ykj36uEhZYIAV0uevzwISTAzMnJqKY2fiAZ0C8Zsz8/
dfSIOjUHLd60bi2oEqx/rZDaxsG8tFnFB/ZLhUTvoPraZFfJHFT7UOG+jPS04UMG
uwyY2F7D/jkoPWU6KA46TrGosPsP7y+E0oUA1CY1SNXA+Dg0wt7c76RDp+hfraiF
e/P0cgldI0bCkaKDKl+HHMD8AiUClQRP0toKlUJF5qSm5O/KpXOWCQHDApioYmJ3
Ce3ggeB+9/Ytkq9uqdcAQo08vTwx3MyB2tXX0U5AWT+jhfaC1qrNrWExQZphd2uT
1+5bEiFYv9r4bmVt/HgvGRpDwkj5+2rANO2k1r5u0qFMCBgWGJUwVEzs3lERjTfr
GAzGhwEvrz9mNBWYEDDM8PjhQ+o5NXGsQfggBoPBoGBC0ELBhIBhBum8WW5OdlOX
iMFgNHcwIWihYELAqAcmsHQ11oO6Ono3seZAoH5lGYPB+NuCCUELBRMCRj3mpKaE
dQ4dOqBf0ugRE8eOShg0QB9qxvDONwaDwZDAhKCFggkBox6fGYWioyl53Bh2J2Qw
GCpgQtBCwYSAUQ96Kbg+pU6b3NxOQzEYjGYLJgQtFEwIGPWoD0yri5gW2q7tyIQh
x4oPN3XpGAxGSwITghYKJgSMv3DzxvXiA/u3Z32Ts3VLbva2H44fe1BX19SFYjAY
LQ9MCFoomBAwGAwGw5cAIaBeyeY3mjKaD5gQMBgMRuPi//77X5qaujiNDm2FINB5
5W596OJVxqGLGd6gMUYUEwIGg8FoXExOGhcT0SM2ogf+q7+o+sPD+/fvK8uvXSst
Rbp66eLjhw+bukQfGu7evhXfK0oMqrMnT/gkWyYEDH/j9R9//PbkiZbw76YuDoPR
6OhD7hSeOTm5qYvDaPG4Xl1NHcAPFlhcbK0IJgQMf+B2bW32ls2wk+Jjort36dQ5
pH2XkA5I+HfvqIjRn36SMfvz/F25tddrmrqkDIbv0T8uVsjuz6ZP9SCH//z55/as
bzauXb1p3Vp3Cb9ilkE3XPzxHBvlHzZqa35pG9BKDKrD+wt9ki0TAkbjoqaqCiZR
h7ZB5oGPtBQc2HpQ3z4QbSoXtzMYLQXeE4JnT5+2bxOoMonEmWF8dMmCjMrycp9X
h9HkYELAaHmATUMvS1RP05LHN3XZGQyfwXtC8PzZsy4hHTyYSlAbU8Yn3r97x+eV
YjQhmBAwWhi+XrPKUEIFtfooOCigPgW2DnQjxYr2FTR18RkMn6EJCYGWwjqH/nj6
B5/Xi9FUYELAaEk4erhIEkkd2gbNnJxcuDevsvxa3b17SHdv3yorvQzdv3zxwmFD
BolIJt06hrCzIeNDgs8JwaC+fTJmf56RnkbTvLRZUyYkDu4X3yXUgDp0bB9cXfmT
z6vGaBIwIWC0GPznzz979exOhdGngwdiBJu/9fjRo8L8vFEJQxfMTfdPORkM/8Dn
hODrNavMHwYjH/3pJxInAI14//69p5VgNCMwIWC0GBw95LI8MDC+95vXb9Rf/ztE
bmH8reBzQrBqyZcqb+Vs3RLU6iM6GY8UHfTg64zmBiYEjBaDeWmpYqQGtvro/JnT
TV0iBqMp0VSEAFg8fy4lBMnjxnjwdUZzAxMCRovByIQhYqT26NqZr05m/M3RhITg
2dOn9FqBnt26vHv71oMCMJoVmBAwWgyG9O9L9gvivM/w//773zev37x5/VpLtvZB
If7Ei//580/9A/ijya+Qp6eOHsnesjlr04Ztmzfuy9vjzjMLhaypqjpSdDBn6xY8
jKRdGnn/7h1aeCkZfpTi8cOHZ0+dQlZ/5ZmTff7M6d+ePFGpu3nVkAmtWuHevKqK
Cq2onu3aiM8heeMWija/cvFiYX6eVjak3dtzzpw4/uv9e5bv0qFiOE7QR0X7ClBf
LeeCPbtKL5T8/uK5Z0XFt8qvXCnI263lhq4/Xlx87458xq9/XExTEQKHK0Fv3yZQ
8QgiVE7xgf2iCzR3YA/IhNabmDgiKwzmo4eLqisr0Ud2c7tdW3v0UJHICt13rbTU
1o4kxYvnz/H6wYJ8WjZtzlq+S0eaYbPcvX0LOYuBUXxw/6N/PzDJENMHsgWqnRbm
5JHvb964rh/J5oQA5akoK0Oba/nUz+78PAxUy1nJhIDhe3w6eKAYqXHRkd5nWHfv
XmR4t+5dOmkJskn93cwv5osXE0cO0z+QMmWS9mu/2F5UMUD9zP1slv6s19jhCVIO
EB9LF37ROyqiDZmi9HhFj66dRRmkNCphqLuSY5KP/vQTat6J1Dmk/cSxo6Ajzes+
ZUKi9pW+MdGvXr6kVUtPmaH3RYeI0Yo6ZliCXU4A+R4R1lX7XHiXTmgQW687c/jp
qxXLEgYNcHe+LiS4DX4FOTAp2+NHj2IiemjFmJ+eJv4O9rNu5fL4mGjDPurWMQRt
deHcOfXSQtwvmJuOKuuPzkLpDh3Qb893O0Q5QYubkBDMS5tFt/CgKsw/tHHtajRU
28DWUr3wbq+e4Yvnz9UzHkMc+Fc+JovhkYcA5/Fj9BEegMaCmjfP6o9Xr6DVBvXt
0y4oQC7Vx/9AL6Cv1eOcXq+uRh2HDRnU1U3Z0IOwarZnfWPC10Em+jrjriLNmDSR
/nTxx3MQNfpAUlkbNxhmVVZ6efasmRBxksPHX7MysDWaHWIKTEiUxx0hgCxCB0X3
CNcPS/wFRU2dNhnMwF2lmBAwfI8p4xPFKIQ+g4jxMkPICzq+MVHV3505OVm82MeI
nYwYOljIOxEhEROsa8cQQ2GxYI7LIQhwf3r1u90UGdZVX6RbtTdEqczTtOTxJtat
WKoJIlU7VLjPXdVounrponojA0sWZNDXYWYpvgiteaz4MIiRoao2TFC37nTSg7o6
kU98ryjtj/m7csFRLLPFAAAFVNnhgg4zJGpSGtwvvqbqZzw/fEhDb/qfEKzIXERL
BXvd3ZOwKcEILeuFAY9hb/JFcDu6TGiZoDszM+a7y+3o4SJoRMtMwLyh5s2bAsMS
qjpYx3Xcpf5xMe54BigmGKr2GGwJ2truRvKJI99LmTx9/BgCKqj1xyqFwWNiFkuE
oPjAfvwxe8tmFVmEF9HahqyaCQHD91i/aiUdfzCVvMzwzs2bdPTvzP5W/d3U6VPp
9NY/IE5ngXOAquMvsEENqbqWKB2BXNaLttiIHgPje/frHWOuhDC9MXthi0vlgbzu
pqCwRYIwevjAeClSLNWIqu3N/U5R+sxJTVFv5Hdv31KRHRcVob7A8P79+95REer1
1RIa+dnTp/rc0BTCMusc0h7F2Lxura2cJyWONS/wwnlz1HNDGSrLy2dNnST+4n9C
kDH7c/EidFVNVZXhY/rBbJ7QDob5YAB7QJGhzAxzg1Ud6H4y6lOqafMO6tvHbsF6
dutiuFeF4YfO1Z4BrddW9T8j0kafrldX0xxAFlWIjkjD/jlIvCsRgvNnTq9akmmr
XoYNxYSA4XtUlF2lBj30opeRU/1DCJAu/ngOljEl+DCmxw5PgHaclzYredyY+Jho
PKO9WLg3j04wyGvtFgahC9+8fl1y9gzeoo9179Ipb+eOMyeOV1VUwD6Q7FH8UUiZ
v7IN7ZAyZdKOb7OOFB0sPrgf8jFx5HDJxIGYM1zbpHs3l86fh6SWqgY6gqrBLE4e
N7p/XCxd3QUpobsM5jh76hQtz1crlql3ELB5/TrxbtvA1ihJRnoaaBmyRQPCqvtm
w3pIQ0mipadM12dFCQFaCZaQGIr4B1javLRU2PfoAvDUr9esQsX10bVNlqAksqt1
UOq0ybk52UcPFaGDdmRtTZsxLTK8m3gA/6brPf4nBLCJxYtQ1S+eGywp6eOKYqgv
WZCxL28PDPTC/LzlixeCekrPoDWkfH5/8TwirCt9BtVHT6FJYcViDBftK0B3o4nQ
F2L9HyLC0J8gN3ub9MWYiB4L5qYX7NmFUh0syF+zfKlexy9yw1QAdLp4DHOhb0w0
xj++oo20sydPbNu8cVTCUClDQ45ICQFaFX9Zt3I5fSu6RzhehNxIT5kBIZMwaACd
ULdqb3TXGQzalEQFly1eiMafljwerSQugsGMEK9TQoApgxEoMsGwHz5kMPgBWkkT
Gmj8mZOT9Ttx+btypUoxIWD4HtCIQwf0k+bG5ZISjzP0GyGAOIj73021mOQwLvXu
e5q+h/yC6SBehETTFocNsXHtaqrwSi8YNwXyjHO1laE8DB2RrpWWQpbRJw3NNUoI
YIGJzLWq6S1sqEmaJwSKuxpJoIZRcFAA+kvxRQ0gRtDK0Byrl35p0owoHt3YhuLX
m26UEFBWCnHs7vgrOBw4H614j66dDfWTRBaRZkyaaNhB4GdgBoYXefiZEPzx6hXd
KYf61D8DdUit8I7tg905aoCY0q1xtIa0AUG5Hdp/ReYiE4+/mzeug5yhSIYMsvzK
lWDX7sbDhhs6BXm7pR2ck7rF+YbW6BiC/kXBTK59AtWQqikZ9w5XQoCvg2qIsQEZ
AvZj4oCJnwb0iaUFBq3cumG94aJX3b17e3O/AzmgN1hSQkDHedKoEdWVlYYfxdSY
MGYU/Wivnt2lQjIhYDQKoP6lpWmI8vnpaZ4tFfiNEIilTign8zivB/6VTwUfaLh5
MeguMv5t+Iy014v/NckQTAXWEm1evcyihEBITLzlTulCC4Z37ihegV1rXikNsHuo
U4KJm6QJykovq/icr/hyMW0i/W4UJQQiJY8bY34yBb9Ke97Hi4v1j9H2RJr72Szz
0l788ZyeE/iZEGRt3EC/rt9lB3eJjewpHkCBTZwMAAx1OrXBtOivtImmTkhSLKSe
fOAvg/vFi6zAMk8dPWKSA9heMPE3jO8V5c4XBDxD5VDJNxvW03YD0ZEeoIQAVEB0
9PjRI0E7zDPf5LqNFdU9zDKQqwRpy0BxQKJVpXEu3XDBhIDRWIC1LY1XTS1BINpd
LfAbIdBSWKfQW7U3zLNNmdKwK9w7KsKyGIcK91HlrbehQf+plaOiVs+ePEENO704
kBSYVjXzq6UXzE2n5VTx3C7Mz6OfsHUGxC6kU/WzZ82UHtATAphBKsfSLpw7Rxtz
8fy50gPQ7jTb+JholeOvOVu3NCEhuHrpImUkUGBPHz+WnpGW5em6tDukzZgmngcb
FtMZOhi6Tfy0L2+P3WoKgHaY8xg9Mr+YT185erjI4687nOQYk0XkNmV8ovQAJQQi
jUwYYjkqQKCpk1CHtkHubHoT6AlBv94xKo47YAB0RUGyOpgQMBoR2Vs2Gzr0YkQO
6BOLSW553EiDPwlBoFp414HxvW2JeKhhasHoVxSo7xsMDvOzYaQYDefZutdvxLpo
PokQoGpHD1lIScgmuipuvkqhIXHkcPE8JJ2leeQlqDOB/gionhAo+rRCmFIPr7Ej
PpUeSE+ZTrNVjAEs6UhfEYI1y5dafnf3jhzJuS83J1t6DLWma9eKUUOqK3+ig2Re
Wqr293dv31IHAlAND2qqgW7kg9KpHP349f49sd0eYGd9wh2SRo8QucGwln7VE4Iu
oR3cufdS7M39jr614svFHpRNTwhgcqi8CL4SSfpo4thR9FcmBIzGxaXz56nulBIm
cPK4MZbn6f1JCFTWyTGpons0KA9L6Qy8/P0FXVfX+1RT3ygocsXarV7q4hkunRWU
CMGIT4ao5Ek1LqppHosGEpBKYUNHP9+C+k/pG0oiBNCI6qdex48eSYZKLP0JConS
Beh49fib0qkEnxCCBXPTUVOoQJqgJDAADhbk49dYsp301ytzDO4Mq6n6ma7/K84s
0Ajq7NI3JlrYpnQYDx3Qz4OaOpyqnXbiupXLFV8cOrC/eMv7mIyLSMfB/pZ+1RMC
lWUMhyuBxtxR4RB6SITA1g2xY4Y1eMxIRIcJAaPRAWGxe3tOnOnRsmFDBpnc1+5P
QlC0r8AyTygD6kZufvWchlcvX9IVSClEiaRWFSWLQ3ePlLTeKxEC7bCyJfbl7aFv
6Q9PU9Al8cCP/+HOX9KHoPqVHsTSIBECdWoFzJ41U7wYG9mT/lR7vYbaxOkpM9Sz
PV5c7HNCgOkQEtwGY4am4MDW+nA02sP64wAaQEzFY3hdccUOmJw0TrzYsX2w8L3N
zHBZt5+WPN7wUIM5XBx06iMpXVV8ce5nDSGY2ga2vnnjut1PU3y1YlnDeIjoIS3I
S4QgtF1b6vTnDvVuOuRwgaKbjh4SIdCfXjYBDc0irQkxIWD4CWDrhwr3JY4cRjUf
TZj5aTOmGS44+40QUNFmAslCEkumJnhQV0crLm2v/nD8GFWrWswAFcDCozpg2eKF
9FfJqdDQh1kPmBrUtdD8Ohzqo0QtxcYD9Su0JATz0izcrCjopVySX8jRwy7Ea2/u
d+rZ3qq9QTfOfEIIFFOgc1fbJMYU1Q3QeerloXGoglp9VFl+Tfs7pqrkRwnqDNph
Kzg0vZAprHOo+otbXT0BvbxWje7iWRICmDQqeVZXVtIlGVvHRykkQqB3eTEB7XTp
1AkTAoa/AZGBmaY/06wl/L3unnyWzG+EgEYcM0fSqIb9xYHxvS2fP3nke0p9hADV
QA01/AppqwUht0x4krrCSdGEKCFQr5rD1bUQPMZdDPbr1dXUblZf2DDH+3fv7t6+
dbmkpPjA/tycbFQTOUN0Ll34xYI56ehEdUJgq0g0xK9ECKiHLHWjU4F21M3/hCA2
sue10lLzbOkae0RYV3HFg3nCY9K6mgjO4XDG59CHEoJZjEElDXt3oJMrrFOo4lxA
qaSYH5Z+he/fv79/907phZLig/t3b88RIw3EGqWlxxwsCYHhjowex4oP0xIeLMhX
eUsPiRC4C+tkCCYEjGYHzC6YxZj5etkR3ytKWifwGyFQPzK3I2ureAsW0tlTp8yf
pzIOklpyRYYAsiXr3SUTQgBLUbFqDp1robsY7DS2nWFUAFtAL0OuJY0eAZtSf3TQ
MFkSAlt+bSaEgJ4ItbsWjaFO/Qp9Qgjwb6ioGNeEv9BVKFjq5ofZnH6U3X0y8C6d
P09zhp4zvMIAg0q7I0B/2IHCg3iChgna1zB/DNQd32Yljxsd3SPc3YKllCwJwaZ1
a1X6EbRDvAJmaev6DAqJENhasmJCwGi+OH/mtH7+Z8z+nD7jN0KQOHK4Yrb1ApqI
vJ7duujDAAhIJzD1dJ6qIm+SdAzPY0LgIFc8aO1meFKc7psYXhyliJqqn6clj1cU
zTRZEgJbgtKEEMD+Ez+FBLcxv7ZOj3gSRcpHxw4z0f76dHh/IW0fKUiAhPfv3qnc
XKCSJELgcN6yg5q6I3aYO2htd4da412Dbnmc9CsEt2tr02ZMU7mHQkqWhEDRRqfh
DWy5R0jw5vpjJgSMZg0IJuo6HuBcpn5QVyce8CMhsKHV6CJBgNOhfc3ypdBtwrf5
9xfPfzz9w5QJifQxyGj9SWUa696b5KsVAodrdIFAoxtxSi+UUPcFxVNPesBeNKQC
6PGwzqHOiyHioPjHDEuYOHYUGooGiLQkBHk7bdyjoUgI0NF2r0umR/t8QghWL3W7
90x9yANMT12+/P2FrVszTJKeEGioqapaMDeduqRI03zRvDn6CNl9fUQIpBWCgj27
DC9ZaBPQCu2gXUGCEQWBMGFM/Uij50p8RQjWr24IfQ1CYHLxoDmYEDA+cNBb25F2
fJslfvKGEHzWaITA4RqhRagxaCyYOLGRPfWXCvaPi3386JE+H6qKICVLzp6pLC/3
IElHmLwhBG9ev6ax1vV+9fPT08Sv7mLRW0IfvQofnfvZrOID+2E+GnqYTp2QJB72
HyFwdaqwe1TM54TAxBkNlJRGvAjrFOru4CWYK10hwETwbNQhmfc++BOUMUag4TWA
cVERUlRQukIAjeVxqej4wUiQjmCgZTCqDxbkQ7mCG+mLjV99Tgh4hYDBUMLlkhLq
T0Av4/KGEFAD3eeEAFi+eKHKCmRQ649RI3fXBVEfgnZBASrnl1TgDSFwuB4hkyIO
/efPP6mlnpGe5kHxqioqaLcGOk9JWBrfyeNG+58QUG8JxQCOAlAk9DpHP0QqlCIf
uItoi4LR6Ne2jq55BvQ4eKR+voBQUldiuoeo4rFriVu1N6RVqIzZn1ueJ6Lrdr4i
BLt35NBieHwOggkB4wPHm9dvwjo3nNSHnhY/eUMIRnzSsPDQGITAYXpvbHBg6149
w2fPmmly9MuhO81fcvaMB8XQw0tCcL26mjY79Yg+dfRIA9fx1NChtn6A8okA6knu
N0KwPesb2kHUqd4SIE90rcUPhACkiq7Sg4y6G34JgwY06LzInn44Nepw3tYDfSwF
2pucNE48QEME6uNveoA5qSn0W8tdT+e6A93H9BUhOEFOGwXYuT9MAhMCxocPundI
FZhECNRdxzGH6cUtjUEIMr+YLxZCU6ZMulxScry4OH/XTqjPH0//AFNSJeK9dH1w
1iZjr3678JIQOFxdC5NGjRB/pzJlQJ9Ykxzc4Y9Xr+gGtsp9EPoi+Y0Q0EARSLDz
1LOVok755y4D6s2ONLhfvOFjdEPN+3MitoAxT2sUHBQgbj5zCXLQ+mPza8Ys8e7t
WxpGTD2C4cSxDXcD+ooQSCd1DS8pVQETAsaHD7qyShcwb9fW0llE3QvM8aCujqoH
nxMCeou8ZzHJNWj3/4qs6OqIN/CeEFDXQpRQOy0mHaz3jL5AygeRHaIFc5WOcb9/
965JnAqhq2i2qXaUev3lwkQ3+4cQQHtJh3cMZ43EGzw2WD3DgX/l05YRWu1I0UFa
qq0b1nvzlbp796hTxaypkxRf7PO/m9B9SAikvTbPyLSDCQHjg8fjhw9do+I3eLFJ
Yf6Wqa34OZwXpVPJ4ltCQC2/uOhI9RcNQbc22gUFWF63qALvCcGb12+o31n+rp0O
V3ntwRk8DWWll2nXfKMm9K9cvEhphN8IAZQBXb7q3qUTJLtittTe9RshcDivEaFt
1SW0g/70/707d6iytBXp2XvAUqfxvEXgbelOSyhmb/YyPAsOWFNVRY0QXxECh2vU
Z3yisrzcdpWYEDA+eEgXkFNRDuFL1ZJeDbiDFMzft4SgaF+BeFE67+cBYJzRotIt
VY/hPSFwuOqzpNH1uwYzJk0Uf5FuS1NH+ZUr1DpUuSDK4eoi6k9C4HB6j9JPa9zI
EvXr1eRyOX8SAoer6Hf3aTr+A5UvvPAV6O2I9IQkHWMB3l2cKN1DobgWRS+28C0h
QAvTnDGkbVeJCQGjpcCzG8aqKiroEWHYB5I1Q3eO2wa2VqHVULHSQSPfEoLcnGzx
4vAhHl5SIgDSI4WN896TwCeEoF70/C8UP+y5B3V11EXOXTA4S9Tdc7msVsXFHQxM
imvpT0JA2wEJDFXlHkV6QY7/CcGv9+9RUzuo1Uf60HiS/0rXjiEmIbZ8i9u1te3I
+gS99bSirIya9aHt2np8b9aL58+pbJFUoCF+OH5MOiHpQ0KAmU4jV0JGHfiX7QDG
TAgYLQOQL0MH9MP0UD+aVXxwP105RMrMmC89Qy8aCXA6SZkffT5SdDAkuI0ki31L
CCRJimn24+kf7ty8Cdn9+4vnUlK5nBTtQDMMdMp9FZ/Exw8fbtu8UX+LtE8IgYNc
Tg8ZvWRBhpDUPbt1UV85lyAFOoR0O3vyhMnzhfl5+rB3/iQEQMqUSdLXzQ9JwuTV
n7z3JyEANq5dTb8+oE+sfvl9UuJY+gwIn+WN5Boqy6+tW7lcnN+DMbB88UJoU5V3
UQzqtQedLd2LSK8u1B5QXL2oqapas3wpjRVBr+ACpzTP5+ihIul+Jt8SAoduORAj
1pIT4Os1VT+LMjAhYLQMiANpwYGtoYAxq3dvz7lcUgJNiQkP/YExDe2I6Xr10sWt
G9bT61W0pL/LAHj07wfSLB0Y3xuiR1JIEEmwJGZNnSRMSfqWbwkBPq0PqQaLBzaZ
PoHx9IvtNXVCUv6unSYXwupjGPfrHbMz+1u0HpVH+DcaBDVFA6LMmgGkX1HwFSGg
myNU3ep5my2sXupyXBO1KMjbLXUo+BAGDz2gSI/O+5kQIPOuriH6oScK9+ZJ4SVQ
BRjidHeDclM/EwIUJpa0mOE4gUaP7hFOnwlq9dHkpHEnjnwvLdS9ef0GZv2x4sPg
hf3jYkENwXiE6sWw1DzmMNRXLclEIxgG/EEmmLnoO/pFfSgLSAkMfmk6JI0aAd4s
BepAHe/evgXJsyJzEUwFTVPS+yZQZZpJh7ZBudnbpNOMKPy10tLUaZOF4wVGWiDp
aB8SAodrOI0AJ/tPHjcGNgYdSxj8dffunTzy/eL5czEgQaCZEDBaGKQDWlSRQJjC
+IgM7xbWOVTPwcXEu3fnjmHOkq2jpciwrrBfZ0yaCPk7fMhg/C/dJkgYNADatJEI
gcN5HtKDMKvhXTrlbN1imCEm/LTk8fpXwDOiuodh9qJGkJJoQ310lx1ZW6XcfEUI
JNfov3RG64+rKio8ztPhVHL0bngtoZqQjPPSUtNTpkP69+oZTjsU8po6H/iZEDic
58j1Rn94544jhg5Gx4G4DBsySGor0FMYrOJ//UwIHLq7m0G89JEWYVXru1h7GHoI
rB1Gdlx0JOYvdUIMcO7uCa9SadUnwLkBgUELboHehMqHKsI41F+ggFlvyJLv371D
jw3Tj+IVFGnogH59oiORobR6hD4CcRH5gFvEuLKiAOf61oQxo9Dp6Skzxo8eiQ9R
H8yJY0ehTYTS9TkhgOI3vMMJlgNECqY5hBWkGd1Wo2OSCQGjZeB4cbFdBSlS0ugR
5kH6pCsPzNOAPvVxgqsrfxJ/6e9rQgCTImXKpECb1dSSSXQ/uiyvnvQiyVeEwKFz
lQ9wf7TdFkrOnnFHDfUJggxCGYadUI3+JwQO51V+6mVOHDkcdt6hwn3iL/4nBMDY
4QlSS+qfARGXnHBVUtvA1pQQRLh6UKqkfrG9TM7UYApjVnowv6Q8K8rKDC9gNEzg
B5ovlCBJPicEDuddEjQEk2UCVxbvMiFgtAz8ev/epMSxtu4Tg/ID0y/aV6CSf9bG
DZLDgT6FBLdZOG+Otm0PhkFpvj5DGqwNdp5iNW/euA4hS6kAjBKYU5AR+oTyGJKG
3Jxsd/lfOHcOTEWRFoR1Dk2bMe3OzZtSJgPj48QzaGHFqhmi9npNO1fTUL8g4RnK
Si8PjO9tXkGIcnoYXTyvdxB7UFfn0sJ2vNNplB5oApMnqyoqhF+FSZnXr1qpPX/1
0kXx92nJ49WLJAD1Q9sf/MzW6zVVP0sLG+720XO2bqGX+pikwFYfQZdvXr+O7vJk
bdpAowCZp66hHVARFfea3TtyeruuPbgtlfNyhDXLl+p9jKorK/UblFLCFF63crl4
RRwG7t6lk0QIfnvyhC6WoB1s9AcBhIB+9UKfglp9REdOTVUV/dWWWyKN9dnH9bw0
EwJGowBGA0hrZsb8McMS4mOiMZ1AETq0DYI9gYR/wNzBDAf3h9C0G/gWUxGCHiwe
EwnZQlBqefbo2hkTeNO6tXdv3xIPYxpD6MyYNBHJ8I44aBr8BNaM+abo2F96oYTu
JfeNiYYYra78CQWDJQfZTRP+ApKEOsJalS5wgjllHpa1/MqVVUsyhw0ZFBnWFVZp
MFovoBUsYIgtiF1QmYzZnx8pOujOtW3j2tVa1fBfjwWWAIohSq4/BuINYENDok1O
GterZ3etmhC1+AdMIowfUEBp3Whv7nfoLFRKH+0YTQFuhCprtXZ3C58hCvJ2I1vt
RZXotufPnJ6TmgKliMEsBiGYBLgCBhIt84vnf5UK+dtatBCA1pyXlioG6tFD8sW+
lgCB02qn5WAS+AFjsvjgfhS4X++Ybh1DtGkb7Kxd144hcc5p+/WaVddKS929fry4
eNG8OcOHDMYMBSGmEx8ZYr6gImgHW0Po/bt3J458jwYHzQUDpqUC94qN7ImhAh5w
uaTEPGgBqjZ1QhIK9tdIC2wNvh7h3HnEHJFiNcJK0UbassULpWxpj+C/Z0+dUq+L
BDAq8LPU6VMxliBYMMExzTVvpOge4RAaEFxSa2N04Xkxzm2JUFAQMc6/WrGM/sSE
gOEPYPJAWWIQw7CGrQm6ABHpfeB0KBJke//uHeSJzD27cM8uHj96RM/dQW7a8rSX
3Ab1x8AMgU9Aet6ura2t+QWtB57hsXu/Z3j18iWtNURqY3wFHYpq3qq9cefmTfzD
syOs/gcGc929e9rA9nO/NDbQ76gUqoYewRSze+8zOhSNo018JPzD0M3QLv549QpZ
oVQYKlqp7AoTTXRgQiFhRjefXkNdHj54gGmOEYUS+nkKMCFgMOxhEblKrr+RU4I5
pChsvlp4b2zk79pJeYzi0TIGg9GCwISAwbAByd/exAnABNQTWzFkb5ODHhKL7hHe
Umx3BoOhDiYEDIYN1N+7SMLVlV+54kEm1D1q2+aNPi+kzyHFdV+RuaipS8RgMHwP
JgQMhg1Q1Rj48T+qKyvt5vD44UN6aK34oF9Dx3uGjNmfiwKDD9GQLwwG44MBEwIG
wwbu33W5Hc4DZ+/MjPni9Q5tg/QhYpoboP5pdJTkcWOaukQMBqNRwISAwbCB9+/e
0SuIEgYNsPX6zuxvaWiB5HGjG6mcvsKb129oPLU2Aa0qysqaulAMBqNRwISAwbCH
Za7X4E5KHCudXTZEZfk1KSZx+zaBNVVVfiiwx0DxaNQm7YxlUxeKwWA0FpgQMBj2
8PzZMyk+a6cO7VKmTNqb+13phZLa6zXgB3du3oQ2vXDuXMGeXZkZ82FkS3Hi8L+F
+XlNXRUXbFy7es3ypTuzvy3I2711w/rkcaPpTgFSZHg3lQt/GQxGCwUTAgbDNirK
ruovaBGaHno0OLA1vShFSt27dDp62LbzQWNDf7OcRHo8O1LBYDBaCpgQMBie4EFd
3ZQJifqL78xTt44hC+fNefzoUVMX3wCGd69pKS46ktkAg/HBgwkBg+E5rpWWQsH3
jYl2d/1dYKuPOrYP7hMdmTJlUuHevOa85J44cnig66oG6E5cVMTXa1b5JyY0g8Fo
WjAhYDC8xcvfX8CALszPy9q0Yc3ypYvnz121JHPj2tU7s789UnSwsvya4V3vzQ33
795BabO3bF615MulC7/I2rjhxJHvmzODYTAYvgUTAgaDwWAwGEwIGAwGg8FgMCFg
MBgMBoPhYELAYDAYDAbDwYSAwWAwGAyGgwkBg8FgMBgMBxMCBoPBYDAYwP8HaO0c
Rhl8sV8AAAAASUVORK5CYII=">
<p style="top:709.8pt;left:180.5pt;line-height:6.8pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">&#xa9; The Author(s). 2017</span><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:6.8pt;color:#131313"> Open Access</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313"> This article is distributed under the terms of the Creative Commons Attribution 4.0</span></p>
<p style="top:717.8pt;left:180.4pt;line-height:6.8pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and</span></p>
<p style="top:725.8pt;left:180.4pt;line-height:6.8pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to</span></p>
<p style="top:733.8pt;left:180.4pt;line-height:6.8pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver</span></p>
<p style="top:741.8pt;left:180.4pt;line-height:6.8pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:42.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">DOI 10.1186/s13018-017-0534-y</span></p>


<p style="top:87.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">vulnerable to shear stresses and prone to breaking down</span></p>
<p style="top:99.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">over time [20]. Subchondral osseous overgrowth has also</span></p>
<p style="top:111.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">been reported after microfracture [25, 26]. Osteochon-</span></p>
<p style="top:123.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">dral grafts can lead to donor site morbidity and healing</span></p>
<p style="top:135.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">seams at the recipient site [27, 28]. Autologous chondro-</span></p>
<p style="top:147.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cyte implantation (ACI) [9, 10] and its later evolution,</span></p>
<p style="top:159.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">matrix-induced</span></p>
<p style="top:159.5pt;left:127.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">autologous</span></p>
<p style="top:159.5pt;left:179.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chondrocyte</span></p>
<p style="top:159.5pt;left:238.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">implantation</span></p>
<p style="top:171.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(MACI), offered great promise with 80% of patients</span></p>
<p style="top:183.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">showing good or excellent results at 10 years [29] but at</span></p>
<p style="top:195.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">best results in hyaline-like repair and has experienced</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">complications such as graft failure, periosteal hyper-</span></p>
<p style="top:219.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">trophy and delamination [30, 31]. In addition, it has also</span></p>
<p style="top:231.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">been reported that cells may lose their phenotype during</span></p>
<p style="top:243.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">expansion [32, 33].</span></p>
<p style="top:255.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">There is therefore a growing interest in regenerative</span></p>
<p style="top:267.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">medicine, which can broadly be thought of as two main</span></p>
<p style="top:279.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">types: cell therapy, where cells are injected directly into</span></p>
<p style="top:291.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the blood or into tissues, and tissue engineering, where</span></p>
<p style="top:303.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell-scaffold combinations are used to repair or regener-</span></p>
<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ate tissues.</span></p>
<p style="top:327.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Stem cells are cells that have the ability to divide and</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">develop into many different cell types in the body and</span></p>
<p style="top:351.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">can be categorised as pluripotent and multipotent. Pluri-</span></p>
<p style="top:363.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">potent stem cells are often harvested from embryonic</span></p>
<p style="top:375.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sources and can develop into any type of cell in the body</span></p>
<p style="top:387.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">whereas multipotent stem cells are generally taken from</span></p>
<p style="top:399.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">adults and can divide and develop into a more limited</span></p>
<p style="top:411.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">range of cell types. When stem cells divide, the new cells</span></p>
<p style="top:423.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">can either remain stem cells or develop into a new type</span></p>
<p style="top:435.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of cell with a more specific function (Table 1).</span></p>
<p style="top:447.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Mesenchymal</span></p>
<p style="top:447.5pt;left:129.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stem</span></p>
<p style="top:447.5pt;left:156.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells</span></p>
<p style="top:447.5pt;left:182.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(MSCs)</span></p>
<p style="top:447.5pt;left:221.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">are</span></p>
<p style="top:447.5pt;left:242.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">a</span></p>
<p style="top:447.5pt;left:254.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">form</span></p>
<p style="top:447.5pt;left:282.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of</span></p>
<p style="top:459.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">multipotent cells that may offer an alternative to cartil-</span></p>
<p style="top:471.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">age repair techniques not hampered by availability and</span></p>
<p style="top:483.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">donor site morbidity.</span></p>
<p style="top:495.4pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The introduction of stem cell therapies into clinical</span></p>
<p style="top:507.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">practice however is a form of translational research,</span></p>
<p style="top:519.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">which as per any</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bench-to-bedside</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> pathway now has</span></p>
<p style="top:531.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">enormous governance issues [34, 35] and is highly regu-</span></p>
<p style="top:543.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">latory across four phases (Table 2) and by the Tissues</span></p>
<p style="top:555.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and</span></p>
<p style="top:555.5pt;left:81.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Cells</span></p>
<p style="top:555.5pt;left:111.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Directive</span></p>
<p style="top:555.5pt;left:157.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(2004/23/EC)</span></p>
<p style="top:555.5pt;left:222.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">https://www.hta.</span></p>
<p style="top:567.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">gov.uk/policies/eu-tissue-and-cells-directives.</span></p>
<p style="top:579.4pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Many published reviews on cartilage repair only list</span></p>
<p style="top:591.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">human clinical trials [13, 36</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">46], underestimating the</span></p>
<p style="top:603.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">wealth of basic sciences and animal studies that are pre-</span></p>
<p style="top:615.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cursors to future research and may be relevant in clinical</span></p>
<p style="top:279.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">practice further down the line. In addition, true transla-</span></p>
<p style="top:291.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tion would imply that all of the clinical studies would</span></p>
<p style="top:303.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">have supporting pre-clinical data.</span></p>
<p style="top:315.4pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">We therefore set out to perform a systematic review of</span></p>
<p style="top:327.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the literature to assess the translation of stem cell</span></p>
<p style="top:339.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">therapy to explore what research had been carried out at</span></p>
<p style="top:351.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">each of the stages of translation from bench-top (in</span></p>
<p style="top:363.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">vitro)</span><span style="font-family:NqykfcAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> animal (pre-clinical), and human studies (clinical)</span></p>
<p style="top:375.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and assemble an evidence-based cascade for the respon-</span></p>
<p style="top:387.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sible introduction of stem cell therapy for cartilage</span></p>
<p style="top:399.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">defects. In particular, we wanted to focus on the key</span></p>
<p style="top:411.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">burning questions pertaining to cartilage repair such as</span></p>
<p style="top:423.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell source, dosage (how many cells should be used),</span></p>
<p style="top:435.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">requirement for scaffolds and the role for extrinsic</span></p>
<p style="top:447.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">growth factors.</span></p>
<p style="top:471.1pt;left:304.7pt;line-height:10.3pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Main text</span></p>
<p style="top:484.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Search methodology</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">This review was conducted in accordance to PRISMA</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">guidelines [47] using CINHAL, MEDLINE, EMBASE,</span></p>
<p style="top:519.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Scopus and Web of Knowledge databases from 1st</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">January 1900 to 30th June 2015.</span></p>
<p style="top:543.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The keywords used in the selection were</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mesenchy-</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mal stem cells</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All Fields] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mesenchymal stem</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[MeSH Terms] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mesenchymal</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All Fields] OR</span></p>
<p style="top:579.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stem cells</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All Fields] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Stem Cells</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[MeSH Terms]</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">MSC</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All Fields]) AND (</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Articular Cartilage</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[MeSH</span></p>
<p style="top:603.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Terms]</span></p>
<p style="top:603.5pt;left:342.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">OR</span></p>
<p style="top:603.5pt;left:363.8pt;line-height:9.8pt"><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">articular</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All</span></p>
<p style="top:603.5pt;left:427.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Fields]</span></p>
<p style="top:603.5pt;left:461.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">OR</span></p>
<p style="top:603.5pt;left:483.2pt;line-height:9.8pt"><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cartilage</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Fields] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cartilage</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[MeSH Terms]) AND (</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">healing</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All</span></p>
<p style="top:627.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Terms] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">repair</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All Terms] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Regeneration</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[MeSH</span></p>
<p style="top:639.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Terms] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">regeneration</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All Fields] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tissue engi-</span></p>
<p style="top:651.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">neering</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[MeSH Terms] OR</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tissue engineering</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Fields]) AND (</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">defect</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All Terms]) AND (</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chond*</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[All</span></p>
<p style="top:675.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Terms])</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:687.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">All review and non-English studies were excluded. For</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">analysis, only original research studies were included.</span></p>
<p style="top:711.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Any duplicates were excluded. Initially, KM and JS inde-</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pendently screened studies</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2019;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> title and abstract. Those</span></p>
<p style="top:637.7pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 1</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Table describing the three main properties of stem cells</span></p>
<p style="top:651.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Stem cell properties</span></p>
<p style="top:664.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2022;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt"> They are unspecialized (</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x201c;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">blank slates</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x201d;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt"> that can become specific</span></p>
<p style="top:673.8pt;left:61.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">types of cells).</span></p>
<p style="top:687.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2022;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt"> They can develop into specialized cell types (cells that do specific</span></p>
<p style="top:696.8pt;left:61.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">work in the body).</span></p>
<p style="top:710.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2022;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt"> They are capable of surviving over long periods and divide to make</span></p>
<p style="top:719.8pt;left:61.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">additional stem cells.</span></p>
<p style="top:87.9pt;left:304.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 2</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Description of the different phases of clinical trials</span></p>
<p style="top:101.8pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical trial phases (http://www.nlm.nih.gov/services/ctphases.html)</span></p>
<p style="top:115.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Phase I: Safety Studies or First-In-Man. Researchers test a new drug or</span></p>
<p style="top:124.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">treatment in a small group of people for the first time to evaluate its</span></p>
<p style="top:133.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">safety, determine a safe dosage range, and identify side effects.</span></p>
<p style="top:147.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Phase II: Uncontrolled Efficacy Studies. The drug or treatment is given</span></p>
<p style="top:156.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">to a larger group of people to see if it is effective and to further</span></p>
<p style="top:165.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">evaluate its safety.</span></p>
<p style="top:179.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Phase III: Randomised Clinical Trials. The drug or treatment is given to</span></p>
<p style="top:188.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">large groups of people to confirm its effectiveness, monitor side</span></p>
<p style="top:197.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">effects, compare it to commonly used treatments, and collect</span></p>
<p style="top:206.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">information that will allow the drug or treatment to be used safely.</span></p>
<p style="top:220.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Phase IV: Post-Market Surveillance. Studies are done after the drug or</span></p>
<p style="top:229.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">treatment has been marketed to gather information on the drug</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">s</span></p>
<p style="top:238.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">effect in various populations and any side effects associated with</span></p>
<p style="top:247.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">long-term use.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 2 of 30</span></p>


<p style="top:87.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">included had the full text reviewed. Any disparities were</span></p>
<p style="top:99.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">discussed with the senior author (AJG). The references</span></p>
<p style="top:111.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of eligible studies were also searched and included where</span></p>
<p style="top:123.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">relevant.</span></p>
<p style="top:135.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Unpublished trial databases (e.g. ClinicalTrials.gov)</span></p>
<p style="top:147.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">were reviewed as the grey literature using popular search</span></p>
<p style="top:159.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">engines, including Google.</span></p>
<p style="top:159.5pt;left:182.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The keywords used for</span></p>
<p style="top:171.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">registered clinical trials in clinical trial databases were</span></p>
<p style="top:183.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stem cells</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cartilage</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> and</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">orthopaedics</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:195.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Eligible studies were drafted into tables tabulating the</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">key data.</span></p>
<p style="top:234.9pt;left:56.7pt;line-height:9.2pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Results</span></p>
<p style="top:246.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The initial search identified 2880 study articles, of which</span></p>
<p style="top:258.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">239 were included for analysis. The PRISMA flow</span></p>
<p style="top:270.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">diagram is shown in Fig. 1.</span></p>
<p style="top:298.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:DsylsqAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">In vitro studies</span></p>
<p style="top:321.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">MSC source</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> A list of cell sources used in the in vitro</span></p>
<p style="top:333.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies is shown in Table 3. The commonest being</span></p>
<p style="top:345.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">human MSCs (66%) followed by rabbit MSCs (15%). The</span></p>
<p style="top:357.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">majority of the studies used bone marrow-derived MSCs</span></p>
<p style="top:369.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(63%) followed by adipose tissue (33%). Two studies</span></p>
<p style="top:381.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">used commercial cell lines [48, 49].</span></p>
<p style="top:408.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Scaffold</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Within the in vitro studies, 26 different types</span></p>
<p style="top:420.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of natural scaffold and 9 types of synthetic scaffolds were</span></p>
<p style="top:432.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">identified with a further 18 different types of hybrids,</span></p>
<p style="top:444.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the most popular being a fibrin-polyurethane scaffold</span></p>
<p style="top:456.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(Table 4).</span></p>
<p style="top:483.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Growth factors</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> The commonest used growth factors</span></p>
<p style="top:495.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">were TGF-</span><span style="font-family:JgcgcsAdvTT86d47313+03,serif;font-size:9.8pt;color:#131313">&#x3b2;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> and the bone morphogenetic protein (BMP)</span></p>
<p style="top:87.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">family. A list of growth factors used can be seen in</span></p>
<p style="top:99.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Table 5.</span></p>
<p style="top:123.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Cell seeding and passage</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> There was wide heterogeneity</span></p>
<p style="top:135.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in cell seeding density and there appeared to be no</span></p>
<p style="top:147.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">standard form of measurement. Li et al. [50] examined</span></p>
<p style="top:159.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">three different seeding densities: 2, 5 and 10 &#xd7; 10</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells/</span></p>
<p style="top:171.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">scaffold, and found that scaffolds seeded with 5 &#xd7; 10</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup></p>
<p style="top:183.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells per scaffold induced the highest chondrogenesis;</span></p>
<p style="top:195.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">however, other groups [51</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">53] found that a higher</span></p>
<p style="top:207.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">seeding density results in better chondrogenesis.</span></p>
<p style="top:219.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Apart from 26 studies which did not state cell passage</span></p>
<p style="top:231.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">number, most studies used MSC of an early passage,</span></p>
<p style="top:243.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">anything between uncultured fresh (passage zero (P0)</span></p>
<p style="top:255.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and five times passaged cells (P5). One study used cells</span></p>
<p style="top:267.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of P6 [54], and another study used cells between P4 and</span></p>
<p style="top:279.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">P7 [48]. No relationship was apparent between chondro-</span></p>
<p style="top:291.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">genesis and number of passages.</span></p>
<p style="top:315.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Length of study</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> The length of each in vitro study can</span></p>
<p style="top:327.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">be seen in Table 6. The majority of studies were short-</span></p>
<p style="top:339.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">term models; 27 studies (25%) ended between 1 and</span></p>
<p style="top:351.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">2 weeks, 35 studies (33%) ended between 2 and 3 weeks</span></p>
<p style="top:363.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and 15 studies (14%) ended between 3 and 4 weeks.</span></p>
<p style="top:387.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Method of assessment</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> A range of techniques was used</span></p>
<p style="top:399.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">to assess chondrogenesis within the in vitro studies.</span></p>
<p style="top:411.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">These techniques consisted of histology, immunohisto-</span></p>
<p style="top:423.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chemistry, qPCR, biochemical analysis, imagery and</span></p>
<p style="top:435.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mechanical testing. The techniques used are summarised</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in Table 7.</span></p>
<p style="top:472.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:DsylsqAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Animal studies (pre-clinical)</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">One hundred eleven animal studies were included of</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">which 109 were controlled laboratory studies, one was a</span></p>
<img style="position:absolute;transform:matrix(.31994138,0,-0,.31979914,-194.18268,455.778)" src="data:image/jpeg;base64,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">
<p style="top:718.7pt;left:62.7pt;line-height:8.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:8.0pt;color:#131313">Fig. 1</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> Flow chart of literature search used for the review</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 3 of 30</span></p>


<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pilot study [49] and one was a longitudinal case study</span></p>
<p style="top:327.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">on a race horse [55]. The commonest animal studied</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with 59 studies was rabbit (53%). The different species</span></p>
<p style="top:351.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of animals studied is shown in Table 8.</span></p>
<p style="top:375.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Defect</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> The size of the defect varied from 2 to 25 mm</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">2</span></sup></p>
<p style="top:387.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in the smaller animals and from 1 to 64 mm</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">2</span></sup><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in the</span></p>
<p style="top:399.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">larger animals. All but two studies [56, 57] used the knee</span></p>
<p style="top:411.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">for defect creation.</span></p>
<p style="top:435.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Stem cell type</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Bone marrow-derived stem cells were</span></p>
<p style="top:447.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">used in 84 studies (75%). Thirteen studies (11%) used</span></p>
<p style="top:459.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">adipose stem cells [54, 58</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">69], six (5%) used synovia</span></p>
<p style="top:471.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[70</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">75] and three (2%) used periostium-derived MSCs</span></p>
<p style="top:483.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[76</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">78]. Three studies (3%) used embryonic stem cell-</span></p>
<p style="top:495.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">derived MSCs [79</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">81] whereas 2 studies (2%) used</span></p>
<p style="top:507.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">muscle-derived MSCs [82, 83]. One group showed</span></p>
<p style="top:519.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">promising results of allogenic MSCs in a rabbit model</span></p>
<p style="top:531.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">when compared to autologous cells, although numbers</span></p>
<p style="top:543.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">were small [84, 85]. Another used compared autologous</span></p>
<p style="top:555.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chondroprogenitor cells and allogenic chondroprogeni-</span></p>
<p style="top:567.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tor cells against controls in an equine model and</span></p>
<p style="top:579.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">reported that repair tissue quality in the allogenic cell</span></p>
<p style="top:591.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">group was not superior to that in the control (fibrin</span></p>
<p style="top:603.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">only)</span></p>
<p style="top:603.4pt;left:85.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">group</span></p>
<p style="top:603.4pt;left:117.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and</span></p>
<p style="top:603.4pt;left:141.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">also</span></p>
<p style="top:603.4pt;left:165.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">showed</span></p>
<p style="top:603.4pt;left:203.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">poorer</span></p>
<p style="top:603.4pt;left:239.3pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">radiographic</span></p>
<p style="top:615.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">changes in the allogenic group [23].</span></p>
<p style="top:639.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Cell culture, dose and delivery</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> There was much vari-</span></p>
<p style="top:651.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ation in the number of cells implanted and the number</span></p>
<p style="top:663.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of cell passages from 3</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">10 or more [79, 86].</span></p>
<p style="top:675.4pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The number of cells varied from 4 &#xd7; 10</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">3</span></sup><sup><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> 1 &#xd7; 10</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">10</span></sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:687.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The majority of studies used between 10</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and 10</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">8</span></sup></p>
<p style="top:699.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells.</span></p>
<p style="top:699.5pt;left:85.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Some</span></p>
<p style="top:699.5pt;left:115.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">did</span></p>
<p style="top:699.5pt;left:136.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">not</span></p>
<p style="top:699.5pt;left:158.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">specify</span></p>
<p style="top:699.5pt;left:195.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the</span></p>
<p style="top:699.5pt;left:216.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">number</span></p>
<p style="top:699.5pt;left:256.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of</span></p>
<p style="top:699.5pt;left:272.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells</span></p>
<p style="top:711.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">implanted.</span></p>
<p style="top:711.5pt;left:110.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Two</span></p>
<p style="top:711.5pt;left:137.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies</span></p>
<p style="top:711.5pt;left:176.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">suggested</span></p>
<p style="top:711.5pt;left:225.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">that</span></p>
<p style="top:711.5pt;left:251.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">improved</span></p>
<p style="top:723.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chondrogenesis occurs with a higher implanted cell</span></p>
<p style="top:315.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">number [75, 87], although others suggested that the high</span></p>
<p style="top:327.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell numbers increase the risk of synovitis [75] and</span></p>
<p style="top:339.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">synovial proliferation [88].</span></p>
<p style="top:351.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The cells were transplanted into the defect both as</span></p>
<p style="top:363.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell therapy (injection directly into the joint) (17</span></p>
<p style="top:375.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies, 15%) or by tissue engineering (cell-scaffold</span></p>
<p style="top:387.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">combinations) (94 studies, 85%). Fifteen studies [49, 65,</span></p>
<p style="top:399.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">72, 75, 81, 86, 89</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">97] used a mixture of solutions pre-</span></p>
<p style="top:411.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pared from hyaluronic acid [65, 92, 94</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">97], phosphate</span></p>
<p style="top:423.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">buffer solution [91], plasma [75], basal medium with</span></p>
<p style="top:435.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chondrogenesis [89], collagen acid [93], sodium alginate</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[86] or a growth factor medium [90]. Two studies used</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">MSCs only [49, 72].</span></p>
<p style="top:489.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Scaffold</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Ninety-two studies (82%) used a scaffold. The</span></p>
<p style="top:501.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">material used was a synthetic polymer either collagen</span></p>
<p style="top:513.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">based, fibrinogen glue or a synthetic protein (e.g.</span></p>
<p style="top:525.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">rHuBMP-2) in 62 (56%) studies (Table 9).</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Growth factors</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Thirty-two studies (29%) assessed the</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">effect of growth factors on MSC chondrogenesis. Seven-</span></p>
<p style="top:579.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">teen out of 38 (44%) used TGF-</span><span style="font-family:JgcgcsAdvTT86d47313+03,serif;font-size:9.8pt;color:#131313">&#x3b2;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">1/3 (Table 10), the ma-</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">jority of which show a positive effect on chondrogenesis.</span></p>
<p style="top:621.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Associated procedures</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Ten of the studies compared</span></p>
<p style="top:633.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">MSC treatment against other surgical modalities such as</span></p>
<p style="top:645.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">debridement [55], microfracture [49, 91, 96, 98, 99] and</span></p>
<p style="top:657.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mosaicplasty [77, 100</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">102].</span></p>
<p style="top:687.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Outcome measures</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> There were a variety of outcome</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">measures used to analyse the results of the studies. The</span></p>
<p style="top:711.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">majority of studies (79%) used evidence of hyaline-like</span></p>
<p style="top:723.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cartilage as being a positive outcome (Tables 11 and 12).</span></p>
<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 3</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Cell species and cell sources</span></p>
<p style="top:101.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cell species</span></p>
<p style="top:101.8pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">No. of</span></p>
<p style="top:110.8pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">studies</span></p>
<p style="top:101.8pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">References</span></p>
<p style="top:101.8pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cell Source</span></p>
<p style="top:101.8pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">No. of</span></p>
<p style="top:110.8pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">studies</span><sup><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:5.7pt">a</span></sup></p>
<p style="top:101.8pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">References</span></p>
<p style="top:124.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Human</span></p>
<p style="top:124.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">73</span></p>
<p style="top:124.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">48</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 50</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 52</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 53</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 168</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">236</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:124.0pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:124.0pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">62</span></p>
<p style="top:124.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">48</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 50</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">53</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 168</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 170</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">173</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 177</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">180</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 182</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">185</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:133.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">187</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 188</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 192</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 195</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 203</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 206</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">210</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 212</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 216</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:142.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">217</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 219</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 221</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 223</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 227</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 230</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 232</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">235</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 237</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">255</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:156.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Rabbit</span></p>
<p style="top:156.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">17</span></p>
<p style="top:156.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">240</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">242</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 246</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 249</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 252</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 255</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">265</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:156.0pt;left:263.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:156.0pt;left:344.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">36</span></p>
<p style="top:156.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">66</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 169</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 175</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 176</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 181</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 186</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 189</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 193</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 194</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 199</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:165.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">201</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 202</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 211</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 214</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 216</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 218</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">220</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 224</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 228</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 229</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:174.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">231</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 235</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 242</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 256</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 257</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 260</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">269</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:188.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bovine</span></p>
<p style="top:188.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">5</span></p>
<p style="top:188.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">51</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 243</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 245</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:188.0pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Synovium</span></p>
<p style="top:188.0pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">9</span></p>
<p style="top:188.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">174</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 191</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 200</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 213</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 222</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 226</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 258</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 259</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:202.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Rat/mouse</span></p>
<p style="top:202.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">5</span></p>
<p style="top:202.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">239</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 250</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 266</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 269</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:202.0pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical cord blood</span></p>
<p style="top:202.0pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:202.0pt;left:382.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">205</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 236</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 190</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:216.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Porcine</span></p>
<p style="top:216.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:216.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">247</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 248</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 268</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:216.0pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Commercial cell line</span></p>
<p style="top:216.0pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2</span></p>
<p style="top:216.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">215</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:230.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Equine</span></p>
<p style="top:230.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:230.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">238</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 253</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 254</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:230.0pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Placental</span></p>
<p style="top:230.0pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2</span></p>
<p style="top:230.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">198</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 225</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:244.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Goat</span></p>
<p style="top:244.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:244.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">244</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:244.0pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Embryonic</span></p>
<p style="top:244.0pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:244.0pt;left:382.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">216</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:258.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Ovine</span></p>
<p style="top:258.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2</span></p>
<p style="top:258.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">237</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 251</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:258.0pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not stated</span></p>
<p style="top:258.0pt;left:344.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">0</span></p>
<p style="top:272.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not stated</span></p>
<p style="top:272.0pt;left:107.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:272.0pt;left:142.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">267</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:284.4pt;left:56.7pt;line-height:4.9pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:4.9pt">a</span><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.0pt">Some studies used cells from more than one cell source</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 4 of 30</span></p>


<p style="top:412.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:DsylsqAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Human studies (clinical)</span></p>
<p style="top:423.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Thirty-one published studies by 15 different groups</span></p>
<p style="top:435.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">looked at clinical applications of MSCs. One used allo-</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">genic stem cells [103] and the rest autologous stem cells.</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The types of studies can be seen in Tables 13 and 14.</span></p>
<p style="top:471.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">There were 52 unpublished clinical trials, majority of</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">which are early phase studies (I</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">II; 63%) and only 5</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">trials were phase II/III. Table 15 shows a summary of</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">these clinical trials.</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Defects</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> The majority of studies (42%) used MSCs to</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">treat knee osteoarthritis [103</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">115]. The rest of the</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies looked at knee cartilage defects except for two</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">which studied the ankle talar dome [116, 117]. One</span></p>
<p style="top:579.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">study used MSCs to treat knee osteoarthritis (OA), knee</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">OA and ankle OA [112].</span></p>
<p style="top:603.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Of the knee cartilage defects, the patients were</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heterogeneous with varying defect sizes and locations,</span></p>
<p style="top:627.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">including the patellae [118</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">121], patella-femoral joints</span></p>
<p style="top:639.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[122, 123], femoral condyle [113, 119</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">121, 123</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">132],</span></p>
<p style="top:651.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">trochlear [119</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">121] and tibial plateau [121]; and several</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">had multiple defect sites [105, 120, 123, 128].</span></p>
<p style="top:687.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Previous treatment and associated procedures</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> The</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">majority of patients who received MSC treatment had</span></p>
<p style="top:711.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">undergone previous arthroscopy [103, 104, 118, 119,</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">122, 124, 130], failed debridement [113, 118, 119,</span></p>
<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 4</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Types of scaffolds</span></p>
<p style="top:101.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Number of studies using types of scaffold</span></p>
<p style="top:114.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Natural</span></p>
<p style="top:114.6pt;left:120.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Synthetic</span></p>
<p style="top:114.6pt;left:190.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hybrid</span></p>
<p style="top:114.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Growth factor</span></p>
<p style="top:122.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">combined</span></p>
<p style="top:114.6pt;left:275.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">None</span></p>
<p style="top:122.6pt;left:275.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">used</span></p>
<p style="top:135.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">47</span></p>
<p style="top:135.6pt;left:120.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">14</span></p>
<p style="top:135.6pt;left:190.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">22</span></p>
<p style="top:135.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">6</span></p>
<p style="top:135.6pt;left:275.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">29</span></p>
<p style="top:148.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Scaffold</span></p>
<p style="top:148.6pt;left:190.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">No. of</span></p>
<p style="top:156.7pt;left:190.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">studies</span></p>
<p style="top:148.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">References</span></p>
<p style="top:169.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Types of scaffolds used</span></p>
<p style="top:182.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Natural scaffolds</span></p>
<p style="top:195.7pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Type I collagen hydrogel</span></p>
<p style="top:195.7pt;left:190.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">6</span></p>
<p style="top:195.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">185</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 190</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 211</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 226</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:203.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">241</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 251</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:216.6pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Agarose hydrogel</span></p>
<p style="top:216.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">4</span></p>
<p style="top:216.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">53</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 247</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 248</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 268</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:229.6pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Alginate bead</span></p>
<p style="top:229.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3</span></p>
<p style="top:229.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">223</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 231</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:242.7pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Fibrin hydrogel</span></p>
<p style="top:242.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3</span></p>
<p style="top:242.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">208</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 211</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 263</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:255.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Silk fibroin</span></p>
<p style="top:255.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3</span></p>
<p style="top:255.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">198</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 216</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 256</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:268.6pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Chitosan microspheres</span></p>
<p style="top:268.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:268.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">260</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 262</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:281.6pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hyaluronic acid</span></p>
<p style="top:281.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:281.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">195</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 237</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:294.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Cartilage-derived matrix</span></p>
<p style="top:294.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:294.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">193</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 238</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:307.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">K-carrageenan</span></p>
<p style="top:307.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:307.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">169</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 199</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:320.6pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Chitosan</span></p>
<p style="top:320.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:320.6pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">168</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 216</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:333.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hyaluronic acid hydrogel</span></p>
<p style="top:333.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:333.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 245</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:346.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Gelatin-based scaffold</span></p>
<p style="top:346.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:346.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">176</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 233</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:359.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Devitalised cartilage ECM</span></p>
<p style="top:359.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:359.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">220</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:372.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Bead in bead alginate polysaccharide capsules</span></p>
<p style="top:372.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:372.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">221</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:385.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Atelocollagen gel</span></p>
<p style="top:385.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:385.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">225</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:398.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Fibrin disk</span></p>
<p style="top:398.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:398.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">254</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:411.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Methacrylated hyaluronic acid</span></p>
<p style="top:411.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:411.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:424.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Gelatin microspheres</span></p>
<p style="top:424.6pt;left:190.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:424.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">260</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:437.6pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Decellularised cell matrix</span></p>
<p style="top:437.6pt;left:190.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:437.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">191</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:450.6pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Collagen type I microspheres</span></p>
<p style="top:450.6pt;left:190.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:450.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">52</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:463.7pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Alginate microbeads</span></p>
<p style="top:463.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:463.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">266</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:476.6pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Alginate disks</span></p>
<p style="top:476.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:476.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:489.6pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Platelet rich plasma</span></p>
<p style="top:489.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:489.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">242</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:502.7pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Free oligosaccharide chondroitin sulphate C</span></p>
<p style="top:502.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:502.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">205</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:515.7pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Collagen type I sponge</span></p>
<p style="top:515.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:515.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">237</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:528.6pt;left:63.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3D printed chitosan</span></p>
<p style="top:528.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:528.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">181</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:541.7pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Synthetic scaffolds</span></p>
<p style="top:554.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polycaprolactone</span></p>
<p style="top:554.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3</span></p>
<p style="top:554.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 207</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 209</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:567.6pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">PLGA</span></p>
<p style="top:567.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3</span></p>
<p style="top:567.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">194</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 204</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 257</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:580.6pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polylactic acid</span></p>
<p style="top:580.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:580.6pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">230</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 232</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:593.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">PVA</span></p>
<p style="top:593.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:593.7pt;left:230.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">244</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:606.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">PGA</span></p>
<p style="top:606.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:606.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">178</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:619.6pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Poly-DL-lactide-co-glycolide</span></p>
<p style="top:619.6pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:619.6pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">194</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:632.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polylactide-co-caprolactone</span></p>
<p style="top:632.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:632.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">214</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:645.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">GFOGER modified PEG hydrogel</span></p>
<p style="top:645.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:645.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">183</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:658.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">OPF hydrogel</span></p>
<p style="top:658.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:658.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">240</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:671.7pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hybrid scaffolds</span></p>
<p style="top:684.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Fibrin</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">polurethane hydrogel</span></p>
<p style="top:684.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">4</span></p>
<p style="top:684.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">50</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 188</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 192</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 267</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:697.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Esterified hyaluronan and gelatin polymer</span></p>
<p style="top:697.7pt;left:190.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2</span></p>
<p style="top:697.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">212</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 255</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:710.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">TruFit CB (PLGA, calcium sulphate and</span></p>
<p style="top:718.7pt;left:63.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">polycolide)</span></p>
<p style="top:710.7pt;left:190.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:710.7pt;left:230.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">187</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:87.9pt;left:304.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 4</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Types of scaffolds</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:104.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">PCL</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">HA bilayer</span></p>
<p style="top:104.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:104.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">243</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:117.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">PEGDG</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">crosslinked hyaluronic acid</span></p>
<p style="top:117.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:117.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">202</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:130.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polylactic acid</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">alginate</span></p>
<p style="top:130.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:130.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">232</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:143.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Sodium alginate</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">hyaluronic acid</span></p>
<p style="top:143.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:143.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">189</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:156.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Chitosan</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">collagen type I</span></p>
<p style="top:156.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:156.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">258</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:169.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polyvinylalcohol</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">polycaprolactone</span></p>
<p style="top:169.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:169.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">246</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:182.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Tricalcium phosphate-collagen-hyaluronan</span></p>
<p style="top:182.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:182.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">180</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:195.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Poly-L-lactic acid</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">hydroxyapatite</span></p>
<p style="top:195.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:195.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">215</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:208.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Collagen type I</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">polylactic acid</span></p>
<p style="top:208.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:208.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">217</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:221.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polylactic acid</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">polyglycolic acid with fibrin</span></p>
<p style="top:221.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:221.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">261</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:234.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Collagen</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">polyglycolic acid</span></p>
<p style="top:234.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:234.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">252</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:247.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Chondroitin sulphate C</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">collagen type II</span></p>
<p style="top:247.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:247.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">236</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:260.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Fibrin hydrogel with chondroitin sulphate</span></p>
<p style="top:260.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:260.5pt;left:478.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">263</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:273.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Chitosan-demineralised bone matrix</span></p>
<p style="top:273.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:273.5pt;left:478.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">239</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:286.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Alginate foam-chondroitin sulphate</span></p>
<p style="top:286.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:286.5pt;left:478.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">170</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:299.5pt;left:304.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Growth factor combined with scaffolds</span></p>
<p style="top:312.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1-loaded microspheres with chitosan</span></p>
<p style="top:320.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">microspheres</span></p>
<p style="top:312.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:312.5pt;left:478.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">262</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:333.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 releasing chitosan-collagen hydrogel</span></p>
<p style="top:333.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:333.5pt;left:478.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">174</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:346.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">PEOT/PBT TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 loaded scaffolds</span></p>
<p style="top:346.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:346.5pt;left:478.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">173</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:359.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1-activated chitosan/gelatin</span></p>
<p style="top:359.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:359.5pt;left:478.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">249</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:372.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">PLGA nanospheres with TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:372.5pt;left:438.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:372.5pt;left:478.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">172</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:385.5pt;left:311.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 loaded Gelatin Microspheres</span></p>
<p style="top:385.5pt;left:438.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1</span></p>
<p style="top:385.5pt;left:478.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">175</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 5 of 30</span></p>


<p style="top:387.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">121</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">123, 125, 127, 131] or bone marrow stimulation</span></p>
<p style="top:399.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[114, 116, 117, 126].</span></p>
<p style="top:423.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Cell harvest source</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Twenty-one studies (68%) used</span></p>
<p style="top:435.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bone marrow-derived MSCs from the anterior or pos-</span></p>
<p style="top:447.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">terior superior iliac spine [103</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">105, 109, 111</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">113,</span></p>
<p style="top:459.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">115</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">118, 120, 122</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">128, 130</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">132]. Five studies (18%)</span></p>
<p style="top:471.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">used adipose-derived MSCs [106</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">108, 110, 114], two</span></p>
<p style="top:387.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies (7%) used synovium-derived MSCs [129, 133]</span></p>
<p style="top:399.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and two studies (7%) used peripheral blood progenitor</span></p>
<p style="top:411.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells collected by apheresis [119, 121].</span></p>
<p style="top:435.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Cell stage</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Twenty</span></p>
<p style="top:435.5pt;left:397.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies</span></p>
<p style="top:435.5pt;left:434.3pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(61%)</span></p>
<p style="top:435.5pt;left:465.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">culture-expanded</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">their cells [103</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">105, 107</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">113, 115, 118, 120, 122</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">126, 129, 133], whereas 11 studies (39%) used fresh</span></p>
<p style="top:471.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">concentrated stem cells from bone marrow [116, 117,</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">127, 128, 130</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">132], fat tissues [106, 114] or periph-</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">eral blood [119, 121] in a one stage-procedure. In</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies using bone marrow concentrate, approximately</span></p>
<p style="top:519.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">60 ml of bone marrow aspirate was harvested and</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">concentrated down to a volume of 2</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">4 ml before use</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[116, 117, 127, 130</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">132]. In studies using culture-</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">expanded cells, the majority used cells from early</span></p>
<p style="top:567.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">passages, P1</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">P3 [103, 105, 109, 110, 112, 113, 115,</span></p>
<p style="top:579.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">118, 120, 122</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">125, 129]. One study reported the use</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of cells at a late passage (P5) [104] ,and five studies</span></p>
<p style="top:603.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">did not specify a passage number [107, 108, 111,</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">126, 133].</span></p>
<p style="top:627.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Thirteen studies (42%) confirmed the phenotype of</span></p>
<p style="top:639.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells before clinical application [105, 108</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">110, 112, 115,</span></p>
<p style="top:651.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">119,</span></p>
<p style="top:651.4pt;left:329.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">120,</span></p>
<p style="top:651.4pt;left:354.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">122</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">125,</span></p>
<p style="top:651.4pt;left:400.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">129].</span></p>
<p style="top:651.4pt;left:428.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Commonly</span></p>
<p style="top:651.4pt;left:482.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">used</span></p>
<p style="top:651.4pt;left:509.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">surface</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">markers to select MSCs were CD29, CD44, CD73, CD90</span></p>
<p style="top:675.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and CD105. Also CD14, CD34 and HLA-DR were used</span></p>
<p style="top:687.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">to eliminate non-MSCs.</span></p>
<p style="top:711.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Cell dose and delivery</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> The number of cells applied</span></p>
<p style="top:723.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(dose) varied from 2</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">57 million for bone marrow-derived</span></p>
<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 5</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Number of in vitro studies using different growth factors</span></p>
<p style="top:101.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Growth factor</span></p>
<p style="top:101.8pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">No. of</span></p>
<p style="top:110.8pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">studies (%)</span></p>
<p style="top:101.8pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">References</span></p>
<p style="top:101.8pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Growth factor</span></p>
<p style="top:101.8pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">No. of</span></p>
<p style="top:110.8pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">studies (%)</span></p>
<p style="top:101.8pt;left:421.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">References</span></p>
<p style="top:124.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:124.0pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">48 (44%)</span></p>
<p style="top:124.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">50</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 169</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">175</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 189</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 190</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 192</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 193</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 195</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 199</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 202</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:133.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">208</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 210</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 211</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 213</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 214</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 216</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 217</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 220</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 222</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">224</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:142.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">228</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 230</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">232</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 234</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 235</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 244</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 246</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 249</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 252</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">256</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:151.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">258</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 260</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">263</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 266</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 267</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:124.0pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">SOX-5</span></p>
<p style="top:124.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:124.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">204</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:165.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:165.0pt;left:109.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">32 (29%)</span></p>
<p style="top:165.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">51</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 162</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 168</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 177</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 181</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">184</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 200</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 205</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">207</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:174.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">218</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 223</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">225</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 227</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 237</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 239</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 240</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 245</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 247</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 248</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:183.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">250</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 251</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 257</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 259</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 267</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 268</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:165.0pt;left:324.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">SOX-6</span></p>
<p style="top:165.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:165.0pt;left:421.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">204</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:197.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">BMP-2</span></p>
<p style="top:197.0pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">13 (12%)</span></p>
<p style="top:197.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">188</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 202</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 213</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 219</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 225</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">227</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 229</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 264</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 265</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:206.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">267</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:197.0pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WNT3A</span></p>
<p style="top:197.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:197.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">171</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:220.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">FGF</span></p>
<p style="top:220.0pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">9 (8%)</span></p>
<p style="top:220.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">171</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 183</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 193</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 198</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 213</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 225</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 246</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 258</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:220.0pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IL-1</span></p>
<p style="top:220.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:220.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:234.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IGF-1</span></p>
<p style="top:234.0pt;left:109.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">7 (6%)</span></p>
<p style="top:234.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">179</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 184</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 192</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 213</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 224</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 254</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 265</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:234.0pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">EGF</span></p>
<p style="top:234.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1(1%)</span></p>
<p style="top:234.0pt;left:421.2pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">193</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:248.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">BMP-6</span></p>
<p style="top:248.0pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">7 (6%)</span></p>
<p style="top:248.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">181</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 216</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 219</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 224</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 227</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 250</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 266</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:248.0pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">OP-1</span></p>
<p style="top:248.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:248.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">222</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:262.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2</span></p>
<p style="top:262.0pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 (4%)</span></p>
<p style="top:262.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">209</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 219</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 238</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:262.0pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">AA2P</span></p>
<p style="top:262.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:262.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">266</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:276.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">GDF-5</span></p>
<p style="top:276.0pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 (3%[</span></p>
<p style="top:276.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">48</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 186</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 269</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:276.0pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IL-10</span></p>
<p style="top:276.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:276.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">178</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:290.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">SOX-9</span></p>
<p style="top:290.0pt;left:109.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 (2%)</span></p>
<p style="top:290.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">204</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 221</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:290.0pt;left:325.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">TNF</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:8.0pt">&#x3b1;</span></p>
<p style="top:290.0pt;left:378.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:290.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">178</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:304.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">BMP-4</span></p>
<p style="top:304.0pt;left:109.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 (2%)</span></p>
<p style="top:304.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">227</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:304.0pt;left:324.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">PRP</span></p>
<p style="top:304.0pt;left:377.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:304.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">242</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:318.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">DEX</span></p>
<p style="top:318.0pt;left:109.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 (2%)</span></p>
<p style="top:318.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">224</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 266</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:318.0pt;left:324.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IWP2</span></p>
<p style="top:318.0pt;left:377.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:318.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">171</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:332.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">BMP-7</span></p>
<p style="top:332.0pt;left:109.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:332.0pt;left:152.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">219</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:332.0pt;left:324.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">None</span></p>
<p style="top:332.0pt;left:377.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">15 (14%)</span></p>
<p style="top:332.0pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">52</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 176</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 180</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 185</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 187</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 191</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 194</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 196</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:340.9pt;left:421.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">201</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 212</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 215</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 233</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 236</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 241</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 243</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:354.9pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">PDGF</span></p>
<p style="top:355.0pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (1%)</span></p>
<p style="top:355.0pt;left:152.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">202</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:503.7pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 6</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Length of studies</span></p>
<p style="top:517.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Length of study</span></p>
<p style="top:517.6pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">No. of</span></p>
<p style="top:526.6pt;left:124.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">studies</span></p>
<p style="top:517.6pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">References</span></p>
<p style="top:539.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Up to 1 week</span></p>
<p style="top:539.8pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">9</span></p>
<p style="top:539.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">172</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 203</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 210</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 212</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 224</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 229</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 239</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 266</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:553.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 weeks</span></p>
<p style="top:553.8pt;left:124.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">27</span></p>
<p style="top:553.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">50</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 170</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 174</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 178</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 182</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 189</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 192</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 194</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 198</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:562.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">202</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 215</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 218</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 220</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 223</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 228</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 234</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 235</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 237</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:571.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">240</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 249</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 254</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 260</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">265</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:585.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 weeks</span></p>
<p style="top:585.8pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">36</span></p>
<p style="top:585.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">52</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 53</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 168</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 169</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 173</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 175</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 179</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 180</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 183</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">186</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:594.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">190</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 191</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 195</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 196</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 199</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 200</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 204</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 205</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 209</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 213</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:603.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">217</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 225</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 226</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 230</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 232</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 233</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 236</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 246</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 250</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 256</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:612.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">258</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 269</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:626.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 weeks</span></p>
<p style="top:626.8pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">15</span></p>
<p style="top:626.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">51</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 176</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 181</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 188</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 193</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 201</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 211</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 216</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 219</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:635.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">221</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 241</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 251</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 253</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 255</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 257</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:649.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">5 weeks</span></p>
<p style="top:649.8pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">7</span></p>
<p style="top:649.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">171</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 177</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 206</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 214</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 231</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 259</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 267</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:663.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">5</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 weeks</span></p>
<p style="top:663.8pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">10</span></p>
<p style="top:663.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">48</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 187</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 208</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 222</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 238</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 244</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 247</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 248</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 252</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 268</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:677.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">7 weeks</span></p>
<p style="top:677.8pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:677.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">207</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:691.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">7</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">8 weeks</span></p>
<p style="top:691.8pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:691.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:705.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">8</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">9 weeks</span></p>
<p style="top:705.8pt;left:124.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:705.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 243</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 245</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:719.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not stated</span></p>
<p style="top:719.8pt;left:124.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:719.8pt;left:153.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">242</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 6 of 30</span></p>


<p style="top:267.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">MSCs [103</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">105, 109, 111</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">113, 118, 120, 122</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">125, 129]</span></p>
<p style="top:279.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and from 1.2</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">100 million for adipose-derived MSCs</span></p>
<p style="top:291.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[107, 108, 110, 114]. For synovial MSCs, 8</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">77 million</span></p>
<p style="top:303.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells were used [129, 133], and for peripheral blood</span></p>
<p style="top:315.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">progenitor cells, 20 million cells were used [119].</span></p>
<p style="top:327.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Also,</span></p>
<p style="top:327.4pt;left:86.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the</span></p>
<p style="top:327.4pt;left:108.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">methods</span></p>
<p style="top:327.4pt;left:153.3pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">for</span></p>
<p style="top:327.4pt;left:174.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">implantation</span></p>
<p style="top:327.4pt;left:236.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">varied</span></p>
<p style="top:327.4pt;left:270.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">from</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">arthroscopic implantation (35%) [107, 108, 116, 117,</span></p>
<p style="top:351.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">127, 128, 130</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">133], intra-articular injection [103</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">106,</span></p>
<p style="top:363.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">109</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">112, 114, 115, 119, 121, 123] or open surgery</span></p>
<p style="top:375.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(29%) [113, 118, 120, 122</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">126, 129].</span></p>
<p style="top:387.4pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">In the cell therapy studies, the cells were sus-</span></p>
<p style="top:399.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pended with a variety of different co-stimulators,</span></p>
<p style="top:411.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">including hydroxyapatite (HA) [106, 119, 121, 123],</span></p>
<p style="top:423.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">platelet rich plasma (PRP) [106, 114] and platelet</span></p>
<p style="top:435.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lysate [104]. Some studies also administered multiple</span></p>
<p style="top:447.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">injections of stem cells [119, 121] and/or further</span></p>
<p style="top:459.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">injection of HA [115, 119, 121, 123], PRP [106,</span></p>
<p style="top:471.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">114] or nucleated cells [104] following a stem cell</span></p>
<p style="top:483.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">injection.</span></p>
<p style="top:267.4pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The most frequently used scaffolds were type I</span></p>
<p style="top:279.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">collagen of porcine or bovine origin [113, 118, 122,</span></p>
<p style="top:291.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">124, 126, 129], followed by ascorbic acid sheet [120,</span></p>
<p style="top:303.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">123] and platelet-rich fibrin glue mixture [108, 125].</span></p>
<p style="top:327.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Rehabilitation</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Early continuous passive motion was</span></p>
<p style="top:339.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">employed in 14 studies [113, 117</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">122, 124</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">127, 129</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span></p>
<p style="top:351.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">131]. Six studies did not report details on post-</span></p>
<p style="top:363.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">operation</span></p>
<p style="top:363.4pt;left:352.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">rehabilitation</span></p>
<p style="top:363.4pt;left:417.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[104</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">106,</span></p>
<p style="top:363.4pt;left:466.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">109,</span></p>
<p style="top:363.4pt;left:492.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">116,</span></p>
<p style="top:363.4pt;left:518.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">132].</span></p>
<p style="top:375.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Three studies aimed for full weight bearing very early</span></p>
<p style="top:387.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">by week 4 [107, 108, 122] whereas 11 studies (40%)</span></p>
<p style="top:399.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">aimed for full weight bearing by the 6th</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">8th week</span></p>
<p style="top:411.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[113, 117</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">121, 124, 125, 127, 131, 133]. No study</span></p>
<p style="top:423.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">addressed the effect of rehabilitation on the quality of</span></p>
<p style="top:435.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the repair.</span></p>
<p style="top:459.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Outcomes</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> Most commonly used outcome measures for</span></p>
<p style="top:471.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">treatment efficacy were radiological (77%) [103</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">106,</span></p>
<p style="top:483.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">109</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">112, 115</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">117, 119, 121, 123</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">125, 127</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">134] and</span></p>
<p style="top:495.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">arthroscopic assessment (61%) [107, 108, 113, 116</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">122,</span></p>
<p style="top:507.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">124</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">126,</span></p>
<p style="top:507.4pt;left:350.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">130</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">133].</span></p>
<p style="top:507.4pt;left:399.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Most</span></p>
<p style="top:507.4pt;left:428.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">commonly</span></p>
<p style="top:507.4pt;left:480.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">used</span></p>
<p style="top:507.4pt;left:506.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">patient-</span></p>
<p style="top:519.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">reported outcomes are International Knee Documenta-</span></p>
<p style="top:531.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tion Committee (IKDC) score (36%), followed by a visual</span></p>
<p style="top:543.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">analogue scale (VAS) pain (39%) and Tegner activity</span></p>
<p style="top:555.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">scale (29%).</span></p>
<p style="top:579.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:JcmsqlAdvTT4fa15320.B,serif;font-size:9.8pt;color:#131313">Adverse effects</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> None of the studies reported any severe</span></p>
<p style="top:591.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">adverse effects related to the MSC treatment. Two</span></p>
<p style="top:603.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">group reported minor adverse events including mild</span></p>
<p style="top:615.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pain and effusion after the injections, which persisted</span></p>
<p style="top:627.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">for no more than 7 days [103, 114].</span></p>
<p style="top:651.1pt;left:304.7pt;line-height:10.3pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Conclusions</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">There is a growing fascination with the role of mesen-</span></p>
<p style="top:675.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chymal stem cells in cartilage repair.</span></p>
<p style="top:687.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">As early as the 1950s, Pridie showed fibrocartilagi-</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">nous repair through subchondral drilling [135</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">137].</span></p>
<p style="top:711.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Initially, Pridie drilling was reported as a treatment</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">for osteoarthritis [135, 138] and was often associated</span></p>
<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 7</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Types of techniques used to assess chondrogenesis of MSCs</span></p>
<p style="top:101.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Type of techniques</span></p>
<p style="top:101.8pt;left:157.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">No. of studies (%) References</span></p>
<p style="top:115.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Histology</span></p>
<p style="top:115.0pt;left:157.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">87 (79%)</span></p>
<p style="top:115.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">48</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 50</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">53</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 168</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">170</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 173</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">175</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 177</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">179</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 181</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">187</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 191</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">195</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 197</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">201</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 204</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">211</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 213</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">217</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 219</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">222</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 226</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:124.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">229</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 230</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 232</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">238</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 240</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">248</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 250</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 252</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">264</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 267</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:138.0pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Immunohistochemistry</span></p>
<p style="top:138.0pt;left:157.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">78 (71%)</span></p>
<p style="top:138.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">48</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 50</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 52</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 53</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 168</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">171</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 173</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">175</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 178</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">183</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 185</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">191</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 193</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 194</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 198</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 201</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 203</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">205</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 207</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 212</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">215</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:147.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">217</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 218</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 220</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 221</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 224</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 226</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 228</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">238</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 241</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 242</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 244</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 246</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">248</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 250</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">259</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 264</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 265</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 267</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:161.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">qPCR</span></p>
<p style="top:161.0pt;left:157.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">70 (64%)</span></p>
<p style="top:161.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">53</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 168</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 169</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 173</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 174</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 176</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 178</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">186</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 188</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 190</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 192</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">194</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 196</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 199</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 200</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 202</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">205</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 207</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">209</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 211</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 214</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 216</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">220</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:170.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">222</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">232</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 235</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 236</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 239</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 240</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 242</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 246</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 249</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">251</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 256</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 258</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 259</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 261</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">263</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 265</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">267</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 269</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">271</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:184.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Biochemical analysis</span></p>
<p style="top:184.0pt;left:157.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">64 (58%)</span></p>
<p style="top:184.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">48</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 50</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">52</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 168</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 170</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">172</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 176</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 177</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 179</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 180</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 182</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">184</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 188</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 189</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 191</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 192</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 199</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 200</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 202</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 204</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 205</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:193.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">209</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 212</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 214</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 216</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">219</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 222</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">224</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 226</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 227</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 233</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">240</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 244</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 245</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 247</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">249</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 252</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 254</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 257</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 260</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">266</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 268</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">270</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:207.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Imaging (confocal, SEM, TEM)</span></p>
<p style="top:207.0pt;left:157.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">24 (22%)</span></p>
<p style="top:207.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">52</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 172</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 176</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 180</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 185</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 187</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 194</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 198</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 208</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 215</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">217</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 225</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 226</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 230</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 232</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 241</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 242</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 249</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 252</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 255</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 262</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 263</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 265</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:221.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mechanical testing</span></p>
<p style="top:221.0pt;left:157.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">15 (14%)</span></p>
<p style="top:221.0pt;left:219.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">51</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 52</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 164</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 169</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 175</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 193</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 197</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 207</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 220</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 245</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 247</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 248</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 256</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 257</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 268</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:528.7pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 8</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Different species of animals used to assess reparative</span></p>
<p style="top:539.7pt;left:56.7pt;line-height:9.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313">effect of MSCs on cartilage defect</span></p>
<p style="top:553.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Animals</span></p>
<p style="top:553.6pt;left:97.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">No. of</span></p>
<p style="top:562.6pt;left:97.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">studies (%)</span></p>
<p style="top:553.6pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">References</span></p>
<p style="top:575.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Rabbits</span></p>
<p style="top:575.8pt;left:97.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">57 (51%)</span></p>
<p style="top:575.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">49</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 54</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">102</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 134</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 150</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">154</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 161</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 207</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 272</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">324</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:589.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Pigs</span></p>
<p style="top:589.8pt;left:97.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">16 (14%)</span></p>
<p style="top:589.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">61</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 62</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 68</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">72</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 87</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 90</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 153</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 273</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 276</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 279</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 290</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:598.8pt;left:137.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">308</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">310</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:612.8pt;left:56.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Rats</span></p>
<p style="top:612.8pt;left:97.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">13 (12%)</span></p>
<p style="top:612.8pt;left:137.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">60</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 78</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">82</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 91</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 152</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 278</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 286</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 311</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 312</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:626.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Sheep</span></p>
<p style="top:626.8pt;left:97.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">8 (7%)</span></p>
<p style="top:626.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">89</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 272</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 282</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 283</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 313</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">316</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:640.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Goats</span></p>
<p style="top:640.8pt;left:97.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">5 (5%)</span></p>
<p style="top:640.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">49</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 95</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 100</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 101</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 318</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:654.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Horses</span></p>
<p style="top:654.8pt;left:97.0pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 (4%)</span></p>
<p style="top:654.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">55</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 96</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 98</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 317</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:668.7pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Dogs</span></p>
<p style="top:668.8pt;left:97.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 (4%)</span></p>
<p style="top:668.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">86</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 97</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 151</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 287</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:682.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Monkeys</span></p>
<p style="top:682.8pt;left:97.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 (2%)</span></p>
<p style="top:682.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">319</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 320</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:696.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Guinea</span></p>
<p style="top:705.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">pigs</span></p>
<p style="top:696.8pt;left:97.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:696.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">281</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:719.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Donkeys</span></p>
<p style="top:719.8pt;left:97.1pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:719.8pt;left:137.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">57</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:496.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 7 of 30</span></p>


<p style="top:687.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with many additional procedures such as synovectomy</span></p>
<p style="top:699.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and trimming of osteophytes.</span></p>
<p style="top:711.4pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Since Pridie</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2019;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">s initial experiments, the process of mar-</span></p>
<p style="top:723.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">row stimulation techniques or exposure of mesenchymal</span></p>
<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 9</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Table showing the types of scaffold used in animal</span></p>
<p style="top:98.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313">studies</span></p>
<p style="top:112.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Scaffold type</span></p>
<p style="top:112.6pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">No. of</span></p>
<p style="top:120.7pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">studies</span></p>
<p style="top:112.6pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">References</span></p>
<p style="top:132.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">No Scaffold</span></p>
<p style="top:132.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">19 (17%)</span></p>
<p style="top:132.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">49</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 54</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 61</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 70</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 72</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">75</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 81</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:140.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">86</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 89</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">91</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 97</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 100</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 102</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:148.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">280</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">282</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 284</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:161.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Poly (lactide-co-glycoside) PLGA</span></p>
<p style="top:161.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">17 (16%)</span></p>
<p style="top:161.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">56</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 59</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 62</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 63</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 83</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 88</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 150</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:169.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">153</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 277</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 285</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 286</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:177.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">289</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">292</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 316</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:190.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Fibrin/Fribrin glue</span></p>
<p style="top:190.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">11 (9%)</span></p>
<p style="top:190.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">55</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 64</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 76</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">78</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 152</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 278</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:198.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">293</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 308</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 317</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 318</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:211.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hydrogel</span></p>
<p style="top:211.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">9 (8%)</span></p>
<p style="top:211.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">65</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 69</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 81</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 94</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 279</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 288</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 314</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:219.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">321</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 323</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:232.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Collagen</span></p>
<p style="top:232.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">9 (8%)</span></p>
<p style="top:232.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">79</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 80</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 134</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 276</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 299</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 301</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:240.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">309</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 320</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 322</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:253.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hyaluronic acid</span></p>
<p style="top:253.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">7 (6%)</span></p>
<p style="top:253.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">57</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 92</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 95</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 96</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 273</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 304</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:261.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">324</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:274.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Alginate beads</span></p>
<p style="top:274.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">4 (3%)</span></p>
<p style="top:274.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">65</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 84</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 101</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 294</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:287.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Tissue membrane</span></p>
<p style="top:287.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">4 (3%)</span></p>
<p style="top:287.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">82</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 98</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 303</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 305</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:300.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polyglycolic acid</span></p>
<p style="top:300.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3 (3%)</span></p>
<p style="top:300.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">99</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 161</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 274</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:313.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">PGA/PLA</span></p>
<p style="top:313.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3 (3%)</span></p>
<p style="top:313.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">68</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 290</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 296</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:326.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hylauronan crosslinked matrix</span></p>
<p style="top:326.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2 (2%)</span></p>
<p style="top:326.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">154</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 297</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:339.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Poly-L-lactide-co-caprolactone</span></p>
<p style="top:339.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2 (2%)</span></p>
<p style="top:339.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">275</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 300</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:352.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polycaprolactone cartilage (PCL)</span></p>
<p style="top:352.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2 (2%)</span></p>
<p style="top:352.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">87</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 272</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:365.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Animal-origin osteochondral plug scaffold</span></p>
<p style="top:365.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2 (2%)</span></p>
<p style="top:365.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">272</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 298</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:378.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Chitosan microspheres and fibrin glue</span></p>
<p style="top:378.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:378.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">60</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:391.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Gel carries (collagen/HA/Fibrogen)</span></p>
<p style="top:391.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:391.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">71</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:404.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Polychoxanone/poly(vinyl alcholo) PDO/PVA</span></p>
<p style="top:404.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:404.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">302</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:417.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Cartilage aggregate</span></p>
<p style="top:417.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:417.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">306</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:430.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Collagen/glycosaminoglycan porous</span></p>
<p style="top:438.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">titanium biphasic scaffold</span></p>
<p style="top:430.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:430.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">151</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:451.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Articular chondrocyte seeded matrix</span></p>
<p style="top:459.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">associated autologous chondrocyte</span></p>
<p style="top:467.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">transplant (MACT)</span></p>
<p style="top:451.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:451.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">313</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:480.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">MSC-ADM (accellulo-dermal matrix)</span></p>
<p style="top:480.8pt;left:183.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:480.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">319</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:493.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hyaff-11 scaffold</span></p>
<p style="top:493.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:493.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">295</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:506.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Porous-gelatin-chonroitin hyaluronate</span></p>
<p style="top:506.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:506.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">291</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:519.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Bone protein 7 PCL</span></p>
<p style="top:519.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:519.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">66</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:532.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Human acellular amniotic membrane</span></p>
<p style="top:532.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:532.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">307</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:545.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Pluronic-F 127</span></p>
<p style="top:545.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:545.8pt;left:216.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">102</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:558.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Tricalcium phosphate</span></p>
<p style="top:558.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:558.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">315</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:571.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Agarose</span></p>
<p style="top:571.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:571.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">311</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:584.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">GCH-GCBB</span></p>
<p style="top:584.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:584.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">93</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:597.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">ACHMS (atelocollagen honeycomb-shaped</span></p>
<p style="top:605.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">membrane)</span></p>
<p style="top:597.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:597.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">58</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:618.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Magnet</span></p>
<p style="top:618.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:618.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">310</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:631.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Human cartilage extra cellular matrix 3D</span></p>
<p style="top:639.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">porous acellular</span></p>
<p style="top:631.8pt;left:183.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:631.8pt;left:216.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">67</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:87.9pt;left:304.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 10</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Table showing growth factors used in animal studies</span></p>
<p style="top:101.8pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Growth factor</span></p>
<p style="top:101.8pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">No. of</span></p>
<p style="top:110.8pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">studies</span></p>
<p style="top:101.8pt;left:438.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">References</span></p>
<p style="top:124.0pt;left:304.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3/1/2</span></p>
<p style="top:124.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">17</span></p>
<p style="top:133.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(15%)</span></p>
<p style="top:124.0pt;left:438.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">56</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 65</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 66</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 70</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 76</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 85</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 90</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 100</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:133.0pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">280</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 282</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 285</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 287</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 290</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 291</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 309</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span></p>
<p style="top:142.0pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">311</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 323</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:156.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">CDMP</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:156.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 (2%)</span></p>
<p style="top:156.0pt;left:438.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">56</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 134</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:170.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">FGF-2</span></p>
<p style="top:170.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 (2%)</span></p>
<p style="top:170.0pt;left:438.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">90</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> 304</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:184.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Ad-hTGF-B1</span></p>
<p style="top:184.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:184.0pt;left:438.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">321</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:198.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">AdBMP</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2</span></p>
<p style="top:198.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:198.0pt;left:438.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">78</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:212.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">chABC</span></p>
<p style="top:212.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:212.0pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">74</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:226.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">PRP</span></p>
<p style="top:226.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:226.0pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">75</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:240.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Gene modified MSCs (gene</span></p>
<p style="top:249.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">modification to BcL-xL gene)</span></p>
<p style="top:240.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:240.0pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">299</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:263.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">hiGF-1-DNA</span></p>
<p style="top:263.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:263.0pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">101</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:277.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">AdIGF</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:277.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:277.0pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">78</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:291.0pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">rHuBMP</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2</span></p>
<p style="top:291.0pt;left:404.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:291.0pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">82</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:304.9pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Ham-F-12</span></p>
<p style="top:304.9pt;left:404.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:304.9pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">303</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:318.9pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NaO11</span></p>
<p style="top:318.9pt;left:404.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:318.9pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">277</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:332.9pt;left:304.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NSC23766-Rac1 inhibitor</span></p>
<p style="top:332.9pt;left:404.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 (&lt;1%)</span></p>
<p style="top:332.9pt;left:438.6pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">60</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:434.7pt;left:304.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 11</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Outcome measures used in animal studies (some</span></p>
<p style="top:445.7pt;left:304.7pt;line-height:9.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313">studies used more than one outcome measure)</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Outcome score</span></p>
<p style="top:459.5pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">No. of studies</span></p>
<p style="top:467.4pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">using the</span></p>
<p style="top:475.4pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">score (%)</span></p>
<p style="top:459.5pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">References</span></p>
<p style="top:487.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Histology scores</span></p>
<p style="top:487.6pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">111 (100%)</span></p>
<p style="top:487.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">49</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 54</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">102</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 134</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 150</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">154</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 161</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:495.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">272</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">324</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:508.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">International Cartilage</span></p>
<p style="top:516.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Repair Society Score</span></p>
<p style="top:508.6pt;left:384.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">26 (23%)</span></p>
<p style="top:508.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">49</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 60</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 61</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 63</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 66</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 69</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 72</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 74</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 79</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 89</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 92</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:516.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">94</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 98</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 99</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 272</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 282</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 283</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 289</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 305</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 306</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:524.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">310</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 313</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 314</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 316</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 319</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 324</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:537.6pt;left:304.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Wakitani score</span></p>
<p style="top:537.6pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">21 (19%)</span></p>
<p style="top:537.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">58</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 62</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 67</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 68</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 72</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 73</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 80</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 82</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 97</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 151</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:545.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">273</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 277</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 279</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 284</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 285</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 290</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 299</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 304</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:553.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">310</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 321</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:566.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">O</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Driscoll score</span></p>
<p style="top:566.6pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2018%</span></p>
<p style="top:566.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">49</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 71</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 81</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 84</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 85</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 93</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 100</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 272</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 276</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:574.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">290</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 296</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">298</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 302</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 306</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 308</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 313</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 314</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 322</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:587.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Functional scores/</span></p>
<p style="top:595.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">mechanical</span></p>
<p style="top:587.6pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">11 (10%)</span></p>
<p style="top:587.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">55</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 57</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 62</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 67</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 69</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 81</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 101</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 277</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 287</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:595.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">290</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 315</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:608.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">MRI scores</span></p>
<p style="top:608.6pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">5 (5%)</span></p>
<p style="top:608.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">63</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 69</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 96</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 101</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 316</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:621.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Arthroscopy scores</span></p>
<p style="top:621.6pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">5 (5%)</span></p>
<p style="top:621.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">72</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 96</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 310</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 317</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 318</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:634.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Macroscopic osteoarthritis</span></p>
<p style="top:642.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">score</span></p>
<p style="top:634.6pt;left:384.0pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3 (3%)</span></p>
<p style="top:634.6pt;left:428.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">57</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 281</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 295</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:655.6pt;left:304.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Pineda score</span></p>
<p style="top:655.6pt;left:384.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">3 (3%)</span></p>
<p style="top:655.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">290</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 293</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 309</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:668.6pt;left:304.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Schreiber score</span></p>
<p style="top:668.6pt;left:384.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2 (2%)</span></p>
<p style="top:668.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">101</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 300</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:681.6pt;left:304.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Britternberg score</span></p>
<p style="top:681.6pt;left:384.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">2 (2%)</span></p>
<p style="top:681.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">84</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 85</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:694.6pt;left:304.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Slochagg score</span></p>
<p style="top:694.6pt;left:384.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:694.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">300</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:707.6pt;left:304.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Moran score</span></p>
<p style="top:707.6pt;left:384.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:707.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">64</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:720.6pt;left:304.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Gill score</span></p>
<p style="top:720.6pt;left:384.1pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">1 (&lt;1%)</span></p>
<p style="top:720.6pt;left:428.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">95</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 8 of 30</span></p>


<p style="top:315.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stem cells from cancellous bone has changed its guise</span></p>
<p style="top:327.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">on several occasions.</span></p>
<p style="top:339.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Ficat in 1979 described</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Spongialization</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> in which</span></p>
<p style="top:351.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the cancellous bed was exposed in 85 patients with</span></p>
<p style="top:363.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chondral lesions of the patella with encouraging re-</span></p>
<p style="top:375.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sults [139]. Johnson et al. [140] described abrasion</span></p>
<p style="top:387.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">arthroplasty</span></p>
<p style="top:387.4pt;left:115.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and</span></p>
<p style="top:387.4pt;left:138.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">encouraged</span></p>
<p style="top:387.4pt;left:194.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">its</span></p>
<p style="top:387.4pt;left:212.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">use</span></p>
<p style="top:387.4pt;left:234.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">especially</span></p>
<p style="top:387.4pt;left:282.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in</span></p>
<p style="top:399.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">younger patients [141, 142]. Other authors had less</span></p>
<p style="top:411.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">positive outcomes [143</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">146]. Dandy wrote an enter-</span></p>
<p style="top:423.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">taining</span></p>
<p style="top:423.4pt;left:93.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">article</span></p>
<p style="top:423.4pt;left:127.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">on</span></p>
<p style="top:423.4pt;left:146.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">abrasion</span></p>
<p style="top:423.4pt;left:189.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">arthroplasty</span></p>
<p style="top:423.4pt;left:247.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">where</span></p>
<p style="top:423.4pt;left:280.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">he</span></p>
<p style="top:435.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">highlighted that at least in the treatment of osteo-</span></p>
<p style="top:447.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">arthritis, its effects could relate to the arthroscopic</span></p>
<p style="top:459.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">washout, rest or even the placebo effects of the cha-</span></p>
<p style="top:471.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">rismatic surgeon [147]. The final evolution of marrow</span></p>
<p style="top:483.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stimulation</span></p>
<p style="top:483.4pt;left:112.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">was</span></p>
<p style="top:483.4pt;left:135.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the</span></p>
<p style="top:483.4pt;left:156.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">term</span></p>
<p style="top:483.4pt;left:184.7pt;line-height:9.8pt"><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Microfracture</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span></p>
<p style="top:483.4pt;left:258.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">enabled</span></p>
<p style="top:495.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">by commercially manufactured bone picks used to</span></p>
<p style="top:507.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">breach the subchondral bone [8]. Marrow-stimulating</span></p>
<p style="top:519.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">technique</span></p>
<p style="top:519.4pt;left:106.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">procedures,</span></p>
<p style="top:519.4pt;left:164.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in</span></p>
<p style="top:519.4pt;left:181.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">particular</span></p>
<p style="top:519.4pt;left:231.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">microfracture,</span></p>
<p style="top:531.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">are now considered the first-line treatment for full-</span></p>
<p style="top:543.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">thickness</span></p>
<p style="top:543.4pt;left:103.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cartilage</span></p>
<p style="top:543.4pt;left:146.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lesions</span></p>
<p style="top:543.4pt;left:183.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and</span></p>
<p style="top:543.4pt;left:206.3pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">have</span></p>
<p style="top:543.4pt;left:233.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">demonstrated</span></p>
<p style="top:87.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">good to excellent results in 60</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">80% of patients [148,</span></p>
<p style="top:99.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">149].</span></p>
<p style="top:111.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Cartilage repair has evolved from marrow stimula-</span></p>
<p style="top:123.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tion techniques through to chondrocyte transplant</span></p>
<p style="top:135.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and now stem cells at rapid pace. An ideal transla-</span></p>
<p style="top:147.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tional pipeline would demonstrate how in vitro data</span></p>
<p style="top:159.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">was used to inform a pre-clinical model, which would</span></p>
<p style="top:171.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">later form a phase I/IIa first-in-man study and subse-</span></p>
<p style="top:183.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">quently a phase III clinical trial. This would of course</span></p>
<p style="top:195.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">be the safe and responsible method by which novel</span></p>
<p style="top:207.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">therapies are brought to the market.</span></p>
<p style="top:219.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">This systematic review is the first of its kind to explore</span></p>
<p style="top:231.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the full spectrum of evidence from in vitro studies,</span></p>
<p style="top:243.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">through animal studies to human clinical trials, and yet,</span></p>
<p style="top:255.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">we found little evidence of connectivity between in vitro,</span></p>
<p style="top:267.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">animal and then human work. In fact, we did not find a</span></p>
<p style="top:279.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">single group that had carried out and reported studies in</span></p>
<p style="top:291.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">all three categories.</span></p>
<p style="top:303.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Indeed, even from groups, which showed a seemingly</span></p>
<p style="top:315.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">hierarchical</span></p>
<p style="top:315.4pt;left:362.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">approach</span></p>
<p style="top:315.4pt;left:410.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">to</span></p>
<p style="top:315.4pt;left:428.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">translation,</span></p>
<p style="top:315.4pt;left:484.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">discrepancies</span></p>
<p style="top:327.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">became apparent. For example, Saw et al. from Korea</span></p>
<p style="top:339.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">used a pre-clinical goat model to repair cartilage defects</span></p>
<p style="top:351.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">using HA plus bone marrow-derived cells [150] and then</span></p>
<p style="top:363.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">moved into a first-in-man study, but in doing so, elected</span></p>
<p style="top:375.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">to change from bone marrow aspirate to peripheral</span></p>
<p style="top:387.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">blood and justified this change because it was easier to</span></p>
<p style="top:399.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">harvest peripheral blood than marrow [151].</span></p>
<p style="top:411.4pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">There are several sources of cells that have been</span></p>
<p style="top:423.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">used in cartilage repair including bone marrow, per-</span></p>
<p style="top:435.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ipheral blood, synovium, adipose tissue and umbilicus</span></p>
<p style="top:447.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(Table 14) without any clear evidence of superiority</span></p>
<p style="top:459.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of one over the other.</span></p>
<p style="top:484.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">One stage vs. two stages</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">As two stage procedures involving cell culture are</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">expensive and cumbersome, there is an increasing push</span></p>
<p style="top:519.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">towards a single stage stem cell treatment. In this</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">situation there is some supportive pre-clinical data</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[91, 95, 98, 152</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">154], but there does not appear to</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">be a pre-clinical study that directly compares bone</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">marrow concentrates against cultured MSCs.</span></p>
<p style="top:579.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Several groups have reported the use of bone marrow</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">concentrates in clinical practice [116, 117, 127, 128,</span></p>
<p style="top:603.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">130</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">132], in which the buffy coat is used containing the</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">nucleated cells, of which a few will be stem cells.</span></p>
<p style="top:627.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Briefly, the patient has approximately 60 mL of bone</span></p>
<p style="top:639.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">marrow harvested from the iliac crest which is then</span></p>
<p style="top:651.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">spun down in a cell centrifuge (SmartPrep, Harvest</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Technologies</span></p>
<p style="top:663.5pt;left:368.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Corp.,</span></p>
<p style="top:663.5pt;left:402.3pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">USA,</span></p>
<p style="top:663.5pt;left:433.0pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">or</span></p>
<p style="top:663.5pt;left:450.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">IOR-G1,</span></p>
<p style="top:663.5pt;left:494.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Novagenit,</span></p>
<p style="top:675.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Mezzolombardo, TN, Italy) to provide 6 mL of concentrate</span></p>
<p style="top:687.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">containing nucleated cells. A small amount of the nucle-</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ated cells are then placed onto a hyaluronic acid mem-</span></p>
<p style="top:711.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">brane (Hyalofast, Fidia Advanced Biopolymers, Italy) or</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">collagen membrane (IOR-G1, Novagenit, Mezzolombardo,</span></p>
<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 12</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Analysis technique used on repaired tissue</span></p>
<p style="top:101.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Analysis used</span></p>
<p style="top:101.6pt;left:119.2pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">No. of</span></p>
<p style="top:109.7pt;left:119.2pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">studies (%)</span></p>
<p style="top:101.6pt;left:155.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">References</span></p>
<p style="top:121.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Hyaline-like</span></p>
<p style="top:129.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">cartilage</span></p>
<p style="top:121.8pt;left:119.2pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">88 (79%)</span></p>
<p style="top:121.8pt;left:155.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">49</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 54</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">56</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 58</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 59</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 61</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 62</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 64</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">69</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 71</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">73</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 75</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:129.8pt;left:155.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">76</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 78</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">89</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 92</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 95</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 97</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 98</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 100</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 101</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 134</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 150</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">152</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:137.8pt;left:155.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">154</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 161</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 273</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">280</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 285</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">302</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 304</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 305</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 307</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:145.8pt;left:155.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">309</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 310</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 312</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 314</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">324</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:158.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Collagen type II</span></p>
<p style="top:158.8pt;left:119.2pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">84 (76%)</span></p>
<p style="top:158.8pt;left:155.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">54</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 56</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">59</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 62</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 65</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">73</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 75</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">88</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 90</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 91</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 93</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">96</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 98</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:166.8pt;left:155.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">100</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">102</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 134</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 150</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">154</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 161</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 272</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">276</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:174.8pt;left:155.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">278</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">282</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 284</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">288</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 292</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 294</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">296</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 300</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 302</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">306</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:182.8pt;left:155.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">308</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 309</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 311</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 313</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">315</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 317</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">319</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 321</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 323</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:195.8pt;left:56.9pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Cluster</span></p>
<p style="top:203.8pt;left:56.9pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Chondrocytes</span></p>
<p style="top:195.8pt;left:119.2pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">34 (31%)</span></p>
<p style="top:195.8pt;left:155.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">57</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 60</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 62</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 63</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 72</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 74</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 77</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 78</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 80</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 81</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 83</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 84</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 91</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 97</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:203.8pt;left:155.4pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">102</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 151</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 152</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 161</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 273</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 276</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 280</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 281</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 283</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 291</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:211.8pt;left:155.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">292</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 296</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 297</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 304</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 312</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 318</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 319</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 322</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 324</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:224.8pt;left:56.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Glycosaminoglycan</span></p>
<p style="top:224.8pt;left:119.2pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">40 (36%)</span></p>
<p style="top:224.8pt;left:155.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">49</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 62</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 65</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 67</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">71</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 73</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">75</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 81</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 85</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 87</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 94</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 96</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">101</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:232.8pt;left:155.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">160</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 272</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 274</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 279</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 282</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 286</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 288</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 290</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 291</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 296</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:240.8pt;left:155.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">300</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 301</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 308</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 309</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 311</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 312</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 315</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 319</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 323</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:253.8pt;left:56.8pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Genes</span></p>
<p style="top:253.8pt;left:119.3pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">22 (20%)</span></p>
<p style="top:253.8pt;left:155.6pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">56</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 60</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 61</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 63</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 64</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 66</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 78</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 80</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 82</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 90</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 94</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 96</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 134</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span></p>
<p style="top:261.8pt;left:155.7pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">275</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 277</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 283</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 285</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 294</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 311</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 316</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 321</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 323</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:274.8pt;left:56.9pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">Proteoglycan</span></p>
<p style="top:274.8pt;left:119.2pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">8 (7%)</span></p>
<p style="top:274.8pt;left:155.5pt;line-height:7.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313">56</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 63</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 84</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 95</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 98</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 287</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 294</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt;color:#131313"> 295</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:586.1pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 13</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Number of publications for each study type and phase</span></p>
<p style="top:599.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">Category</span></p>
<p style="top:599.9pt;left:187.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">No. of studies</span></p>
<p style="top:608.2pt;left:187.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">(total 28)</span></p>
<p style="top:599.9pt;left:234.9pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">References</span></p>
<p style="top:620.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">Phases of clinical studies</span></p>
<p style="top:633.9pt;left:64.0pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">Pilot/feasibility study incl. case report</span></p>
<p style="top:633.9pt;left:187.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">15 (54%)</span></p>
<p style="top:633.9pt;left:234.9pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">104</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 118</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 119</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span></p>
<p style="top:642.2pt;left:234.9pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">122</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 124</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">129</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">]</span></p>
<p style="top:655.5pt;left:64.0pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">Phase 1 (safety assessment)</span></p>
<p style="top:655.5pt;left:187.6pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">8 (26%)</span></p>
<p style="top:655.5pt;left:234.9pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">109</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 116</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 123</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span></p>
<p style="top:663.8pt;left:234.9pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">130</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 131</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">]</span></p>
<p style="top:677.1pt;left:64.0pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">Phase 2 (efficacy assessment)</span></p>
<p style="top:677.1pt;left:187.6pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">8 (26%)</span></p>
<p style="top:677.1pt;left:234.9pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 113</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">115</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span></p>
<p style="top:685.4pt;left:234.9pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">120</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 121</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">]</span></p>
<p style="top:698.7pt;left:64.0pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">Phase 3 (large scale efficacy assessment</span></p>
<p style="top:707.0pt;left:64.0pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">through a multi-centre RCT)</span></p>
<p style="top:698.7pt;left:187.6pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">0 (0%)</span></p>
<p style="top:698.7pt;left:234.8pt;line-height:7.3pt"><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt">&#x2013;</span></p>
<p style="top:720.3pt;left:64.0pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">Phase 4 (post-market surveillance)</span></p>
<p style="top:720.3pt;left:187.6pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt">0 (0%)</span></p>
<p style="top:720.3pt;left:234.8pt;line-height:7.3pt"><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt">&#x2013;</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 9 of 30</span></p>


<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 14</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Summary of the published clinical studies</span></p>
<p style="top:101.6pt;left:56.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Category</span></p>
<p style="top:101.6pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">No. of</span></p>
<p style="top:109.7pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">studies</span></p>
<p style="top:101.6pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">References</span></p>
<p style="top:122.0pt;left:56.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Cell source</span></p>
<p style="top:135.1pt;left:63.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Bone marrow</span></p>
<p style="top:135.1pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">22 (71%)</span></p>
<p style="top:135.1pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">105</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 111</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">113</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:143.2pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">115</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">118</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 120</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 122</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">128</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:151.3pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">130</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:164.4pt;left:63.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Adipose</span></p>
<p style="top:164.4pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">5 (16%)</span></p>
<p style="top:164.4pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">106</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 110</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 114</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:177.5pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Peripheral blood</span></p>
<p style="top:177.5pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:177.5pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">119</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 121</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:190.6pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Synovium</span></p>
<p style="top:190.6pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:190.6pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">129</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:203.7pt;left:56.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Cell delivery</span></p>
<p style="top:216.8pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Arthroscopic implantation</span></p>
<p style="top:229.9pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Hyaluronic acid membrane</span></p>
<p style="top:229.9pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:229.9pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 130</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:242.9pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Hyaluronic acid with fibrin</span></p>
<p style="top:251.1pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">glue or platelet gel</span></p>
<p style="top:242.9pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:242.9pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">116</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 128</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:264.1pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Polyglycolic acid/hyaluronan</span></p>
<p style="top:264.1pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:264.1pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">127</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 131</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:277.3pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Collagen with platelet gel</span></p>
<p style="top:277.3pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:277.3pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">116</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:290.4pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Fibrin glue</span></p>
<p style="top:290.4pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:290.4pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:303.5pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">HYAFF 11 scaffold</span></p>
<p style="top:303.5pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:303.5pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:316.6pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Acetate Ringer solution</span></p>
<p style="top:316.6pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:316.6pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:329.7pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Unspecified</span></p>
<p style="top:329.7pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:329.7pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">107</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:342.8pt;left:56.6pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Intra-articular injection</span></p>
<p style="top:355.9pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">PBS only</span></p>
<p style="top:355.9pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:355.9pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">104</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 110</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:368.9pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">PBS with HA</span></p>
<p style="top:368.9pt;left:175.0pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:368.9pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">119</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 121</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:382.0pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Autologous serum</span></p>
<p style="top:382.0pt;left:175.0pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:382.0pt;left:217.0pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">115</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 123</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:395.1pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Ringer lactate solution</span></p>
<p style="top:395.1pt;left:175.0pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">3 (10%)</span></p>
<p style="top:395.1pt;left:217.0pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 111</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:408.2pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">PBS with serum albumin</span></p>
<p style="top:408.3pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:408.3pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">105</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:421.4pt;left:70.9pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">HA and PRP</span></p>
<p style="top:421.4pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:421.4pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">106</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:434.5pt;left:70.9pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">PRP</span></p>
<p style="top:434.5pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:434.5pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">114</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:447.6pt;left:70.9pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Commercial serum</span></p>
<p style="top:447.6pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:447.6pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">109</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:460.7pt;left:56.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Transplantation by open surgery</span></p>
<p style="top:473.8pt;left:70.9pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Collagen</span></p>
<p style="top:473.8pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">6 (21%)</span></p>
<p style="top:473.8pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 113</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 118</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 122</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 124</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:481.9pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">126</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 129</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:495.0pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Ascorbic acid-mediated sheet</span></p>
<p style="top:495.0pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (7%)</span></p>
<p style="top:495.0pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">120</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 123</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:508.1pt;left:70.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Fibrin glue</span></p>
<p style="top:508.1pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (4%)</span></p>
<p style="top:508.1pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:521.2pt;left:56.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Cell dose</span></p>
<p style="top:534.3pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Less than 10 million</span></p>
<p style="top:534.3pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">8 (26%)</span></p>
<p style="top:534.3pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">105</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 107</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 114</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 120</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:542.4pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">122</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 124</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 129</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:555.5pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">10</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">20 million</span></p>
<p style="top:555.5pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">5 (16%)</span></p>
<p style="top:555.5pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">113</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 118</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 119</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 123</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:568.6pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Over 20 million</span></p>
<p style="top:568.6pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">7 (23%)</span></p>
<p style="top:568.6pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 104</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:581.7pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Unspecified</span></p>
<p style="top:581.7pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">11 (35%)</span></p>
<p style="top:581.7pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">106</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 115</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 121</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:589.8pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">126</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">128</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 130</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:602.9pt;left:56.6pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Follow-up</span></p>
<p style="top:616.0pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Up to 6 months</span></p>
<p style="top:616.0pt;left:175.0pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">4 (13%)</span></p>
<p style="top:616.0pt;left:217.0pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">104</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">106</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 110</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:629.1pt;left:63.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Up to 12 months</span></p>
<p style="top:629.1pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">6 (19%)</span></p>
<p style="top:629.1pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 111</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 124</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 127</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:642.2pt;left:63.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Up to 2 years</span></p>
<p style="top:642.2pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">11 (35%)</span></p>
<p style="top:642.2pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">107</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 113</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">116</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 120</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 121</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:650.3pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">128</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">131</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:663.4pt;left:63.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Up to 3 years</span></p>
<p style="top:663.4pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">7 (23%)</span></p>
<p style="top:663.4pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 119</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 122</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:671.5pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">126</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:684.6pt;left:63.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Over 3 years</span></p>
<p style="top:684.6pt;left:175.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:684.6pt;left:217.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">118</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:87.9pt;left:304.7pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 14</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Summary of the published clinical studies</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:104.5pt;left:304.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Assessments</span></p>
<p style="top:117.6pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Radiology (MRI, X-ray)</span></p>
<p style="top:117.6pt;left:423.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">24 (77%)</span></p>
<p style="top:117.6pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">106</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 115</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:125.7pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">119</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 121</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 127</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:138.8pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Arthroscopic assessment incl.</span></p>
<p style="top:146.9pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">histology</span></p>
<p style="top:138.8pt;left:423.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">17 (54%)</span></p>
<p style="top:138.8pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">107</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 113</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 116</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">122</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:146.9pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">124</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">126</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 130</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:160.0pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">IKDC</span></p>
<p style="top:160.0pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">10 (32%)</span></p>
<p style="top:160.0pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">107</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 115</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 121</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 122</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:168.1pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">126</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 128</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 130</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:181.2pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">VAS pain</span></p>
<p style="top:181.2pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">12 (39%)</span></p>
<p style="top:181.2pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">106</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 114</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:189.3pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">129</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 131</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:202.4pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Tegner activity scale</span></p>
<p style="top:202.4pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">8 (26%)</span></p>
<p style="top:202.4pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">107</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 114</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 115</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 129</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:210.5pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">131</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:223.6pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Lysholm</span></p>
<p style="top:223.6pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">6 (19%)</span></p>
<p style="top:223.6pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">114</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 115</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 128</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 131</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:236.7pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">KOOS</span></p>
<p style="top:236.7pt;left:423.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">5 (16%)</span></p>
<p style="top:236.7pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">126</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 128</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">130</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:249.8pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Function (no scoring systems</span></p>
<p style="top:257.9pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">or unspecified)</span></p>
<p style="top:249.8pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">4 (13%)</span></p>
<p style="top:249.8pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">104</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">106</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:271.0pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">ICRS cartilage injury evaluation package</span></p>
<p style="top:271.0pt;left:423.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">3 (10%)</span></p>
<p style="top:271.0pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">120</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 123</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:284.1pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Clinical symptoms/outcomes</span></p>
<p style="top:292.2pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">(no scoring system or unspecified)</span></p>
<p style="top:284.1pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">3 (10%)</span></p>
<p style="top:284.1pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">105</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 124</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:305.3pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">(Revised) Hospital for special</span></p>
<p style="top:313.4pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">surgery knee-rating scale</span></p>
<p style="top:305.3pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:305.3pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">113</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:326.5pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Functional Rating Index</span></p>
<p style="top:326.5pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:326.5pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">104</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 106</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:339.6pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">WOMAC</span></p>
<p style="top:339.6pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">5 (16%)</span></p>
<p style="top:339.6pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:352.6pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">AOFAS score</span></p>
<p style="top:352.6pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:352.6pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 116</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:365.8pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Knee Society Score</span></p>
<p style="top:365.8pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:365.8pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">110</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:378.9pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Harris Hip Score</span></p>
<p style="top:378.9pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:378.9pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:392.0pt;left:304.6pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Concomitant procedures</span></p>
<p style="top:405.1pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Subchondral bone marrow</span></p>
<p style="top:413.2pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">stimulation (multiple perforation,</span></p>
<p style="top:421.3pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">drilling, abrasion chondroplasty)</span></p>
<p style="top:405.1pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">11 (35%)</span></p>
<p style="top:405.1pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">113</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 115</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 118</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 119</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 121</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">123</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:413.2pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 127</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 128</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 131</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:434.4pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Debridement, synovectomy, excision</span></p>
<p style="top:442.4pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">of degenerative tears (no subchondral</span></p>
<p style="top:450.5pt;left:311.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">bone marrow stimulation)</span></p>
<p style="top:434.4pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">8 (26%)</span></p>
<p style="top:434.4pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">107</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 114</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 116</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:442.5pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">124</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 130</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:463.7pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">ACL reconstruction, meniscus</span></p>
<p style="top:471.8pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">repair, osteotomy, or patella</span></p>
<p style="top:479.9pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">alignment, ACL calcification</span></p>
<p style="top:488.0pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">removal, trochlear resurfacing,</span></p>
<p style="top:496.1pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">osteochondral fragment fixation</span></p>
<p style="top:463.7pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">8 (26%)</span></p>
<p style="top:463.7pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">115</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 123</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 126</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 129</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:509.2pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">None</span></p>
<p style="top:509.2pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">6 (19%)</span></p>
<p style="top:509.2pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 105</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 106</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 110</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:522.3pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Not specified</span></p>
<p style="top:522.3pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">3 (10%)</span></p>
<p style="top:522.3pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">104</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 120</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:535.4pt;left:304.7pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Previous procedures</span></p>
<p style="top:548.5pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Microfractures/multiple</span></p>
<p style="top:556.6pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">perforation/multiple drilling</span></p>
<p style="top:548.5pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">6 (19%)</span></p>
<p style="top:548.5pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">104</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 116</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 122</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 125</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 130</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:569.7pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Menisectomy</span></p>
<p style="top:569.7pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">6 (19%)</span></p>
<p style="top:569.7pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 111</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 124</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 129</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 131</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:582.8pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">ACL reconstruction</span></p>
<p style="top:582.8pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">4 (13%)</span></p>
<p style="top:582.8pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">103</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 111</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 131</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 133</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:595.9pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Multiple (microfracture, debridement)</span></p>
<p style="top:595.9pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">1 (3%)</span></p>
<p style="top:595.9pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">119</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:609.0pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">ACI</span></p>
<p style="top:609.0pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">2 (6%)</span></p>
<p style="top:609.0pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">116</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 117</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:622.1pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">None</span></p>
<p style="top:622.1pt;left:423.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">6 (19%)</span></p>
<p style="top:622.1pt;left:465.1pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">106</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.1pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">108</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 110</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 114</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 118</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:635.2pt;left:311.8pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">Not specified</span></p>
<p style="top:635.2pt;left:423.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">9 (29%)</span></p>
<p style="top:635.2pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">[</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">105</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 109</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 112</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 115</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 120</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span></p>
<p style="top:643.3pt;left:465.2pt;line-height:7.1pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">121</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 126</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 128</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">,</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313"> 132</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.1pt">]</span></p>
<p style="top:656.0pt;left:304.7pt;line-height:7.1pt"><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:7.1pt">PBS</span><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt"> phosphate-buffered saline,</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:7.1pt"> HA</span><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt"> hyaluronic acid,</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:7.1pt"> PRP</span><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt"> plate-rich-plasma,</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:7.1pt"> RCT</span></p>
<p style="top:664.1pt;left:304.7pt;line-height:7.1pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt">randomised controlled study,</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:7.1pt"> KOOS</span><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt"> Knee and Osteoarthritis Outcome Score,</span></p>
<p style="top:672.3pt;left:304.7pt;line-height:7.1pt"><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:7.1pt">IKDC score</span><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt"> International Knee Documentation Committee Score,</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:7.1pt"> WOMAC</span><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt"> the</span></p>
<p style="top:680.4pt;left:304.7pt;line-height:7.1pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt">Western Ontario and McMaster Universities Arthritis Index,</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:7.1pt"> AOFAS</span><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt"> the American</span></p>
<p style="top:688.5pt;left:304.7pt;line-height:7.1pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.1pt">Orthopaedic Foot &amp; Ankle Society</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 10 of 30</span></p>


<p style="top:724.2pt;left:54.4pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span></p>
<p style="top:725.0pt;left:68.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Title</span></p>
<p style="top:554.2pt;left:68.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cell source</span></p>
<p style="top:479.5pt;left:68.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Country</span></p>
<p style="top:419.7pt;left:68.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical trial</span></p>
<p style="top:419.6pt;left:77.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">phase</span></p>
<p style="top:375.9pt;left:68.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Condition</span></p>
<p style="top:241.9pt;left:68.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Study design</span></p>
<p style="top:115.3pt;left:68.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Enrolment</span></p>
<p style="top:725.0pt;left:90.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous cells</span></p>
<p style="top:725.0pt;left:104.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells in Knee Cartilage Injuries</span></p>
<p style="top:554.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:104.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Jordan</span></p>
<p style="top:419.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.9pt;left:104.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Advanced knee articular cartilage injury</span></p>
<p style="top:241.9pt;left:104.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Non-randomized parallel assignment;</span></p>
<p style="top:241.8pt;left:113.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blind</span></p>
<p style="top:115.3pt;left:104.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">13</span></p>
<p style="top:725.0pt;left:127.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adult Stem Cell Therapy for Repairing Articular</span></p>
<p style="top:725.0pt;left:136.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartilage in Gonarthrosis</span></p>
<p style="top:554.2pt;left:127.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:127.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Spain</span></p>
<p style="top:419.7pt;left:127.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.9pt;left:127.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Gonarthrosis grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:241.8pt;left:127.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Open label; single group assignment</span></p>
<p style="top:115.3pt;left:127.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">15</span></p>
<p style="top:725.0pt;left:150.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Bone Marrow Mesenchymal Stem</span></p>
<p style="top:725.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cells Transplantation for Articular Cartilage</span></p>
<p style="top:725.0pt;left:168.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Defects Repair</span></p>
<p style="top:554.2pt;left:150.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:150.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">UK</span></p>
<p style="top:419.6pt;left:150.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.9pt;left:150.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee articular cartilage defects</span></p>
<p style="top:241.9pt;left:150.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomized parallel assignment;</span></p>
<p style="top:241.8pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blind</span></p>
<p style="top:115.3pt;left:150.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">10</span></p>
<p style="top:725.0pt;left:182.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cell for Osteonecrosis of the</span></p>
<p style="top:725.0pt;left:191.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Femoral Head</span></p>
<p style="top:554.2pt;left:182.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:182.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">China</span></p>
<p style="top:419.6pt;left:182.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">0</span></p>
<p style="top:375.9pt;left:182.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteochondritis of the femoral head</span></p>
<p style="top:241.8pt;left:182.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Open label single group assignment</span></p>
<p style="top:115.3pt;left:182.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">15</span></p>
<p style="top:725.0pt;left:205.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">The Effects of Intra-articular Injection of</span></p>
<p style="top:725.0pt;left:214.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells in Knee Joint</span></p>
<p style="top:725.0pt;left:223.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.2pt;left:205.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:205.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Iran</span></p>
<p style="top:419.6pt;left:205.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.9pt;left:205.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee joint osteoarthritis</span></p>
<p style="top:241.8pt;left:205.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single centre, randomised, placebo</span></p>
<p style="top:241.8pt;left:214.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">controlled, double blind</span></p>
<p style="top:115.3pt;left:205.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">40</span></p>
<p style="top:725.0pt;left:237.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Efficacy of Autologous Bone Marrow</span></p>
<p style="top:725.0pt;left:246.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Stem Cells for Treating Osteoarthritis</span></p>
<p style="top:554.2pt;left:237.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:237.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">India</span></p>
<p style="top:419.6pt;left:237.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.9pt;left:237.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA Kellgren and Lawrence</span></p>
<p style="top:375.9pt;left:246.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">classification 3</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4</span></p>
<p style="top:241.8pt;left:237.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Open label single group assignment;</span></p>
<p style="top:241.8pt;left:246.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">multi-centre</span></p>
<p style="top:115.3pt;left:237.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">10</span></p>
<p style="top:725.0pt;left:260.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment of Knee Osteoarthritis by Intra-articular</span></p>
<p style="top:725.0pt;left:269.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection of Bone Marrow Mesenchymal Stem Cells</span></p>
<p style="top:554.2pt;left:260.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:260.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Spain</span></p>
<p style="top:419.7pt;left:260.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.9pt;left:260.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA</span></p>
<p style="top:241.9pt;left:260.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised parallel assignment;</span></p>
<p style="top:241.9pt;left:269.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.3pt;left:260.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">30</span></p>
<p style="top:725.0pt;left:283.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-Articular Autologous Bone Marrow</span></p>
<p style="top:725.0pt;left:292.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells Transplantation to</span></p>
<p style="top:725.0pt;left:301.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treat Mild to Moderate Osteoarthritis</span></p>
<p style="top:554.2pt;left:283.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:283.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Malaysia</span></p>
<p style="top:419.6pt;left:283.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.9pt;left:283.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mild to moderate OA based on</span></p>
<p style="top:375.9pt;left:292.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Kellgren-Lawrence radiographic</span></p>
<p style="top:375.9pt;left:301.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">classification</span></p>
<p style="top:241.9pt;left:283.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised parallel assignment;</span></p>
<p style="top:241.9pt;left:292.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.3pt;left:283.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">50</span></p>
<p style="top:725.0pt;left:315.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment of Osteoarthritis by Intra-articular</span></p>
<p style="top:725.0pt;left:324.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection of Bone Marrow Mesenchymal Stem</span></p>
<p style="top:725.0pt;left:333.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cells With Platelet Rich Plasma (CMM-PRGF/ART)</span></p>
<p style="top:554.2pt;left:315.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:315.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Spain</span></p>
<p style="top:419.7pt;left:315.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.9pt;left:315.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA</span></p>
<p style="top:241.9pt;left:315.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised parallel assignment;</span></p>
<p style="top:241.9pt;left:324.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label; multi-centre</span></p>
<p style="top:115.3pt;left:315.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">38</span></p>
<p style="top:725.0pt;left:347.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells Enhanced With PRP</span></p>
<p style="top:725.0pt;left:356.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Versus PRP In OA Knee (MSCPRPOAK)</span></p>
<p style="top:554.2pt;left:347.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:347.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">India</span></p>
<p style="top:419.7pt;left:347.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.9pt;left:347.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA grade 1</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 Ahlbacks</span></p>
<p style="top:375.9pt;left:356.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">radiographic staging</span></p>
<p style="top:241.9pt;left:347.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised parallel assignment</span></p>
<p style="top:241.9pt;left:356.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blinded</span></p>
<p style="top:115.3pt;left:347.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">24</span></p>
<p style="top:725.0pt;left:370.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Side Effects of Autologous Mesenchymal Stem</span></p>
<p style="top:725.0pt;left:379.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cell Transplantation in Ankle Joint Osteoarthritis</span></p>
<p style="top:554.2pt;left:370.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:370.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Iran</span></p>
<p style="top:419.7pt;left:370.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I</span></p>
<p style="top:375.9pt;left:370.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Severe ankle OA</span></p>
<p style="top:241.9pt;left:370.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment open label</span></p>
<p style="top:115.3pt;left:370.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6</span></p>
<p style="top:725.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Human Autologous MSCs for the Treatment of</span></p>
<p style="top:725.0pt;left:402.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mid to Late Stage Knee OA</span></p>
<p style="top:554.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Canada</span></p>
<p style="top:419.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.9pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mid- to late-stage knee OA</span></p>
<p style="top:241.8pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.3pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12</span></p>
<p style="top:725.0pt;left:416.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">A Controlled Surveillance of the Osteoarthritic</span></p>
<p style="top:725.0pt;left:425.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee Microenvironment With Regenexx&#xae; SD</span></p>
<p style="top:725.0pt;left:434.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment</span></p>
<p style="top:554.2pt;left:416.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:416.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.7pt;left:416.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NA</span></p>
<p style="top:375.9pt;left:416.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA Kellgren-Lawrence grade 2</span></p>
<p style="top:375.9pt;left:425.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">or greater</span></p>
<p style="top:241.9pt;left:416.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Observational cohort study</span></p>
<p style="top:115.3pt;left:416.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">20</span></p>
<p style="top:725.0pt;left:448.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">The Effect of Platelet-rich Plasma in Patients With</span></p>
<p style="top:725.0pt;left:457.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis of the Knee</span></p>
<p style="top:554.2pt;left:448.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:448.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Iran</span></p>
<p style="top:419.6pt;left:448.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">III</span></p>
<p style="top:375.9pt;left:448.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA grade 2 and above</span></p>
<p style="top:375.9pt;left:457.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(radiographic)</span></p>
<p style="top:241.9pt;left:448.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.9pt;left:457.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">placebo controlled, double blinded</span></p>
<p style="top:115.3pt;left:448.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">50</span></p>
<p style="top:725.0pt;left:471.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Outcomes Data of Bone Marrow Stem Cells to</span></p>
<p style="top:725.0pt;left:480.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treat Hip and Knee Osteoarthritis</span></p>
<p style="top:554.2pt;left:471.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:471.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.7pt;left:471.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NA</span></p>
<p style="top:375.9pt;left:471.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Hip and knee OA</span></p>
<p style="top:241.9pt;left:471.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Observational cohort study</span></p>
<p style="top:115.3pt;left:471.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12</span></p>
<p style="top:725.0pt;left:494.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Use of Autologous Bone Marrow Aspirate</span></p>
<p style="top:725.0pt;left:503.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Concentrate in Painful Knee Osteoarthritis (BMAC)</span></p>
<p style="top:554.2pt;left:494.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.5pt;left:494.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.7pt;left:494.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.9pt;left:494.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bilateral knee OA Kellgren-Lawrence</span></p>
<p style="top:375.9pt;left:503.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">grade 1</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:241.9pt;left:494.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.9pt;left:503.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">placebo controlled, single blinded</span></p>
<p style="top:115.3pt;left:494.9pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">25</span></p>
<p style="top:725.0pt;left:517.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Stem Cells in Osteoarthritis</span></p>
<p style="top:554.2pt;left:517.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:517.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mexico</span></p>
<p style="top:419.6pt;left:517.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I</span></p>
<p style="top:375.9pt;left:517.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA Kellgren-Lawrence</span></p>
<p style="top:375.9pt;left:526.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">radiographic scale grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:241.9pt;left:517.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised parallel assignment,</span></p>
<p style="top:241.9pt;left:526.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.3pt;left:517.8pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">61</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 11 of 30</span></p>


<p style="top:724.1pt;left:55.2pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:724.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">The Use of Autologous Bone Marrow Mesenchymal</span></p>
<p style="top:724.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Stem Cells in the Treatment of Articular Cartilage</span></p>
<p style="top:724.9pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Defects</span></p>
<p style="top:554.1pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Egypt</span></p>
<p style="top:419.6pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not given</span></p>
<p style="top:375.8pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">An isolated osteochondral defect with</span></p>
<p style="top:375.8pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">no more than grade 1 or 2 Outerbridge</span></p>
<p style="top:241.8pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.3pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">25</span></p>
<p style="top:724.9pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Transplantation of Mesenchymal Stem</span></p>
<p style="top:724.9pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cells (MSCs) and Scaffold in Full-thickness Articular</span></p>
<p style="top:724.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartilage</span></p>
<p style="top:554.1pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Iran</span></p>
<p style="top:419.6pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I</span></p>
<p style="top:375.8pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Full-thickness chondral defects</span></p>
<p style="top:241.8pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.3pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6</span></p>
<p style="top:724.9pt;left:136.3pt;line-height:8.0pt"><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x201c;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">One-step</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x201d;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt"> Bone Marrow Mononuclear Cell</span></p>
<p style="top:724.9pt;left:145.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Transplantation in Talar Osteochondral Lesions</span></p>
<p style="top:724.9pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(BMDC)</span></p>
<p style="top:554.1pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.6pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">III</span></p>
<p style="top:375.8pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">ICRS grade 3</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 Osteochondral lesions</span></p>
<p style="top:375.8pt;left:145.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">of the talar dome</span></p>
<p style="top:241.8pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.3pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">140</span></p>
<p style="top:724.9pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Transplantation of Bone Marrow Stem Cells</span></p>
<p style="top:724.9pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Stimulated by Proteins Scaffold to Heal Defects</span></p>
<p style="top:724.9pt;left:186.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Articular Cartilage of the Knee</span></p>
<p style="top:554.1pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">France</span></p>
<p style="top:419.6pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">0</span></p>
<p style="top:375.8pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA ICRS classification grade 4</span></p>
<p style="top:241.8pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.3pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">50</span></p>
<p style="top:724.9pt;left:200.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">INSTRUCT for Repair of Knee Cartilage Defects</span></p>
<p style="top:554.1pt;left:200.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:200.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">The Netherlands</span></p>
<p style="top:419.6pt;left:200.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not given</span></p>
<p style="top:375.8pt;left:200.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee articular cartilage defect</span></p>
<p style="top:241.8pt;left:200.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label;</span></p>
<p style="top:241.8pt;left:209.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">multi-centre</span></p>
<p style="top:115.3pt;left:200.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">40</span></p>
<p style="top:724.9pt;left:223.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">HyaloFAST Trial for Repair of Articular Cartilage</span></p>
<p style="top:724.9pt;left:232.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">in the Knee (FastTRACK)</span></p>
<p style="top:554.1pt;left:223.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:223.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Hungary</span></p>
<p style="top:419.6pt;left:223.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not given</span></p>
<p style="top:375.8pt;left:223.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee articular cartilage defect</span></p>
<p style="top:241.8pt;left:223.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:232.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">placebo controlled, single blinded,</span></p>
<p style="top:241.8pt;left:241.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">multi-centre</span></p>
<p style="top:115.3pt;left:223.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">200</span></p>
<p style="top:724.9pt;left:255.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Adipose Stem Cells and Platelet Rich</span></p>
<p style="top:724.9pt;left:264.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Plasma Therapy for Patients With Knee</span></p>
<p style="top:724.9pt;left:273.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:255.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:255.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Vietnam</span></p>
<p style="top:419.6pt;left:255.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:255.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Idiopathic or secondary knee OA</span></p>
<p style="top:375.8pt;left:264.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 radiographic severity</span></p>
<p style="top:241.8pt;left:255.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">non-randomised unblinded</span></p>
<p style="top:115.3pt;left:255.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">16</span></p>
<p style="top:724.9pt;left:287.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Effectiveness and Safety of Autologous ADRC for</span></p>
<p style="top:724.9pt;left:296.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment of Degenerative Damage of Knee</span></p>
<p style="top:724.9pt;left:305.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Articular Cartilage</span></p>
<p style="top:554.1pt;left:287.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:287.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Russia</span></p>
<p style="top:419.6pt;left:287.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:287.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA (degenerative damage of</span></p>
<p style="top:375.8pt;left:296.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">knee articular cartilage)</span></p>
<p style="top:241.8pt;left:287.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.3pt;left:287.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12</span></p>
<p style="top:724.9pt;left:319.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Adipose-Derived Stromal Cells</span></p>
<p style="top:724.9pt;left:328.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Delivered Intra-articularly in Patients With</span></p>
<p style="top:724.9pt;left:337.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:319.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:319.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.6pt;left:319.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:319.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">OA</span></p>
<p style="top:241.8pt;left:319.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label,</span></p>
<p style="top:241.8pt;left:328.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">multi-centre</span></p>
<p style="top:115.3pt;left:319.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">500</span></p>
<p style="top:724.9pt;left:351.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cell Treatment for Primary</span></p>
<p style="top:724.9pt;left:360.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis Knee</span></p>
<p style="top:554.1pt;left:351.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:351.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Taiwan</span></p>
<p style="top:419.6pt;left:351.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I</span></p>
<p style="top:375.8pt;left:351.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bilateral primary OA Kellgren and</span></p>
<p style="top:375.8pt;left:360.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Lawrence grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 as determined</span></p>
<p style="top:375.8pt;left:369.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">by X-ray</span></p>
<p style="top:241.8pt;left:351.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label,</span></p>
<p style="top:115.3pt;left:351.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">10</span></p>
<p style="top:724.9pt;left:383.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Adipose Tissue-Derived Mesenchymal</span></p>
<p style="top:724.9pt;left:392.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Progenitor Cells Therapy for Patients With Knee</span></p>
<p style="top:724.9pt;left:401.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:383.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:383.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">China</span></p>
<p style="top:419.6pt;left:383.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.8pt;left:383.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA</span></p>
<p style="top:241.8pt;left:383.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, double</span></p>
<p style="top:241.8pt;left:392.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">blinded</span></p>
<p style="top:115.2pt;left:383.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">48</span></p>
<p style="top:724.9pt;left:415.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Trial of Autologous Adipose Tissue-Derived</span></p>
<p style="top:724.9pt;left:424.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Progenitor Cells (MPCs) Therapy</span></p>
<p style="top:724.9pt;left:433.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">for Knee Osteoarthritis</span></p>
<p style="top:554.1pt;left:415.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:415.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">China</span></p>
<p style="top:419.6pt;left:415.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.8pt;left:415.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA</span></p>
<p style="top:241.8pt;left:415.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:424.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">placebo controlled, single blinded</span></p>
<p style="top:115.2pt;left:415.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">48</span></p>
<p style="top:724.9pt;left:447.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Outcomes Data of Adipose Stem Cells to Treat</span></p>
<p style="top:724.9pt;left:456.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:447.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:447.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.6pt;left:447.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NA</span></p>
<p style="top:375.8pt;left:447.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA</span></p>
<p style="top:241.8pt;left:447.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Observational cohort study</span></p>
<p style="top:115.2pt;left:447.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">50</span></p>
<p style="top:724.9pt;left:470.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Trial to Evaluate Efficacy and Safety of</span></p>
<p style="top:724.9pt;left:479.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">JOINTSTEM in Patients With Degenerative Arthritis</span></p>
<p style="top:554.1pt;left:470.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:470.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Korea</span></p>
<p style="top:419.6pt;left:470.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II/III</span></p>
<p style="top:375.8pt;left:470.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA</span></p>
<p style="top:241.8pt;left:470.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised parallel assignment,</span></p>
<p style="top:241.8pt;left:479.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blinded</span></p>
<p style="top:115.2pt;left:470.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">120</span></p>
<p style="top:724.9pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">ADIPOA</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Study</span></p>
<p style="top:554.1pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">France</span></p>
<p style="top:419.5pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I</span></p>
<p style="top:375.8pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Moderate or severe knee OA</span></p>
<p style="top:241.7pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Non-randomised parallel assignment,</span></p>
<p style="top:241.8pt;left:502.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.2pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12</span></p>
<p style="top:724.9pt;left:516.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Clinical Effectiveness of A3 SVF in</span></p>
<p style="top:724.9pt;left:525.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:516.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:516.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.6pt;left:516.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not given</span></p>
<p style="top:375.8pt;left:516.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">OA</span></p>
<p style="top:241.8pt;left:516.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.2pt;left:516.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">30</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 12 of 30</span></p>


<p style="top:724.1pt;left:55.2pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:724.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Clinical Outcomes Study: SVF</span></p>
<p style="top:724.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Deployment for Orthopaedic, Neurologic,</span></p>
<p style="top:724.9pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Urologic, and Cardio-pulmonary Conditions</span></p>
<p style="top:554.1pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.6pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not given</span></p>
<p style="top:375.8pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Neurodegenerative diseases, OA,</span></p>
<p style="top:375.8pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">erectile dysfunction, autoimmune</span></p>
<p style="top:375.8pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">diseases, cardiomyopathies or</span></p>
<p style="top:375.8pt;left:99.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">emphysema</span></p>
<p style="top:241.8pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.3pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3000</span></p>
<p style="top:724.9pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Microfracture Versus Adipose-Derived Stem Cells</span></p>
<p style="top:724.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">for the Treatment of Articular Cartilage Defects</span></p>
<p style="top:554.1pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.6pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Not given</span></p>
<p style="top:375.8pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA</span></p>
<p style="top:241.8pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blind</span></p>
<p style="top:115.3pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">90</span></p>
<p style="top:724.9pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Mesenchymal Stem Cells vs.</span></p>
<p style="top:724.9pt;left:145.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Chondrocytes for the Repair of Chondral Knee</span></p>
<p style="top:724.9pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Defects (ASCROD)</span></p>
<p style="top:554.1pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Spain</span></p>
<p style="top:419.6pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Articular cartilage lesion of the femoral</span></p>
<p style="top:375.8pt;left:145.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">condyle</span></p>
<p style="top:241.8pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:145.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.3pt;left:136.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">30</span></p>
<p style="top:724.9pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">A Phase 2 Study to Evaluate the Efficacy and</span></p>
<p style="top:724.9pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety of JointStem in Treatment of Osteoarthritis</span></p>
<p style="top:554.1pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.6pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.8pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA</span></p>
<p style="top:241.8pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blinded</span></p>
<p style="top:115.2pt;left:168.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">45</span></p>
<p style="top:724.9pt;left:191.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Allogenic cells</span></p>
<p style="top:724.9pt;left:205.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment of Knee Osteoarthritis With Allogenic</span></p>
<p style="top:724.9pt;left:214.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells (MSV_allo)</span></p>
<p style="top:554.1pt;left:205.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:205.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Spain</span></p>
<p style="top:419.6pt;left:205.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:205.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee OA grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 of Kellgren and</span></p>
<p style="top:375.8pt;left:214.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Lawrence</span></p>
<p style="top:241.8pt;left:205.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:214.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blinded</span></p>
<p style="top:115.2pt;left:205.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">30</span></p>
<p style="top:724.9pt;left:228.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Trial of Allogenic Adipose Tissue-Derived</span></p>
<p style="top:724.9pt;left:237.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Progenitor Cells Therapy for Knee</span></p>
<p style="top:724.9pt;left:246.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:228.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:479.4pt;left:228.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">China</span></p>
<p style="top:419.6pt;left:228.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I</span></p>
<p style="top:375.8pt;left:228.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Degenerative arthritis by radiographic</span></p>
<p style="top:375.8pt;left:237.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">criteria of Kellgren Lawrence</span></p>
<p style="top:241.8pt;left:228.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:237.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blind</span></p>
<p style="top:115.2pt;left:228.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">18</span></p>
<p style="top:724.9pt;left:260.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Study of Umbilical Cord Tissue</span></p>
<p style="top:724.9pt;left:269.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells (UC-MSC) for Treatment</span></p>
<p style="top:724.9pt;left:278.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">of Osteoarthritis</span></p>
<p style="top:554.1pt;left:260.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical Cord</span></p>
<p style="top:479.4pt;left:260.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Panama</span></p>
<p style="top:419.6pt;left:260.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Modified Kellgren-Lawrence</span></p>
<p style="top:375.8pt;left:269.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">classification grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 radiographic</span></p>
<p style="top:375.8pt;left:278.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">OA severity.</span></p>
<p style="top:241.8pt;left:260.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:269.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.2pt;left:260.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">40</span></p>
<p style="top:724.9pt;left:292.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Feasibility Study of Mesenchymal</span></p>
<p style="top:724.9pt;left:301.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Trophic Factor (MTF) for Treatment of</span></p>
<p style="top:724.9pt;left:310.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:292.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical Cord</span></p>
<p style="top:479.4pt;left:292.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Panama</span></p>
<p style="top:419.6pt;left:292.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:292.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Modified Kellgren-Lawrence</span></p>
<p style="top:375.8pt;left:301.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">classification grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 radiographic</span></p>
<p style="top:375.8pt;left:310.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">OA severity.</span></p>
<p style="top:241.8pt;left:292.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Non-Randomised, single group</span></p>
<p style="top:241.8pt;left:301.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">assignment,</span></p>
<p style="top:241.8pt;left:310.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.2pt;left:292.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">40</span></p>
<p style="top:724.9pt;left:324.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">A Study to Assess Safety and Efficacy of Umbilical</span></p>
<p style="top:724.9pt;left:333.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cord-derived Mesenchymal Stromal Cells in Knee</span></p>
<p style="top:724.9pt;left:342.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:324.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical Cord</span></p>
<p style="top:479.4pt;left:324.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Chile</span></p>
<p style="top:419.6pt;left:324.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:324.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Kellgren-Lawrence classification</span></p>
<p style="top:375.8pt;left:333.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">grade 1</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 radiographic OA severity</span></p>
<p style="top:241.8pt;left:324.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:333.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blind</span></p>
<p style="top:115.2pt;left:324.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">30</span></p>
<p style="top:724.9pt;left:356.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Human Umbilical Cord Mesenchymal Stem Cell</span></p>
<p style="top:724.9pt;left:365.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Transplantation in Articular Cartilage Defect</span></p>
<p style="top:554.1pt;left:356.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical Cord</span></p>
<p style="top:479.4pt;left:356.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">China</span></p>
<p style="top:419.6pt;left:356.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I</span></p>
<p style="top:375.8pt;left:356.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Kellgren-Lawrence classification</span></p>
<p style="top:375.8pt;left:365.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 radiographic OA severity</span></p>
<p style="top:241.8pt;left:356.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.2pt;left:356.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">20</span></p>
<p style="top:724.9pt;left:379.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Evaluation of Safety and Exploratory Efficacy of</span></p>
<p style="top:724.9pt;left:388.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">CARTISTEM&#xae;, a Cell Therapy Product for Articular</span></p>
<p style="top:724.9pt;left:397.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartilage Defects</span></p>
<p style="top:554.1pt;left:379.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical cord blood</span></p>
<p style="top:479.3pt;left:379.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Korea</span></p>
<p style="top:419.5pt;left:379.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:379.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Focal, full-thickness grade 3</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">4 articular</span></p>
<p style="top:375.8pt;left:388.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">cartilage defects</span></p>
<p style="top:241.8pt;left:379.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single group assignment, open label</span></p>
<p style="top:115.2pt;left:379.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12</span></p>
<p style="top:724.9pt;left:411.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Study to Compare the Efficacy and Safety of</span></p>
<p style="top:724.9pt;left:420.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartistem&#xae; and Microfracture in Patients With</span></p>
<p style="top:724.9pt;left:429.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee Articular Cartilage Injury or Defect</span></p>
<p style="top:554.1pt;left:411.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical cord blood</span></p>
<p style="top:479.4pt;left:411.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Korea</span></p>
<p style="top:419.6pt;left:411.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">III</span></p>
<p style="top:375.8pt;left:411.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee Articular Cartilage Injury or Defect</span></p>
<p style="top:241.8pt;left:411.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:420.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.2pt;left:411.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">104</span></p>
<p style="top:724.9pt;left:443.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Follow-Up Study of CARTISTEM&#xae; vs. Microfracture</span></p>
<p style="top:724.9pt;left:452.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">for the Treatment of Knee Articular Cartilage Injury</span></p>
<p style="top:724.9pt;left:461.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">or Defect</span></p>
<p style="top:554.1pt;left:443.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical cord blood</span></p>
<p style="top:479.3pt;left:443.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Korea</span></p>
<p style="top:419.5pt;left:443.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">III</span></p>
<p style="top:375.8pt;left:443.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee articular cartilage injury or defect</span></p>
<p style="top:241.8pt;left:443.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:452.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.2pt;left:443.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">103</span></p>
<p style="top:724.9pt;left:475.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injections of FloGraft Therapy, Autologous Stem</span></p>
<p style="top:724.9pt;left:484.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cells, or Platelet Rich Plasma for the Treatment of</span></p>
<p style="top:724.9pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Degenerative Joint Pain</span></p>
<p style="top:554.1pt;left:475.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Amniotic fluid</span></p>
<p style="top:479.4pt;left:475.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">USA</span></p>
<p style="top:419.6pt;left:475.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NA</span></p>
<p style="top:375.8pt;left:475.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Pain associated with one of the</span></p>
<p style="top:375.8pt;left:484.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">following conditions: lumbar facet</span></p>
<p style="top:375.8pt;left:493.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">degeneration, degenerative condition</span></p>
<p style="top:375.8pt;left:502.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">causing upper extremity joint pain or</span></p>
<p style="top:375.8pt;left:511.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">degenerative condition causing lower</span></p>
<p style="top:375.8pt;left:520.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">extremity joint pain</span></p>
<p style="top:241.8pt;left:475.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cohort observational study</span></p>
<p style="top:115.3pt;left:475.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">300</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 13 of 30</span></p>


<p style="top:724.1pt;left:55.2pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:724.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IMPACT: Safety and Feasibility of a Single-stage</span></p>
<p style="top:724.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Procedure for Focal Cartilage Lesions of the Knee</span></p>
<p style="top:554.1pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unspecified</span></p>
<p style="top:479.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">The Netherlands</span></p>
<p style="top:419.6pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:375.8pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Full-thickness articular cartilage lesion</span></p>
<p style="top:375.8pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">on the femoral condyle or trochlea</span></p>
<p style="top:241.8pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Single-group assignment, open label</span></p>
<p style="top:115.3pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">35</span></p>
<p style="top:724.9pt;left:95.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Allogeneic Mesenchymal Stem Cells in</span></p>
<p style="top:724.9pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:95.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unspecified</span></p>
<p style="top:479.4pt;left:95.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">India</span></p>
<p style="top:419.6pt;left:95.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.8pt;left:95.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Kellgren and Lawrence classification</span></p>
<p style="top:375.8pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 radiographic OA severity</span></p>
<p style="top:241.8pt;left:95.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, double blind,</span></p>
<p style="top:241.8pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">multi-centre</span></p>
<p style="top:115.3pt;left:95.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">60</span></p>
<p style="top:724.9pt;left:118.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Allogeneic Mesenchymal Stem Cells for</span></p>
<p style="top:724.9pt;left:127.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:554.1pt;left:118.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unspecified</span></p>
<p style="top:479.4pt;left:118.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Malaysia</span></p>
<p style="top:419.6pt;left:118.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II</span></p>
<p style="top:375.8pt;left:118.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Kellgren and Lawrence classification</span></p>
<p style="top:375.8pt;left:127.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">grade 2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 OA</span></p>
<p style="top:241.8pt;left:118.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, double blind,</span></p>
<p style="top:241.8pt;left:127.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">multi-centre</span></p>
<p style="top:115.3pt;left:118.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">72</span></p>
<p style="top:724.9pt;left:141.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous or allogenic unspecified</span></p>
<p style="top:724.9pt;left:155.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Transplantation of Bone Marrow Derived</span></p>
<p style="top:724.9pt;left:164.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells in Affected Knee</span></p>
<p style="top:724.9pt;left:173.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis by Rheumatoid Arthritis</span></p>
<p style="top:554.1pt;left:155.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:479.4pt;left:155.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">II/III</span></p>
<p style="top:419.6pt;left:155.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Iran</span></p>
<p style="top:375.8pt;left:155.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Rheumatoid arthritis</span></p>
<p style="top:241.8pt;left:155.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:164.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">open label</span></p>
<p style="top:115.3pt;left:155.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">60</span></p>
<p style="top:724.9pt;left:187.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Efficacy Study of MSB-CAR001 in</span></p>
<p style="top:724.9pt;left:196.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Subjects 6 Weeks Post an Anterior Cruciate</span></p>
<p style="top:724.9pt;left:205.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Ligament Reconstruction</span></p>
<p style="top:554.1pt;left:187.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:479.4pt;left:187.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">I/II</span></p>
<p style="top:419.6pt;left:187.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Australia</span></p>
<p style="top:375.8pt;left:187.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Anterior cruciate ligament injury</span></p>
<p style="top:241.8pt;left:187.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Randomised, parallel assignment,</span></p>
<p style="top:241.8pt;left:196.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double blind</span></p>
<p style="top:115.3pt;left:187.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">24</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 14 of 30</span></p>


<p style="top:724.1pt;left:55.2pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:724.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Title</span></p>
<p style="top:555.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Follow-up</span></p>
<p style="top:514.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Arm(s)</span></p>
<p style="top:409.2pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cell delivery</span></p>
<p style="top:322.3pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Primary outcomes</span></p>
<p style="top:224.7pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Study status (on 8.3.2016)</span></p>
<p style="top:136.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">ClinicalTrials.gov</span></p>
<p style="top:136.4pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Identifier</span></p>
<p style="top:724.9pt;left:94.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous cells</span></p>
<p style="top:724.9pt;left:108.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells in Knee Cartilage Injuries</span></p>
<p style="top:555.4pt;left:108.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Culture expanded MSCs</span></p>
<p style="top:514.9pt;left:117.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">alone vs. MSC with</span></p>
<p style="top:514.9pt;left:126.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">platelet lysate</span></p>
<p style="top:409.2pt;left:108.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:108.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Therapeutic benefit</span></p>
<p style="top:224.7pt;left:108.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in August</span></p>
<p style="top:224.7pt;left:117.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2015; no publication</span></p>
<p style="top:224.7pt;left:126.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:108.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02118519</span></p>
<p style="top:724.9pt;left:140.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adult Stem Cell Therapy for Repairing Articular</span></p>
<p style="top:724.9pt;left:149.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartilage in Gonarthrosis</span></p>
<p style="top:555.4pt;left:140.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Culture expanded MSCs</span></p>
<p style="top:514.9pt;left:149.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(40 million cells)</span></p>
<p style="top:409.2pt;left:140.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Articular injection</span></p>
<p style="top:322.3pt;left:140.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Feasibility/safety</span></p>
<p style="top:224.7pt;left:140.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in January</span></p>
<p style="top:224.7pt;left:149.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2013; no publication</span></p>
<p style="top:224.7pt;left:158.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:140.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01227694</span></p>
<p style="top:724.9pt;left:172.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Bone Marrow Mesenchymal Stem</span></p>
<p style="top:724.9pt;left:181.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cells Transplantation for Articular Cartilage</span></p>
<p style="top:724.9pt;left:190.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Defects Repair</span></p>
<p style="top:555.4pt;left:172.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months MSCs (fresh or cultured</span></p>
<p style="top:514.9pt;left:181.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">unspecified)</span></p>
<p style="top:409.2pt;left:172.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:172.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Change in WOMAC</span></p>
<p style="top:224.7pt;left:172.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:224.7pt;left:181.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:190.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:199.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">July 2014)</span></p>
<p style="top:136.4pt;left:172.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01895413</span></p>
<p style="top:724.9pt;left:213.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cell for Osteonecrosis of the</span></p>
<p style="top:724.9pt;left:222.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Femoral Head</span></p>
<p style="top:555.4pt;left:213.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">5 years</span></p>
<p style="top:514.9pt;left:213.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Culture expanded MSC</span></p>
<p style="top:514.9pt;left:222.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">and bone marrow</span></p>
<p style="top:514.9pt;left:231.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">nuclear cells</span></p>
<p style="top:409.2pt;left:213.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Infusion through medial</span></p>
<p style="top:409.2pt;left:222.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">femoral circumflex artery,</span></p>
<p style="top:409.2pt;left:231.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">lateral femoral circumflex</span></p>
<p style="top:409.2pt;left:240.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">artery and obturator</span></p>
<p style="top:409.2pt;left:249.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">artery</span></p>
<p style="top:322.3pt;left:213.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Femoral head blood-supply</span></p>
<p style="top:322.3pt;left:222.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">artery angiographies;</span></p>
<p style="top:322.3pt;left:231.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">femoral head necrosis</span></p>
<p style="top:224.7pt;left:213.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:224.7pt;left:222.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:231.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:240.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">August 2015)</span></p>
<p style="top:136.4pt;left:213.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT00813267</span></p>
<p style="top:724.9pt;left:263.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">The Effects of Intra-articular Injection of</span></p>
<p style="top:724.9pt;left:272.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells in Knee Joint</span></p>
<p style="top:724.9pt;left:281.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:263.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 months</span></p>
<p style="top:514.9pt;left:263.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Culture-expanded</span></p>
<p style="top:514.9pt;left:272.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">MSCs vs. placebo</span></p>
<p style="top:409.2pt;left:263.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:263.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Changes in WOMAC</span></p>
<p style="top:322.3pt;left:272.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">physical function and VAS</span></p>
<p style="top:322.3pt;left:281.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">pain</span></p>
<p style="top:224.7pt;left:263.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in November</span></p>
<p style="top:224.7pt;left:272.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2012; no publication</span></p>
<p style="top:224.7pt;left:281.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:263.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01504464</span></p>
<p style="top:724.9pt;left:295.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Efficacy of Autologous Bone Marrow</span></p>
<p style="top:724.9pt;left:304.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Stem Cells for Treating Osteoarthritis</span></p>
<p style="top:555.4pt;left:295.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 year</span></p>
<p style="top:514.9pt;left:295.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">MSCs (fresh or culture-</span></p>
<p style="top:514.9pt;left:304.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">expanded unspecified)</span></p>
<p style="top:409.2pt;left:295.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:322.3pt;left:295.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WOMAC pain score and</span></p>
<p style="top:322.3pt;left:304.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">safety</span></p>
<p style="top:224.7pt;left:295.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going</span></p>
<p style="top:224.7pt;left:304.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:313.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:322.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">January 2012)</span></p>
<p style="top:136.4pt;left:295.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01152125</span></p>
<p style="top:724.9pt;left:336.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment of Knee Osteoarthritis by Intra-articular</span></p>
<p style="top:724.9pt;left:345.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection of Bone Marrow Mesenchymal Stem Cells</span></p>
<p style="top:555.4pt;left:336.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:345.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(10 million or 100 million</span></p>
<p style="top:514.9pt;left:354.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">cells) and hyaluronic acid</span></p>
<p style="top:514.9pt;left:363.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(HyalOne&#xae;) vs. HyalOne&#xae;</span></p>
<p style="top:409.2pt;left:336.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:336.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Pain and function (VAS,</span></p>
<p style="top:322.3pt;left:345.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WOMAC, KOOS, EuroQol,</span></p>
<p style="top:322.3pt;left:354.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">SF-16, Lequesne),</span></p>
<p style="top:322.3pt;left:363.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">radiographic</span></p>
<p style="top:224.7pt;left:336.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going</span></p>
<p style="top:224.7pt;left:345.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:354.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:363.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">February 2015)</span></p>
<p style="top:136.4pt;left:336.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02123368</span></p>
<p style="top:724.9pt;left:377.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-Articular Autologous Bone Marrow</span></p>
<p style="top:724.9pt;left:386.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells Transplantation to</span></p>
<p style="top:724.9pt;left:395.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treat Mild to Moderate Osteoarthritis</span></p>
<p style="top:555.4pt;left:377.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months MSCs (fresh or culture-</span></p>
<p style="top:514.9pt;left:386.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">expanded unspecified)</span></p>
<p style="top:514.9pt;left:395.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">in hyaluronic acid</span></p>
<p style="top:514.9pt;left:404.5pt;line-height:8.0pt"><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x201c;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Orthovisc</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x201d;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt"> vs.</span></p>
<p style="top:514.9pt;left:413.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">hyaluronic acid</span></p>
<p style="top:409.2pt;left:377.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular</span></p>
<p style="top:409.2pt;left:386.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">implantation</span></p>
<p style="top:322.3pt;left:377.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Changes in cartilage</span></p>
<p style="top:322.3pt;left:386.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">thickness (MRI)</span></p>
<p style="top:224.7pt;left:377.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown (estimated</span></p>
<p style="top:224.7pt;left:386.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:395.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">March 2014)</span></p>
<p style="top:136.4pt;left:377.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01459640</span></p>
<p style="top:724.9pt;left:427.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment of Osteoarthritis by Intra-articular</span></p>
<p style="top:724.9pt;left:436.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection of Bone Marrow Mesenchymal Stem</span></p>
<p style="top:724.9pt;left:445.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cells With Platelet Rich Plasma (CMM-PRGF/ART)</span></p>
<p style="top:555.4pt;left:427.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:436.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">with PRP (PRGF&#xae;) vs.</span></p>
<p style="top:514.9pt;left:445.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">PRGF&#xae; only</span></p>
<p style="top:409.2pt;left:427.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:427.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Pain and function (VAS,</span></p>
<p style="top:322.3pt;left:436.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WOMAC, KOOS, EuroQol,</span></p>
<p style="top:322.3pt;left:445.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">SF-16, Lequesne),</span></p>
<p style="top:322.3pt;left:454.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">radiographic</span></p>
<p style="top:224.7pt;left:427.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:436.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:445.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">June 2017)</span></p>
<p style="top:136.4pt;left:427.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02365142</span></p>
<p style="top:724.9pt;left:468.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells Enhanced With PRP</span></p>
<p style="top:724.9pt;left:477.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Versus PRP In OA Knee (MSCPRPOAK)</span></p>
<p style="top:555.4pt;left:468.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 months</span></p>
<p style="top:514.9pt;left:468.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:477.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(10 million cells) with</span></p>
<p style="top:514.9pt;left:486.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">autologous PRP vs. PRP</span></p>
<p style="top:514.9pt;left:495.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">only</span></p>
<p style="top:409.2pt;left:468.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injected by lateral</span></p>
<p style="top:409.2pt;left:477.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">approach</span></p>
<p style="top:322.3pt;left:468.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">VAS pain</span></p>
<p style="top:224.7pt;left:468.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:224.7pt;left:477.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:486.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:495.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">June 2014)</span></p>
<p style="top:136.4pt;left:468.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01985633</span></p>
<p style="top:724.9pt;left:509.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Side Effects of Autologous Mesenchymal Stem</span></p>
<p style="top:724.9pt;left:518.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cell Transplantation in Ankle Joint Osteoarthritis</span></p>
<p style="top:555.4pt;left:509.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 months</span></p>
<p style="top:514.9pt;left:509.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Culture-expanded MSCs</span></p>
<p style="top:409.1pt;left:509.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:509.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:509.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in September</span></p>
<p style="top:224.7pt;left:518.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2011; no publication</span></p>
<p style="top:224.7pt;left:527.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:509.5pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01436058</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 15 of 30</span></p>


<p style="top:724.1pt;left:55.2pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:724.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Human Autologous MSCs for the Treatment of</span></p>
<p style="top:724.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mid to Late Stage Knee OA</span></p>
<p style="top:555.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 year</span></p>
<p style="top:514.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(1 million, 10 million or</span></p>
<p style="top:514.9pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">50 million cells)</span></p>
<p style="top:409.2pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going</span></p>
<p style="top:224.7pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:99.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">February 2021)</span></p>
<p style="top:136.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02351011</span></p>
<p style="top:724.9pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">A Controlled Surveillance of the Osteoarthritic</span></p>
<p style="top:724.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee Microenvironment With Regenexx&#xae; SD</span></p>
<p style="top:724.9pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment</span></p>
<p style="top:555.4pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 weeks</span></p>
<p style="top:514.9pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Regenexx&#xae; SD (bone</span></p>
<p style="top:514.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">marrow concentrate)</span></p>
<p style="top:409.2pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Temporal median change</span></p>
<p style="top:322.3pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">in protein concentration or</span></p>
<p style="top:322.3pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">percentage of cellular</span></p>
<p style="top:322.3pt;left:140.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">subpopulations</span></p>
<p style="top:224.7pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going</span></p>
<p style="top:224.7pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:140.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">March 2016)</span></p>
<p style="top:136.4pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02370823</span></p>
<p style="top:724.9pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">The Effect of Platelet-rich Plasma in Patients With</span></p>
<p style="top:724.9pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis of the Knee</span></p>
<p style="top:555.4pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 year</span></p>
<p style="top:514.9pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow aspirate vs.</span></p>
<p style="top:514.9pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">placebo (saline)</span></p>
<p style="top:409.2pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">VAS pain, WOMAC physical</span></p>
<p style="top:322.3pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">activity, cartilage repair (MRI)</span></p>
<p style="top:224.7pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in April 2014;</span></p>
<p style="top:224.7pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">no publication found</span></p>
<p style="top:136.4pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02582489</span></p>
<p style="top:724.9pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Outcomes Data of Bone Marrow Stem Cells to</span></p>
<p style="top:724.9pt;left:186.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treat Hip and Knee Osteoarthritis</span></p>
<p style="top:555.4pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 year</span></p>
<p style="top:514.9pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow concentrate</span></p>
<p style="top:409.2pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">VAS pain, Harris Hip Score</span></p>
<p style="top:322.3pt;left:186.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">or Knee Society Score,</span></p>
<p style="top:322.3pt;left:195.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Physician Global Assessment</span></p>
<p style="top:224.7pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in March</span></p>
<p style="top:224.7pt;left:186.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2014; no publication</span></p>
<p style="top:224.7pt;left:195.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:177.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01601951</span></p>
<p style="top:724.9pt;left:209.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Use of Autologous Bone Marrow Aspirate</span></p>
<p style="top:724.9pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Concentrate in Painful Knee Osteoarthritis (BMAC)</span></p>
<p style="top:555.4pt;left:209.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Bone marrow concentrate</span></p>
<p style="top:514.9pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">vs. placebo (saline)</span></p>
<p style="top:409.2pt;left:209.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:209.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.8pt;left:209.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going</span></p>
<p style="top:224.7pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:227.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:236.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">December 2016)</span></p>
<p style="top:136.4pt;left:209.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01931007</span></p>
<p style="top:724.9pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Stem Cells in Osteoarthritis</span></p>
<p style="top:555.4pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 months</span></p>
<p style="top:514.9pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Hematopoietic stem cells</span></p>
<p style="top:514.9pt;left:259.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(fresh) vs. acetaminophen</span></p>
<p style="top:514.9pt;left:268.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(750 mg orally TID)</span></p>
<p style="top:409.2pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Infusion</span></p>
<p style="top:322.3pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in May 2014;</span></p>
<p style="top:224.7pt;left:259.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">no publication found</span></p>
<p style="top:136.4pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01485198</span></p>
<p style="top:724.9pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">The Use of Autologous Bone Marrow Mesenchymal</span></p>
<p style="top:724.9pt;left:291.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Stem Cells in the Treatment of Articular Cartilage</span></p>
<p style="top:724.9pt;left:300.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Defects</span></p>
<p style="top:555.4pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Culture-expanded MSCs</span></p>
<p style="top:409.1pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Open surgery or</span></p>
<p style="top:409.2pt;left:291.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">arthroscopy</span></p>
<p style="top:322.3pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical scores and</span></p>
<p style="top:322.3pt;left:291.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">radiological images</span></p>
<p style="top:224.7pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:224.7pt;left:291.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:300.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:309.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">December 2014)</span></p>
<p style="top:136.4pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT00891501</span></p>
<p style="top:724.9pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Transplantation of Mesenchymal Stem</span></p>
<p style="top:724.9pt;left:332.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cells (MSCs) and Scaffold in Full-thickness Articular</span></p>
<p style="top:724.9pt;left:341.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartilage</span></p>
<p style="top:555.4pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:332.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">mixed with collagen I</span></p>
<p style="top:514.9pt;left:341.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">scaffold</span></p>
<p style="top:409.2pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unspecified</span></p>
<p style="top:322.3pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee cartilage defects</span></p>
<p style="top:224.7pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in December</span></p>
<p style="top:224.7pt;left:332.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2010; no publication</span></p>
<p style="top:224.7pt;left:341.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT00850187</span></p>
<p style="top:724.9pt;left:355.3pt;line-height:8.0pt"><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x201c;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">One-step</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x201d;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt"> Bone Marrow Mononuclear Cell</span></p>
<p style="top:724.9pt;left:364.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Transplantation in Talar Osteochondral Lesions</span></p>
<p style="top:724.9pt;left:373.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(BMDC)</span></p>
<p style="top:555.4pt;left:355.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">24 months Bone marrow concentrate</span></p>
<p style="top:409.2pt;left:355.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Arthroscopy</span></p>
<p style="top:322.3pt;left:355.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">American Orthopaedic</span></p>
<p style="top:322.3pt;left:364.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Foot and Ankle Society</span></p>
<p style="top:322.3pt;left:373.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">hindfoot score</span></p>
<p style="top:224.8pt;left:355.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.8pt;left:364.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.8pt;left:373.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">June 2016)</span></p>
<p style="top:136.4pt;left:355.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02005861</span></p>
<p style="top:725.0pt;left:387.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Transplantation of Bone Marrow Stem Cells</span></p>
<p style="top:725.0pt;left:396.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Stimulated by Proteins Scaffold to Heal Defects</span></p>
<p style="top:725.0pt;left:405.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Articular Cartilage of the Knee</span></p>
<p style="top:555.4pt;left:387.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 year</span></p>
<p style="top:514.9pt;left:387.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Freshly isolated bone</span></p>
<p style="top:514.9pt;left:396.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">marrow mononuclear</span></p>
<p style="top:514.9pt;left:405.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">cells mixed with protein</span></p>
<p style="top:514.9pt;left:414.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">scaffold</span></p>
<p style="top:409.2pt;left:387.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Arthroscopy (one step</span></p>
<p style="top:409.2pt;left:396.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">procedure)</span></p>
<p style="top:322.3pt;left:387.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IKS</span></p>
<p style="top:224.8pt;left:387.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:224.8pt;left:396.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated completion</span></p>
<p style="top:224.8pt;left:405.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">date; December 2014))</span></p>
<p style="top:136.4pt;left:387.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01159899</span></p>
<p style="top:725.0pt;left:428.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">INSTRUCT for Repair of Knee Cartilage Defects</span></p>
<p style="top:555.5pt;left:428.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 year</span></p>
<p style="top:514.9pt;left:428.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">INSTRUCT scaffold</span></p>
<p style="top:514.9pt;left:437.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(biodegradable scaffold</span></p>
<p style="top:514.9pt;left:446.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">seeded with autologous</span></p>
<p style="top:514.9pt;left:455.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">primary chondrocytes</span></p>
<p style="top:514.9pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">and bone marrow cells)</span></p>
<p style="top:409.2pt;left:428.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Arthrotomy</span></p>
<p style="top:322.3pt;left:428.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and lesion filling</span></p>
<p style="top:224.8pt;left:428.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in June 2014;</span></p>
<p style="top:224.8pt;left:437.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">no publication found</span></p>
<p style="top:136.4pt;left:428.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01041885</span></p>
<p style="top:725.0pt;left:478.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">HyaloFAST Trial for Repair of Articular Cartilage</span></p>
<p style="top:725.0pt;left:487.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">in the Knee (FastTRACK)</span></p>
<p style="top:555.4pt;left:478.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 years</span></p>
<p style="top:514.9pt;left:478.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Hyalofast&#xae; scaffold with</span></p>
<p style="top:514.9pt;left:487.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">bone marrow aspirate</span></p>
<p style="top:514.9pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">concentrate vs.</span></p>
<p style="top:514.9pt;left:505.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">microfracture</span></p>
<p style="top:409.2pt;left:478.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">One-step arthroscopic</span></p>
<p style="top:409.2pt;left:487.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">procedure</span></p>
<p style="top:322.3pt;left:478.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Changes in KOOS</span></p>
<p style="top:224.7pt;left:478.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:487.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">June 2020)</span></p>
<p style="top:136.4pt;left:478.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02659215</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 16 of 30</span></p>


<p style="top:724.1pt;left:55.2pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:724.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Adipose Stem Cells and Platelet Rich</span></p>
<p style="top:724.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Plasma Therapy for Patients With Knee</span></p>
<p style="top:724.9pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Stromal vascular fraction</span></p>
<p style="top:514.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(10</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">50 million cells) and</span></p>
<p style="top:514.9pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">platelet rich plasma (PRP)</span></p>
<p style="top:409.2pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in December</span></p>
<p style="top:224.7pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2015; no publication</span></p>
<p style="top:224.7pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02142842</span></p>
<p style="top:724.9pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Effectiveness and Safety of Autologous ADRC for</span></p>
<p style="top:724.9pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment of Degenerative Damage of Knee</span></p>
<p style="top:724.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Articular Cartilage</span></p>
<p style="top:555.4pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">24 weeks</span></p>
<p style="top:514.9pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Adipose-derived</span></p>
<p style="top:514.9pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">regenerative cells (ADRC)</span></p>
<p style="top:514.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">extracted using Celution</span></p>
<p style="top:514.9pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">800/CRS System (Cytori</span></p>
<p style="top:514.9pt;left:140.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Therapeutics, Inc.)</span></p>
<p style="top:409.2pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">December 2016)</span></p>
<p style="top:136.4pt;left:104.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02219113</span></p>
<p style="top:724.9pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Adipose-Derived Stromal Cells</span></p>
<p style="top:724.9pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Delivered Intra-articularly in Patients With</span></p>
<p style="top:724.9pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 months</span></p>
<p style="top:514.9pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">MSCs in PRP</span></p>
<p style="top:409.2pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Pain score, functional rating</span></p>
<p style="top:322.3pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">index, visual analogue scale</span></p>
<p style="top:322.3pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(VAS), physical therapy (PT)</span></p>
<p style="top:322.3pt;left:181.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">and range of motion (53),</span></p>
<p style="top:322.3pt;left:190.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">quality of life scores,</span></p>
<p style="top:322.3pt;left:199.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">reduction in analgesics,</span></p>
<p style="top:322.3pt;left:208.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">adverse events</span></p>
<p style="top:224.7pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">December 2016)</span></p>
<p style="top:136.4pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01739504</span></p>
<p style="top:724.9pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cell Treatment for Primary</span></p>
<p style="top:724.9pt;left:231.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis Knee</span></p>
<p style="top:555.4pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months MSCs (8</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">10 million cells)</span></p>
<p style="top:409.2pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injections</span></p>
<p style="top:322.3pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.8pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:231.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:240.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">December 2016)</span></p>
<p style="top:136.4pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02544802</span></p>
<p style="top:724.9pt;left:254.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Adipose Tissue-Derived Mesenchymal</span></p>
<p style="top:724.9pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Progenitor Cells Therapy for Patients With Knee</span></p>
<p style="top:724.9pt;left:272.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:254.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 months</span></p>
<p style="top:514.9pt;left:254.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Fresh MSCs (10 million,</span></p>
<p style="top:514.9pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">20 million, 50 million</span></p>
<p style="top:514.9pt;left:272.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">cells twice) vs. placebo</span></p>
<p style="top:514.9pt;left:281.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(PBS)</span></p>
<p style="top:409.2pt;left:254.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:254.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WOMAC score</span></p>
<p style="top:224.7pt;left:254.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in December</span></p>
<p style="top:224.7pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2013; no publication</span></p>
<p style="top:224.7pt;left:272.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:254.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01809769</span></p>
<p style="top:724.9pt;left:295.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Trial of Autologous Adipose Tissue-Derived</span></p>
<p style="top:724.9pt;left:304.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Progenitor Cells (MPCs) Therapy</span></p>
<p style="top:724.9pt;left:313.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">for Knee Osteoarthritis</span></p>
<p style="top:555.4pt;left:295.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:304.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">vs. sodium hyaluronate</span></p>
<p style="top:409.2pt;left:295.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:295.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WOMAC</span></p>
<p style="top:224.7pt;left:295.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:304.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:313.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">July 2016)</span></p>
<p style="top:136.4pt;left:295.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02162693</span></p>
<p style="top:724.9pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Outcomes Data of Adipose Stem Cells to Treat</span></p>
<p style="top:724.9pt;left:336.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Cellular concentrate</span></p>
<p style="top:409.2pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:322.3pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">KOOS, HOOS</span></p>
<p style="top:224.8pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:336.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:345.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">September 2017)</span></p>
<p style="top:136.4pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02241408</span></p>
<p style="top:724.9pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Trial to Evaluate Efficacy and Safety of</span></p>
<p style="top:724.9pt;left:368.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">JOINTSTEM in Patients With Degenerative Arthritis</span></p>
<p style="top:555.4pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">24 weeks</span></p>
<p style="top:514.9pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">MSCs (100 million cells)</span></p>
<p style="top:514.9pt;left:368.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">vs. sodium chloride</span></p>
<p style="top:409.2pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WOMAC</span></p>
<p style="top:224.8pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:368.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:377.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">July 2017)</span></p>
<p style="top:136.4pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02658344</span></p>
<p style="top:724.9pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">ADIPOA</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Study</span></p>
<p style="top:555.4pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 year</span></p>
<p style="top:514.9pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">MSCs (2 million,</span></p>
<p style="top:514.9pt;left:400.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">10 million, 50 million</span></p>
<p style="top:514.9pt;left:409.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">cells)</span></p>
<p style="top:409.2pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in December</span></p>
<p style="top:224.7pt;left:400.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2014; no publication</span></p>
<p style="top:224.7pt;left:409.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01585857</span></p>
<p style="top:724.9pt;left:423.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Clinical Effectiveness of A3 SVF in</span></p>
<p style="top:724.9pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:423.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 year</span></p>
<p style="top:514.9pt;left:423.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Stromal vascular fraction</span></p>
<p style="top:514.9pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">with activated platelet</span></p>
<p style="top:409.2pt;left:423.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:423.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Pain and inflammation</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:322.3pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WOMAC scores,</span></p>
<p style="top:322.3pt;left:441.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">comprehensive</span></p>
<p style="top:322.3pt;left:450.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">inflammation blood panel</span></p>
<p style="top:224.7pt;left:423.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going</span></p>
<p style="top:224.7pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:441.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:450.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">September 2015)</span></p>
<p style="top:136.4pt;left:423.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01947348</span></p>
<p style="top:724.9pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Clinical Outcomes Study: SVF</span></p>
<p style="top:724.9pt;left:473.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Deployment for Orthopaedic, Neurologic,</span></p>
<p style="top:724.9pt;left:482.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Urologic, and Cardio-pulmonary Conditions</span></p>
<p style="top:555.4pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">36 months Stromal vascular fraction</span></p>
<p style="top:409.2pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-venous,</span></p>
<p style="top:409.2pt;left:473.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">intra-articular, and</span></p>
<p style="top:409.2pt;left:482.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">soft tissue injection</span></p>
<p style="top:322.3pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going</span></p>
<p style="top:224.7pt;left:473.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(estimated study</span></p>
<p style="top:224.7pt;left:482.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">completion date;</span></p>
<p style="top:224.7pt;left:491.4pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">March 2018)</span></p>
<p style="top:136.4pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01953523</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 17 of 30</span></p>


<p style="top:724.1pt;left:55.2pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:724.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Microfracture Versus Adipose-Derived Stem Cells</span></p>
<p style="top:724.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">for the Treatment of Articular Cartilage Defects</span></p>
<p style="top:555.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">24 months Fibrin glue + acellular</span></p>
<p style="top:514.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">collagen dermal matrix +</span></p>
<p style="top:514.9pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">DSCs, + additional layer</span></p>
<p style="top:514.9pt;left:99.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">of fibrin glue vs.</span></p>
<p style="top:514.9pt;left:108.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">microfracture</span></p>
<p style="top:409.2pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Arthroscopy</span></p>
<p style="top:322.3pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">KOOS</span></p>
<p style="top:224.7pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">December 2020)</span></p>
<p style="top:136.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02090140</span></p>
<p style="top:724.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous Mesenchymal Stem Cells vs.</span></p>
<p style="top:724.9pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Chondrocytes for the Repair of Chondral Knee</span></p>
<p style="top:724.9pt;left:140.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Defects (ASCROD)</span></p>
<p style="top:555.4pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">18 months Cultured stem cells vs.</span></p>
<p style="top:514.9pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">cultured autologous</span></p>
<p style="top:514.9pt;left:140.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">chondrocytes</span></p>
<p style="top:409.2pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:322.3pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Hyaline cartilage production</span></p>
<p style="top:322.3pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">for chondral knee lesions</span></p>
<p style="top:322.3pt;left:140.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">repair</span></p>
<p style="top:224.7pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown (estimated</span></p>
<p style="top:224.7pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:140.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">June 2012)</span></p>
<p style="top:136.4pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01399749</span></p>
<p style="top:724.9pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">A Phase 2 Study to Evaluate the Efficacy and</span></p>
<p style="top:724.9pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety of JointStem in Treatment of Osteoarthritis</span></p>
<p style="top:555.4pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 months</span></p>
<p style="top:514.9pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Joint stem adipose-</span></p>
<p style="top:514.9pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">derived (MSCs) vs.</span></p>
<p style="top:514.9pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Synvisc-One (hyaluronic</span></p>
<p style="top:514.9pt;left:181.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">acid)</span></p>
<p style="top:322.3pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartilage volume, cartilage</span></p>
<p style="top:322.3pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">articular surface area,</span></p>
<p style="top:322.3pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">cartilage thickness,</span></p>
<p style="top:322.3pt;left:181.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">subchondral bone surface</span></p>
<p style="top:322.3pt;left:190.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">curvature (MRI)</span></p>
<p style="top:224.7pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">September 2017)</span></p>
<p style="top:136.4pt;left:154.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02674399</span></p>
<p style="top:724.9pt;left:204.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Allogenic cells</span></p>
<p style="top:724.9pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Treatment of Knee Osteoarthritis With Allogenic</span></p>
<p style="top:724.9pt;left:227.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells (MSV_allo)</span></p>
<p style="top:555.4pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 years</span></p>
<p style="top:514.9pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:227.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(40 million cells) vs.</span></p>
<p style="top:514.9pt;left:236.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">hyaluronic acid</span></p>
<p style="top:409.2pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular</span></p>
<p style="top:409.2pt;left:227.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">transplantation</span></p>
<p style="top:322.3pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in June 2014;</span></p>
<p style="top:224.7pt;left:227.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">published in August 2015</span></p>
<p style="top:136.4pt;left:218.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01586312</span></p>
<p style="top:136.4pt;left:227.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(Linked to study</span></p>
<p style="top:136.4pt;left:236.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01183728)</span></p>
<p style="top:724.9pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Trial of Allogenic Adipose Tissue-Derived</span></p>
<p style="top:724.9pt;left:259.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Progenitor Cells Therapy for Knee</span></p>
<p style="top:724.9pt;left:268.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">48 weeks</span></p>
<p style="top:514.9pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">10 million MSCs vs.</span></p>
<p style="top:514.9pt;left:259.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">20 million MSCs</span></p>
<p style="top:409.2pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">WOMAC</span></p>
<p style="top:224.7pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:259.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:268.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">July 2017)</span></p>
<p style="top:136.4pt;left:250.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02641860</span></p>
<p style="top:724.9pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Clinical Study of Umbilical Cord Tissue</span></p>
<p style="top:724.9pt;left:291.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells (UC-MSC) for Treatment</span></p>
<p style="top:724.9pt;left:300.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">of Osteoarthritis</span></p>
<p style="top:555.4pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Single intra-articular</span></p>
<p style="top:514.9pt;left:291.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">injection of MSCs vs.</span></p>
<p style="top:514.9pt;left:300.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IV injections of MSC for</span></p>
<p style="top:514.9pt;left:309.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">3 days</span></p>
<p style="top:409.2pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IVIntra-articular injection;</span></p>
<p style="top:322.3pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:291.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:300.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">March 2017)</span></p>
<p style="top:136.4pt;left:282.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02237846</span></p>
<p style="top:724.9pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Feasibility Study of Mesenchymal</span></p>
<p style="top:724.9pt;left:332.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Trophic Factor (MTF) for Treatment of</span></p>
<p style="top:724.9pt;left:341.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months Intra-articular injection</span></p>
<p style="top:514.9pt;left:332.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">of allogeneic MTF from</span></p>
<p style="top:514.9pt;left:341.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">UC-MSC vs. 12</span></p>
<p style="top:514.9pt;left:350.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">subcutaneous MTF</span></p>
<p style="top:514.9pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">injections, once per</span></p>
<p style="top:514.9pt;left:368.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">week</span></p>
<p style="top:409.2pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection;</span></p>
<p style="top:409.2pt;left:332.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">subcutaneous injection</span></p>
<p style="top:322.3pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:332.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:341.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">June 2017)</span></p>
<p style="top:136.4pt;left:323.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02003131</span></p>
<p style="top:724.9pt;left:382.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">A Study to Assess Safety and Efficacy of Umbilical</span></p>
<p style="top:724.9pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cord-derived Mesenchymal Stromal Cells in Knee</span></p>
<p style="top:724.9pt;left:400.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:382.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months MSCs (single dose of</span></p>
<p style="top:514.9pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">20 million MSCs or</span></p>
<p style="top:514.9pt;left:400.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">double dose at 6 month</span></p>
<p style="top:514.9pt;left:409.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">interval) vs. hyaluronic</span></p>
<p style="top:514.9pt;left:418.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">acid</span></p>
<p style="top:409.2pt;left:382.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:382.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:382.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:391.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:400.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">December 2016)</span></p>
<p style="top:136.4pt;left:382.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02580695</span></p>
<p style="top:724.9pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Human Umbilical Cord Mesenchymal Stem Cell</span></p>
<p style="top:724.9pt;left:441.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Transplantation in Articular Cartilage Defect</span></p>
<p style="top:555.4pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months 20 million cells every</span></p>
<p style="top:514.9pt;left:441.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">month for 4 months</span></p>
<p style="top:409.2pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:441.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:450.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">December 2016)</span></p>
<p style="top:136.4pt;left:432.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02291926</span></p>
<p style="top:724.9pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Evaluation of Safety and Exploratory Efficacy of</span></p>
<p style="top:724.9pt;left:473.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">CARTISTEM&#xae;, a Cell Therapy Product for Articular</span></p>
<p style="top:724.9pt;left:482.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartilage Defects</span></p>
<p style="top:555.4pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">12 months CARTISTEM&#xae; (cultured</span></p>
<p style="top:514.9pt;left:473.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">UC MSCs mixed with</span></p>
<p style="top:514.9pt;left:482.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">sodium hyaluronate)</span></p>
<p style="top:409.2pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:322.3pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:473.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:482.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">May 2017)</span></p>
<p style="top:136.4pt;left:464.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01733186</span></p>
<p style="top:724.9pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Study to Compare the Efficacy and Safety of</span></p>
<p style="top:724.9pt;left:505.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cartistem&#xae; and Microfracture in Patients With</span></p>
<p style="top:724.9pt;left:514.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Knee Articular Cartilage Injury or Defect</span></p>
<p style="top:555.4pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">48 weeks</span></p>
<p style="top:514.9pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">CARTISTEM&#xae; (cultured</span></p>
<p style="top:514.9pt;left:505.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">UC MSCs mixed with</span></p>
<p style="top:514.9pt;left:514.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">sodium hyaluronate) vs.</span></p>
<p style="top:514.9pt;left:523.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Microfracture</span></p>
<p style="top:409.2pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Surgery</span></p>
<p style="top:322.3pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">CRS cartilage repair</span></p>
<p style="top:322.3pt;left:505.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">assessment</span></p>
<p style="top:224.7pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in January</span></p>
<p style="top:224.7pt;left:505.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2011; no publication</span></p>
<p style="top:224.7pt;left:514.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:496.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01041001</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 18 of 30</span></p>


<p style="top:724.1pt;left:55.2pt;line-height:9.0pt"><span style="font-family:SnplnmAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 15</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:9.0pt"> Clinical trials (unpublished/on-going) registered in ClinicalTrials.gov</span><span style="font-family:HvwxmdAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:724.9pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Follow-Up Study of CARTISTEM&#xae; vs. Microfracture</span></p>
<p style="top:724.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">for the Treatment of Knee Articular Cartilage Injury</span></p>
<p style="top:724.9pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">or Defect</span></p>
<p style="top:555.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">60 months CARTISTEM&#xae; (cultured</span></p>
<p style="top:514.9pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">UC MSCs mixed with</span></p>
<p style="top:514.9pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">sodium hyaluronate) vs.</span></p>
<p style="top:514.9pt;left:99.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">microfracture</span></p>
<p style="top:409.2pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:322.3pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IKDC, VAS pain, WOMAC</span></p>
<p style="top:224.7pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:81.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:90.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">May 2015)</span></p>
<p style="top:136.4pt;left:72.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01626677</span></p>
<p style="top:724.9pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injections of FloGraft Therapy, Autologous Stem</span></p>
<p style="top:724.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Cells, or Platelet Rich Plasma for the Treatment of</span></p>
<p style="top:724.9pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Degenerative Joint Pain</span></p>
<p style="top:555.4pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">24 weeks</span></p>
<p style="top:514.9pt;left:109.7pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">FloGraft</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:5.7pt">TM</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt"> (allogenic</span></p>
<p style="top:514.9pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">amniotic fluid-derived</span></p>
<p style="top:514.9pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">allograft) vs. autologous</span></p>
<p style="top:514.9pt;left:140.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">BMMSCs vs. platelet rich</span></p>
<p style="top:514.9pt;left:149.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">plasma</span></p>
<p style="top:409.2pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Pain</span></p>
<p style="top:224.7pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (estimated</span></p>
<p style="top:224.7pt;left:122.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:131.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">June 2016)</span></p>
<p style="top:136.4pt;left:113.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01978639</span></p>
<p style="top:724.9pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">IMPACT: Safety and Feasibility of a Single-stage</span></p>
<p style="top:724.9pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Procedure for Focal Cartilage Lesions of the Knee</span></p>
<p style="top:555.4pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">18 months Autologous chondrons</span></p>
<p style="top:514.9pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">(chondrocytes with their</span></p>
<p style="top:514.9pt;left:181.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">pericellular matrix) and</span></p>
<p style="top:514.9pt;left:190.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">allogeneic MSCs in the</span></p>
<p style="top:514.9pt;left:199.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">fibrin glue carrier</span></p>
<p style="top:409.2pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unspecified (single stage</span></p>
<p style="top:409.2pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">surgery)</span></p>
<p style="top:322.3pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">On-going (Estimated</span></p>
<p style="top:224.7pt;left:172.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Study Completion</span></p>
<p style="top:224.7pt;left:181.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Date: August 2015)</span></p>
<p style="top:136.4pt;left:163.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT02037204</span></p>
<p style="top:724.9pt;left:213.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Allogeneic Mesenchymal Stem Cells in</span></p>
<p style="top:724.9pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:213.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 years</span></p>
<p style="top:514.9pt;left:213.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">in 2 ml plasmalyte +</span></p>
<p style="top:514.9pt;left:231.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 ml, hyaluronan vs.</span></p>
<p style="top:514.9pt;left:240.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 ml, plasmalyte + 2 ml,</span></p>
<p style="top:514.9pt;left:249.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">hyaluronan</span></p>
<p style="top:409.2pt;left:213.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular</span></p>
<p style="top:322.3pt;left:213.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and tolerability</span></p>
<p style="top:224.7pt;left:213.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown (estimated</span></p>
<p style="top:224.7pt;left:222.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:231.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">July 2014</span></p>
<p style="top:136.4pt;left:213.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01453738</span></p>
<p style="top:724.9pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Allogeneic Mesenchymal Stem Cells for</span></p>
<p style="top:724.9pt;left:272.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis</span></p>
<p style="top:555.4pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">1 year</span></p>
<p style="top:514.9pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Culture-expanded MSCs</span></p>
<p style="top:514.9pt;left:272.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">in 2 ml plasmalyte +</span></p>
<p style="top:514.9pt;left:281.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 ml, hyaluronan vs.</span></p>
<p style="top:514.9pt;left:290.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 ml, plasmalyte + 2 ml,</span></p>
<p style="top:514.9pt;left:299.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">hyaluronan</span></p>
<p style="top:409.2pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular</span></p>
<p style="top:322.3pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and tolerability</span></p>
<p style="top:224.7pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown (estimated</span></p>
<p style="top:224.7pt;left:272.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">study completion date;</span></p>
<p style="top:224.7pt;left:281.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">February 2013)</span></p>
<p style="top:136.4pt;left:263.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01448434</span></p>
<p style="top:724.9pt;left:313.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Autologous or allogenic unspecified</span></p>
<p style="top:724.9pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Transplantation of Bone Marrow Derived</span></p>
<p style="top:724.9pt;left:336.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Mesenchymal Stem Cells in Affected Knee</span></p>
<p style="top:724.9pt;left:345.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Osteoarthritis by Rheumatoid Arthritis</span></p>
<p style="top:555.4pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">6 months</span></p>
<p style="top:514.9pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">MSCs vs. saline</span></p>
<p style="top:409.2pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Intra-articular injection</span></p>
<p style="top:322.3pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Pain</span></p>
<p style="top:224.7pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Completed in December</span></p>
<p style="top:224.7pt;left:336.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2011; no publication</span></p>
<p style="top:224.7pt;left:345.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">found</span></p>
<p style="top:136.4pt;left:327.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01873625</span></p>
<p style="top:724.9pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety and Efficacy Study of MSB-CAR001 in</span></p>
<p style="top:724.9pt;left:368.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Subjects 6 Weeks Post an Anterior Cruciate</span></p>
<p style="top:724.9pt;left:377.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Ligament Reconstruction</span></p>
<p style="top:555.4pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">2 year</span></p>
<p style="top:514.9pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">MSB-CAR001 (a preparation</span></p>
<p style="top:514.9pt;left:368.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">of MSCs) with hyaluronan</span></p>
<p style="top:514.9pt;left:377.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">vs. hyaluronan alone</span></p>
<p style="top:409.2pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Injection</span></p>
<p style="top:322.3pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Safety</span></p>
<p style="top:224.7pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">Unknown</span></p>
<p style="top:136.4pt;left:359.3pt;line-height:8.0pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:8.0pt">NCT01088191</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 19 of 30</span></p>


<p style="top:87.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">TN, Italy) as a scaffold, which is then arthroscopically</span></p>
<p style="top:99.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">placed into the cartilage defect which had been pre-</span></p>
<p style="top:111.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">prepared using a burr or drill. The construct is then held</span></p>
<p style="top:123.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with a platelet gel obtained from a harvest of 120 mL of</span></p>
<p style="top:135.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">patient</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2019;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">s venous blood taken the day before surgery</span></p>
<p style="top:147.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(Vivostat system, (Vivolution, Denmark)) [118]. The results</span></p>
<p style="top:159.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of the first 30 patients have been reported as showing</span></p>
<p style="top:171.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">improvements in MRI and arthroscopic appearance as well</span></p>
<p style="top:183.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">as clinical scores at 3 years follow-up [118].</span></p>
<p style="top:195.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">This new technique is of course an evolution of the</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">autologous</span></p>
<p style="top:207.5pt;left:109.3pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">matrix-enhanced</span></p>
<p style="top:207.5pt;left:186.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chondrogenesis</span></p>
<p style="top:207.5pt;left:257.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(AMIC)</span></p>
<p style="top:219.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">which used the stem cells from the adjacent marrow</span></p>
<p style="top:231.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(and</span></p>
<p style="top:231.5pt;left:82.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">not pre-harvested</span></p>
<p style="top:231.5pt;left:168.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bone</span></p>
<p style="top:231.5pt;left:195.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">marrow</span></p>
<p style="top:231.5pt;left:235.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">concentrates)</span></p>
<p style="top:243.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">within either collagen patches [155</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">157] or polyglycolic</span></p>
<p style="top:255.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">acid</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">hyaluronan-based scaffolds [158, 159].</span></p>
<p style="top:267.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">There has also been a further step taken to avoid bone</span></p>
<p style="top:279.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">marrow harvest in which peripheral blood has been used</span></p>
<p style="top:291.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in knee chondral lesions. In an RCT, arthroscopic sub-</span></p>
<p style="top:303.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chondral drilling was followed by postoperative intra-</span></p>
<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">articular injections of hyaluronic acid (HA) with and</span></p>
<p style="top:327.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">without peripheral blood stem cells (PBSC). Fifty pa-</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tients were studied and randomised 1 week after surgery</span></p>
<p style="top:351.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">to receive either 8 injections of HA or 8 injections of</span></p>
<p style="top:363.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">HA plus PBSC. Those that underwent PBSC received</span></p>
<p style="top:375.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stimulation with filgrastim, which contains recombinant</span></p>
<p style="top:387.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">human granulocyte colony-stimulating factor prior to</span></p>
<p style="top:399.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">harvest [106, 151]. At 18 month follow-up, they reported</span></p>
<p style="top:411.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">no adverse effects and improved MRI findings in the</span></p>
<p style="top:423.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">PBSC group compared to HA alone, took biopsies of 16</span></p>
<p style="top:435.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of the 25 patients in each group and claimed better tis-</span></p>
<p style="top:447.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sue morphology in the PBSC group, as graded by the</span></p>
<p style="top:459.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">International Cartilage Repair Society Visual Assessment</span></p>
<p style="top:471.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Scale II. Interestingly, however, the same group</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2019;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">s pre-</span></p>
<p style="top:483.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">clinical used bone marrow aspirates and not peripheral</span></p>
<p style="top:495.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">blood [150].</span></p>
<p style="top:520.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Autologous vs. allogenic</span></p>
<p style="top:531.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">There is an increasing interest in allogenic cells to avoid</span></p>
<p style="top:543.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">donor site morbidity and to reduce cost. The pre-clinical</span></p>
<p style="top:555.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">data with regards to allogenic cells is conflicting. One</span></p>
<p style="top:567.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">group showed promising results of allogenic MSCs in a</span></p>
<p style="top:579.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">rabbit</span></p>
<p style="top:579.5pt;left:88.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">model</span></p>
<p style="top:579.5pt;left:122.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">when</span></p>
<p style="top:579.5pt;left:152.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">compared</span></p>
<p style="top:579.5pt;left:201.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">to</span></p>
<p style="top:579.5pt;left:217.8pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">autologous</span></p>
<p style="top:579.5pt;left:270.5pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells,</span></p>
<p style="top:591.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">although numbers were small [160, 161]. Another group</span></p>
<p style="top:603.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">compared autologous chondroprogenitor cells and allo-</span></p>
<p style="top:615.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">genic chondroprogenitor cells against controls in an</span></p>
<p style="top:627.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">equine model and reported inferior repair in the allo-</span></p>
<p style="top:639.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">genic cell group [23]. Despite conflicting pre-clinical</span></p>
<p style="top:651.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">data, human studies using allogenic cells began in Korea</span></p>
<p style="top:663.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in 2009. A phase I/IIa study to assess safety and efficacy</span></p>
<p style="top:675.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of a combination of human umbilical cord blood-</span></p>
<p style="top:687.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">derived mesenchymal stem cells and sodium hyaluronate</span></p>
<p style="top:699.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(CARTISTEM</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">&#xae;</span></sup><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(MEDIPOST Co., Ltd., Korea)) was per-</span></p>
<p style="top:711.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">formed in knee chondral defects (NCT01041001). A par-</span></p>
<p style="top:723.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">allel phase 3, open-label, multi-centre RCT comparing</span></p>
<p style="top:87.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CARTISTEM</span><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:6.9pt;color:#131313">&#xae;</span></sup><sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and microfracture in knee chondral defects</span></p>
<p style="top:99.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">was carried out in Korea and the USA (NCT01733186).</span></p>
<p style="top:111.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Results are still pending.</span></p>
<p style="top:123.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Another area of huge controversy is the actual dose of</span></p>
<p style="top:135.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells that should be used. In vitro between 50,000 cells/</span></p>
<p style="top:147.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mL and 100 billion cells/ml have been studied. In pre-</span></p>
<p style="top:159.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">clinical animal studies, this ranged from 1000 to 1 billion</span></p>
<p style="top:171.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells/mL, and in human studies, the reported range has</span></p>
<p style="top:183.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">been 1.2 million cells/mL</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">24 million cells/mL.</span></p>
<p style="top:195.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">It remains unclear what the most appropriate cell dose</span></p>
<p style="top:207.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">should be, with some groups reporting that a higher cell</span></p>
<p style="top:219.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">number leads to a better repair [52, 71, 87, 95, 162</span><span style="font-family:DfjcpxAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span></p>
<p style="top:231.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">164], but Zhao et al. [99] highlighted the limitation to</span></p>
<p style="top:243.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell saturation and survival, and thus, there may be a top</span></p>
<p style="top:255.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">limit to cell number that can be used to aid repair.</span></p>
<p style="top:267.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A multitude of methods for cell delivery have also</span></p>
<p style="top:279.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">been adopted, from direct joint injection or embedded</span></p>
<p style="top:291.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in a plethora of scaffolds, such as type I collagen gels of</span></p>
<p style="top:303.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">porcine or bovine origin, ascorbic acid sheets or fibrin</span></p>
<p style="top:315.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">glues (Table 14).</span></p>
<p style="top:327.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">In vitro and in pre-clinical studies, a plethora of</span></p>
<p style="top:339.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">growth factors have been studied including TGF-</span><span style="font-family:JgcgcsAdvTT86d47313+03,serif;font-size:9.8pt;color:#131313">&#x3b2;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">1 and</span></p>
<p style="top:351.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">TGF-</span><span style="font-family:JgcgcsAdvTT86d47313+03,serif;font-size:9.8pt;color:#131313">&#x3b2;</span><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">2 and BMP-7 but none of these have been</span></p>
<p style="top:363.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">included in human clinical trials (Table 5).</span></p>
<p style="top:375.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">It is clear that the relationship between cell passage,</span></p>
<p style="top:387.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell dose, the use of scaffolds and growth factors and the</span></p>
<p style="top:399.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">efficacy of MSC treatment is still to be established.</span></p>
<p style="top:424.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Future</span></p>
<p style="top:435.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">There is no question that the field of cartilage repair</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">accelerates at rapid pace, and it is clear that the single</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stage procedures are likely to win over two stage proce-</span></p>
<p style="top:471.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">dures to save costs and reduce the burden on both pro-</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">vider and the patient. The reduction of donor site</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">morbidity is a further driver helping direct progress.</span></p>
<p style="top:507.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The concept of cell banks of allogenic cells clearly</span></p>
<p style="top:519.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">meets all of the above criteria, but the lack of good sup-</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">porting pre-clinical and long-term safety and efficacy</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">data does little to pacify potential pitfalls of this</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">direction. The fact that the phase 3 RCT of allogenic</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">umbilical</span></p>
<p style="top:567.5pt;left:350.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stem cells</span></p>
<p style="top:567.5pt;left:403.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">was</span></p>
<p style="top:567.5pt;left:426.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">allowed</span></p>
<p style="top:567.5pt;left:465.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">to</span></p>
<p style="top:567.5pt;left:481.2pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">be</span></p>
<p style="top:567.5pt;left:498.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">registered</span></p>
<p style="top:579.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(NCT01041001) before the same group registered their</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">phase I/IIa safety study (NCT01733186) intimates that</span></p>
<p style="top:603.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sometimes clinical pace exceeds that of the regulators to</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lay down new ground.</span></p>
<p style="top:627.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Tools are likely to be introduced to the operating</span></p>
<p style="top:639.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">theatre that might improve the efficacy of treatment,</span></p>
<p style="top:651.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">such</span></p>
<p style="top:651.5pt;left:332.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">as</span></p>
<p style="top:651.5pt;left:349.6pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">fluorescence-activated</span></p>
<p style="top:651.5pt;left:448.9pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell</span></p>
<p style="top:651.5pt;left:471.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sorting</span></p>
<p style="top:651.5pt;left:509.1pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(FACS)</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">machines which can isolate MSCs from the buffy coat of</span></p>
<p style="top:675.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bone marrow aspirate by their cell surface markers. At</span></p>
<p style="top:687.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">present, this technology is expensive and complicated</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and ways to reduce cost and make the process simple</span></p>
<p style="top:711.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">are required before they could enter the operating</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">theatre.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 20 of 30</span></p>


<p style="top:87.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Induced pluripotent</span></p>
<p style="top:87.5pt;left:159.4pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stem cells (iPSCs) are adult</span></p>
<p style="top:99.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">somatic cells that have been genetically reprogrammed</span></p>
<p style="top:111.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">to an embryonic stem cell-like state by being forced to</span></p>
<p style="top:123.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">express genes and factors important for maintaining the</span></p>
<p style="top:135.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">defining properties of embryonic stem cells [165].</span></p>
<p style="top:147.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">These cells show unlimited self-renewal, and some in</span></p>
<p style="top:159.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">vitro studies have shown chondrogenic differentiation by</span></p>
<p style="top:171.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">iPSCs from human chondrocytes biopsied from osteo-</span></p>
<p style="top:183.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">arthritic knees [166] and cartilage formation from hu-</span></p>
<p style="top:195.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">man neural stem cells [167]. However, this work is at a</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">very early stage, and aside from the ethical consider-</span></p>
<p style="top:219.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ations, much research into control of cell phenotype and</span></p>
<p style="top:231.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell fate to alleviate concerns for cancer risk are required</span></p>
<p style="top:243.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">before this technology is ready to move into the pre-</span></p>
<p style="top:255.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">clinical and clinical realms.</span></p>
<p style="top:267.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">In conclusion, this review is a comprehensive assess-</span></p>
<p style="top:279.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ment of the evidence base to date behind the translation</span></p>
<p style="top:291.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of basic science to the clinical practice of cartilage</span></p>
<p style="top:303.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">repair. We have revealed a lack of connectivity between</span></p>
<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the in vitro, pre-clinical and human data and a patch-</span></p>
<p style="top:327.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">work quilt of synergistic evidence. It appears that the</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">drivers for progress in this space are largely driven by</span></p>
<p style="top:351.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">patient demand, surgeon inquisition, and a regulatory</span></p>
<p style="top:363.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">framework that is learning at the same pace as new</span></p>
<p style="top:375.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">developments take place. We strongly recommend fund-</span></p>
<p style="top:387.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ing body commission studies that have a clear transla-</span></p>
<p style="top:399.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tional purpose in order to drive the science towards</span></p>
<p style="top:411.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:TrbphwAdvTT86d47313,serif;font-size:9.8pt;color:#131313">patient benefit.</span></p>
<p style="top:432.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Abbreviations</span></p>
<p style="top:441.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">ACI:</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Autologous chondrocyte implantation; AMIC: Autologous matrix-</span></p>
<p style="top:450.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">enhanced chondrogenesis; AOFAS: American Orthopaedic Foot &amp; Ankle</span></p>
<p style="top:459.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Society; FACS: Fluorescence-activated cell sorting; HA: Hydroxyapatite;</span></p>
<p style="top:468.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">IKDC: International Knee Documentation Committee; iPSCs: Induced</span></p>
<p style="top:477.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">pluripotent stem cells; KOOS: Knee and Osteoarthritis Outcome Score;</span></p>
<p style="top:486.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">MACI: Matrix-induced autologous chondrocyte implantation; MeSH: Medical</span></p>
<p style="top:495.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Subject Headings; MSC: Mesenchymal stem cells; OA: Osteoarthritis;</span></p>
<p style="top:504.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">PBS: Phosphate-buffered saline; PBSC: Peripheral blood stem cells;</span></p>
<p style="top:513.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">PRP: Platelet rich plasma; qPCR: Real-time polymerase chain reaction;</span></p>
<p style="top:522.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">RCT: Randomised controlled trial; VAS: Visual analogue scale;</span></p>
<p style="top:531.2pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">WOMAC: Western Ontario and McMaster Universities Arthritis Index</span></p>
<p style="top:550.0pt;left:56.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Acknowledgements</span></p>
<p style="top:559.1pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">None</span></p>
<p style="top:577.9pt;left:56.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Funding</span></p>
<p style="top:586.9pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">There was no external funding for this work.</span></p>
<p style="top:605.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Availability of data and materials</span></p>
<p style="top:614.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Not applicable</span></p>
<p style="top:633.6pt;left:56.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Authors</span><span style="font-family:PjpphcAdvTT99c4c969+20,serif;font-size:7.5pt;color:#131313">&#x2019;</span><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313"> contributions</span></p>
<p style="top:642.6pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">All authors were involved in the conception and design of the study or</span></p>
<p style="top:651.6pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">acquisition of the data or analysis and interpretation of the data and</span></p>
<p style="top:660.6pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">contributed to drafting the article or revising it critically for important</span></p>
<p style="top:669.6pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">intellectual content. All authors read and approved the final manuscript.</span></p>
<p style="top:688.5pt;left:56.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Competing interests</span></p>
<p style="top:697.5pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">The authors declare that they have no competing interests.</span></p>
<p style="top:716.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Consent for publication</span></p>
<p style="top:725.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Not applicable</span></p>
<p style="top:89.4pt;left:304.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Ethics approval and consent to participate</span></p>
<p style="top:98.3pt;left:304.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Not applicable</span></p>
<p style="top:116.3pt;left:304.7pt;line-height:7.5pt"><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Author details</span></p>
<p style="top:123.8pt;left:304.7pt;line-height:5.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:5.3pt">1</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">Institute of Orthopaedics and Musculoskeletal Science, Royal National</span></p>
<p style="top:134.3pt;left:304.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">Orthopaedic Hospital (RNOH), Brockley Hill Stanmore, London HA7 4LP, UK.</span></p>
<p style="top:141.7pt;left:304.7pt;line-height:5.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:5.3pt">2</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">Joint Research and Enterprise Office, St George</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">s University of London and</span></p>
<p style="top:152.3pt;left:304.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">St George</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">s University Hospitals NHS Foundation Trust, Hunter Wing,</span></p>
<p style="top:161.4pt;left:304.7pt;line-height:7.5pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.5pt">Cranmer Terrace, London SW17 0RE, UK.</span></p>
<p style="top:179.3pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:7.5pt;color:#131313">Received: 2 January 2017 Accepted: 13 February 2017</span></p>
<img style="position:absolute;transform:matrix(.15999878,0,-0,.16000001,-55.701967,211.57337)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAABEwAAABaCAAAAACHqpzzAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAALoklEQVR4nO1a23bjOAzT//909uyZtrElgARl+ZIWeIoligQvQpzO
tJdhGMYCtLsJGIbxO2AxMQxjCSwmhmEsgcXEMIwlsJgYhrEEFhPDMJbAYmIYxhJY
TAzDWAKLiWEYS2AxMQxjCSwmhmEsgcXEMIwlsJgYhrEEFhPDMJbAYmIYxhJYTAzD
WIIzxKQ1xeto1bSDxThFnOJUjFQtgHEArvVyrC9ok64EsGrayVqcIk5xqkYqFuAU
CBzaE3gexZEUtAKoVfr4Ur7RvkszYNJfodANrYlxT5no667J8QKcgrz7lREpztOK
8RNxIIZIUk2Em5Br+WTp+aK2hrd2kFgVYp5S2Ou6dbwAJ+E7ejLhr9hmPKDldVX9
DzVavCB5JbfOhECFOt6Hb2od1SnmrSkXglnpEbU4RZzitBTp7mHZBic8tst6t7S8
rrosRxotXm2hkq9M1ECom+cjRzcbG6Zz1EuDg9b8M+eC8JQSfNiZdAcqv140O53x
PCZDiXdbqGT+awnGunM+BHAxOaQmM1a1cKcU9upxvis6AlAKYDEMiOY4N732rhwQ
k60DLhTw0HZx64QS/D1iMqcm82JS+5fRXygmtQIsBlKK2GLtq8kHiAkQCSwUWSV7
F8HWJ2mJIiY1+gfE5IQ4T3B6cyQNuPmxSanXieXFl2VWTEYfgxuhkr0LtgNXa5wv
RSQmU2piMXlYJA35FaDzIbnOTD9ATLBsnCMmgcQUGF8Ni8npTm+OJIE1P7QQs1DE
RBKchZgTE+gkF1geKxITYl4gfDkkMalkYDF5WCQJgM1KMUn//KbYrMREKPKro/eT
V3J0IAV7fbiYzLyaWEweFkkB731oot3/jVAwy/ZrxESo5OhAifVtrhO+HhaT053e
HElBfgXwIMhiklgKJmsxIybMyxlighk8aGIgLCanO705koKg9/ApPAhsskn6BDHh
bjQxYX8E0Xk8aWIgLCanO705kgDc5aViEt6b3GI1zhIToZLh+TTaJNFrYDE53enN
kQQcFZM4j51UsLd90dcqfKKYPGhgCM4Vk6SKaJmYtj1b/JM+pJRtp24KTnNmcgGO
J5mnJFwB4l2Zj11tyTCkBunpLyt2FC7jpwIG50q06HwWbILjhZDF5N3Q/ggqZ7c/
hqU1xwTCOC8ep/MQ7+tTFTtVmIkFWJCkkJNAMUyjIiZY7SJfu+R4ydA+Pbhdigqb
YDhXaDbjHAarU7wSoZh0VQZFH5fez+kMwGDDGtnFccb8glF79bNY+Y0Wcs6ZSQXQ
XMVJ0kNR4HFZseHuQyJdiigCC4YKhI6Sg7tzWRoktTFioUqVuFMEr0VFTJAN7mD3
KjPWgXRhdN6ZpHHGMFmCI4dXDHAI53GsACVXPEkhKWKxWyZulIp97zPbcB+VpMus
K9Du6P5kz/sVFzYH6SI2s5iQHvCl7+fWIzrV4H9rCh83cbZcB6WLyIMAecvgIZRH
xCwvgOwqSVJIiljslokbpWJhHTb8aZn6cN+f9wXq3Yd1kXqUghUb2/1tMRkrzNo9
mvQjkpyCBIAFiBOeB/l0z2G+AKRKYx6tpza6EQqQuhLpHBUTYiRWLHHBt0lt++e2
EZTN1kC0f4ymRwBtGLQ7JiZ1dtej9oLM2g2Gt3ccjzzz1BtE7BBbEAC/B0MDAFaA
GjOtAEuShJFQXE1MYLCamIxZUxooW5Tcv6WBLs9R6lEK1i9o96fFBLWeztNwbDQ5
LiYvKU54vh8otF8UE/p1WeFK1nJXgpd0DKUrgMahKCbs3YPvkvQpgZ9PWSXFjiQQ
+hUt/3ox6Wcn/T7F7QUm2SsO9tRZVKiM1R8zjAwQOO/hFTo+phRgQZIStCuABgIO
CfATu+A00rlh8RlT6ni6bsDHGWJS5XYLhlnZo7fOe4DOjc64VfdM2ApUKH325UVo
jQZwsTioSgEWJClBuwJgJMiUjH54pHBzWkzS4ko9ysCCWEx+8mo/ANZ5D+DRdChE
T6vFRMhP2G9j4F8oJqN0BIPS+aEuEjEZ8pOmjX9RROfmygaWLCZaXkIPoBs0Q+ld
ikc1pdIo3tuCU2G/4ykNqlKA40lqICdI03YFVGIBujuXCQ2BErbLHWVLMYC5Wsl0
Q4j1QDxYTGI1yag0jve+4FTY73hKgyoV4HCSGsiJcbkPocXaGvQHoj3Cp6XTJuiC
1KMYWsmiZYtJ1gOtvcgqmt06lSybmSlkZNoY+UIxoXRV6Fdg05HGD45+Bgebx4zG
dndy2oi3Q2IiDEK2bDHJeqC1t3KX5IEZ5nTyHSM59IfFpIuv3QXQ+JZvgaiv2Wkj
/j5HTJa0+Xw8Wkz279U1Kkk2U1PIajTckHxQtZQOJimiegU6gxkxaXyLBNra9Gcw
sYRT3qPMAXNrMZHyEnqgtVe7S29aUu8r92xqClmN2hj5k8Rk9kqKV2Fvsj3Ed4Yw
hNMk88NiwkyLfMQKWkzKVtHJkd3BezY1heG4W0y42Xio0R0UhHKaZH5UTKhlkY9e
wU/QkueLCXs5ke5Zpgvaas8kWZcGVSvAwSRVQDfpQIg34QVzatFGv8iZRm3MdTBb
io7LfiM6YgmXNPkCfICYbOVEp5Kko9HEPJJ1aVC1AhxMUgXMKx0I8SYQzWiSmPQr
lWk7T0y4XbGSYgmXNPkCXCkmsaOwm98TyF94+6UknWgKk0O/T0zK7XjvC8FhTq0N
VwQ4HFYK04ZvLz+n17I6V9yzVsM1Pb4AHyIm2y80jUoyUHg7qUHPAR+TBlUrwMEk
ZdTbUbh8OING1/ulKGjUD6j6/Nx0PqkX7pn3r7cSeN2PjxGTnmBKhblr82LCilRk
xiJJVpUkZRxvR+wcnSSZxVOiTVvwCsnPqfnERrVKakUU63w/rhETYUyAp9CJeM/o
QGk84f7jxCS4NSIYm/jA5K+C1uDpcTEvCE2ftDc4JyaU2ZQqKVVRrfP9uFBMEkep
mOy9qPeMDVQwz33cfj9JTxpULfrRJGVoBPXtzhSdZcslVoRGWhapR1IyX8sFziPP
NKTFpDdKHAFPkZecChvZYDetARvSMW7iVynA8SR14NCxuRiE1EtYzQvCeLDuBuek
lIjFQGlwTN3lQfVK342jYjIco7ckcXSemPTjyZgTWsAgTk/yqxRgQZLgEaNyBWpa
clhMInlhREhZonNKTsRgpDg4pv7SoIVK342amJBmKmIS+yG+AzfCOLQ3NguculID
ZJJXYFxSCrAgSRKJJUYfM6KJ5yTY1mvUD23adqb7747onJAUDzU4oo+IZRb0T4jJ
/x9xw4dDoR+8Fvup3bNhtl5gNIHNCDLycW7jklKAFUniF36WF08q4x57ToLtmI4r
3bvkv+cWU5F6X8wK+iSOklxpytgmNHgOpsSk/XRys9K27c1es1Ew2HDqRxmHpO/7
tdbakAwvQZCfwmydmKhJ0nx2hvAhMhTA2g8XUf5f6rFp0M8vC56cUhVwIM6DIcgu
9Cr0pljsWwFVP7Lvi9hXdHAUzA0dnM3C/jHyECyRtg+bbDzAqd1jktu4JBVgSZJC
QmMi0QnRW2yPl7LUhmmLkouqoi0l/kjBX3IlpUtXrPat6CWgpCabZ2Tx88R9RGv7
58waC4HQ9e1mqQTvz0luPDWtAIeSJJnTvGBSwEYFLTy2C1LbPXe7QeTQa7QUeuMF
/zHefUhcMpNPExOtPJsTextkHvpCoWB4Sgqsc/5xVoiHUjXiVWKGuEpWc0my1OO0
gn3JFUpqV6nIbmPbLyjViPMpFTYhSe0TZ9mvsL0d9vBATDDdp57Ufp7Z7k9sRxwl
HrabepwF+S1FwKdEM/RyS75d3BqJG7u0JvKTZizF5zA1DOPRsJgYhrEEFhPDMJbA
YmIYxhJYTAzDWAKLiWEYS2AxMQxjCSwmhmEsgcXEMIwlsJgYhrEEFhPDMJbAYmIY
xhJYTAzDWAKLiWEYS2AxMQxjCSwmhmEsgcXEMIwlsJgYhrEEFhPDMJbAYmIYxhJY
TAzDWAKLiWEYS/Afo//ppWYVjUwAAAAASUVORK5CYII=">
<p style="top:221.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1.</span><sup><span style="font-family:YdwhbkAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">References</span></sup></p>
<p style="top:221.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Oldershaw RA. Cell sources for the regeneration of articular cartilage: the</span></p>
<p style="top:230.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">past, the horizon and the future. Int J Exp Pathol. 2012;93(6):389</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">400.</span></p>
<p style="top:239.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1111/j.1365-2613.2012.00837.x.</span></p>
<p style="top:248.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2.</span></p>
<p style="top:248.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Dozin B, Malpeli M, Cancedda R, et al. Comparative evaluation of</span></p>
<p style="top:257.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous chondrocyte implantation and mosaicplasty: a multicentered</span></p>
<p style="top:266.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">randomized clinical trial. Clin J Sport Med. 2005;15(4):220</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">6. Available at:</span></p>
<p style="top:275.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">https://www.ncbi.nlm.nih.gov/pubmed/16003035. Accessed 12 June 2016.</span></p>
<p style="top:284.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">3.</span></p>
<p style="top:284.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Levy AS, Lohnes J, Sculley S, LeCroy M, Garrett W. Chondral delamination of</span></p>
<p style="top:293.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">the knee in soccer players. Am J Sports Med. 1996;24(5):634</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. Available at:</span></p>
<p style="top:302.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">http://www.ncbi.nlm.nih.gov/pubmed/8883684. Accessed 12 June 2016.</span></p>
<p style="top:311.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">4.</span></p>
<p style="top:311.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Badri A, Burkhardt J. Arthroscopic debridement of unicompartmental</span></p>
<p style="top:320.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">arthritis: fact or fiction? Clin Sports Med. 2014;33(1):23</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41. doi:10.1016/j.</span></p>
<p style="top:329.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">csm.2013.08.008.</span></p>
<p style="top:338.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">5.</span></p>
<p style="top:338.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Moseley JB, O</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Malley K, Petersen NJ, et al. A controlled trial of arthroscopic</span></p>
<p style="top:347.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">surgery for osteoarthritis of the knee. N Engl J Med. 2002;347(2):81</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8.</span></p>
<p style="top:356.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1056/NEJMoa013259.</span></p>
<p style="top:365.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">6.</span></p>
<p style="top:365.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bedi A, Feeley BT, Williams RJ. Management of articular cartilage</span></p>
<p style="top:374.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects of the knee. J Bone Joint Surg Am. 2010;92(4):994</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1009.</span></p>
<p style="top:383.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.2106/JBJS.I.00895.</span></p>
<p style="top:392.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:392.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Steinwachs MR, Guggi T, Kreuz PC. Marrow stimulation techniques. Injury.</span></p>
<p style="top:401.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2008;39 Suppl 1:S26</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">31. doi:10.1016/j.injury.2008.01.042.</span></p>
<p style="top:410.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8.</span></p>
<p style="top:410.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG.</span></p>
<p style="top:419.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Outcomes of microfracture for traumatic chondral defects of the knee:</span></p>
<p style="top:428.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">average 11-year follow-up. Arthroscopy. 19(5):477-84. doi:10.1053/jars.</span></p>
<p style="top:437.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2003.50112.</span></p>
<p style="top:446.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9.</span></p>
<p style="top:446.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Peterson L, Menche D, Grande D PM. Chondrocyte transplantation: an</span></p>
<p style="top:455.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">experimental model in the rabbit. Trans Orthop Res Soc. 1984;9:218.</span></p>
<p style="top:464.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">10.</span></p>
<p style="top:464.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L.</span></p>
<p style="top:473.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Treatment of deep cartilage defects in the knee with autologous</span></p>
<p style="top:482.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrocyte transplantation. N Engl J Med. 1994;331(14):889</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">95.</span></p>
<p style="top:491.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1056/NEJM199410063311401.</span></p>
<p style="top:500.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">11.</span></p>
<p style="top:500.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Jones DG, Peterson L. Autologous chondrocyte implantation. J Bone Joint</span></p>
<p style="top:509.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Surg Am. 2006;88(11):2502</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">20. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:518.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/17115530. Accessed 12 June 2016.</span></p>
<p style="top:527.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12.</span></p>
<p style="top:527.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Minas T. Autologous chondrocyte implantation in the arthritic knee.</span></p>
<p style="top:536.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Orthopedics. 2003;26(9):945</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:545.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/14503759. Accessed 12 June 2016.</span></p>
<p style="top:554.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">13.</span></p>
<p style="top:554.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Brittberg M. Cell carriers as the next generation of cell therapy for</span></p>
<p style="top:563.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage repair: a review of the matrix-induced autologous chondrocyte</span></p>
<p style="top:572.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">implantation procedure. Am J Sports Med. 2010;38(6):1259</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">71. doi:10.1177/</span></p>
<p style="top:581.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">0363546509346395.</span></p>
<p style="top:590.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">14.</span></p>
<p style="top:590.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Matsusue Y, Yamamuro T, Hama H. Arthroscopic multiple osteochondral</span></p>
<p style="top:599.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplantation to the chondral defect in the knee associated with anterior</span></p>
<p style="top:608.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cruciate ligament disruption. Arthroscopy. 1993;9(3):318</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">21. Available at:</span></p>
<p style="top:617.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">http://www.ncbi.nlm.nih.gov/pubmed/8323618. Accessed 12 June 2016.</span></p>
<p style="top:626.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">15.</span></p>
<p style="top:626.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bentley G, Biant LC, Vijayan S, Macmull S, Skinner JA, Carrington RWJ.</span></p>
<p style="top:635.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Minimum ten-year results of a prospective randomised study of autologous</span></p>
<p style="top:644.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrocyte implantation versus mosaicplasty for symptomatic articular</span></p>
<p style="top:653.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage lesions of the knee. J Bone Joint Surg Br. 2012;94(4):504</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9.</span></p>
<p style="top:662.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1302/0301-620X.94B4.27495.</span></p>
<p style="top:671.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">16.</span></p>
<p style="top:671.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">De Caro F, Bisicchia S, Amendola A, Ding L. Large fresh osteochondral</span></p>
<p style="top:680.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">allografts of the knee: a systematic clinical and basic science review of the</span></p>
<p style="top:689.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">literature. Arthroscopy. 2015;31(4):757</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">65. doi:10.1016/j.arthro.2014.11.025.</span></p>
<p style="top:698.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">17.</span></p>
<p style="top:698.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Capeci CM, Turchiano M, Strauss EJ, Youm T. Osteochondral allografts:</span></p>
<p style="top:707.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">applications in treating articular cartilage defects in the knee. Bull Hosp Jt Dis.</span></p>
<p style="top:716.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;71(1):60</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24032585.</span></p>
<p style="top:725.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Accessed 12 June 2016.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 21 of 30</span></p>


<p style="top:89.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">18.</span></p>
<p style="top:89.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bugbee WD, Khanna G, Cavallo M, McCauley JC, G&#xf6;rtz S, Brage ME.</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bipolar fresh osteochondral allografting of the tibiotalar joint. J Bone</span></p>
<p style="top:107.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Joint Surg Am. 2013;95(5):426</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">32. doi:10.2106/JBJS.L.00165.</span></p>
<p style="top:116.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">19.</span></p>
<p style="top:116.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Gossec L, Paternotte S, Maillefert JF, et al. The role of pain and functional</span></p>
<p style="top:125.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">impairment in the decision to recommend total joint replacement in hip</span></p>
<p style="top:134.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">and knee osteoarthritis: an international cross-sectional study of 1909</span></p>
<p style="top:143.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">patients. Report of the OARSI-OMERACT Task Force on total joint</span></p>
<p style="top:152.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">replacement. Osteoarthritis Cartilage. 2011;19(2):147</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">54. doi:10.1016/</span></p>
<p style="top:161.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.joca.2010.10.025.</span></p>
<p style="top:171.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">20.</span></p>
<p style="top:171.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Shapiro F, Koide S, Glimcher MJ. Cell origin and differentiation in the repair</span></p>
<p style="top:180.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of full-thickness defects of articular cartilage. J Bone Joint Surg Am. 1993;</span></p>
<p style="top:189.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">75(4):532</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8478382.</span></p>
<p style="top:198.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Accessed 12 June 2016.</span></p>
<p style="top:207.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">21.</span></p>
<p style="top:207.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Mithoefer K, Williams RJ, Warren RF, Wickiewicz TL, Marx RG. High-impact</span></p>
<p style="top:216.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">athletics after knee articular cartilage repair: a prospective evaluation of the</span></p>
<p style="top:225.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">microfracture technique. Am J Sports Med. 2006;34(9):1413</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8. doi:10.1177/</span></p>
<p style="top:234.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">0363546506288240.</span></p>
<p style="top:243.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">22.</span></p>
<p style="top:243.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Gobbi A, Nunag P, Malinowski K. Treatment of full thickness chondral</span></p>
<p style="top:252.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">lesions of the knee with microfracture in a group of athletes. Knee Surg</span></p>
<p style="top:261.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Sports Traumatol Arthrosc. 2005;13(3):213</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">21. doi:10.1007/s00167-004-0499-3.</span></p>
<p style="top:270.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">23.</span></p>
<p style="top:270.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Frisbie DD, Trotter GW, Powers BE, et al. Arthroscopic subchondral bone</span></p>
<p style="top:279.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">plate microfracture technique augments healing of large chondral defects</span></p>
<p style="top:288.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in the radial carpal bone and medial femoral condyle of horses. Vet Surg.</span></p>
<p style="top:297.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">28(4):242-55. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10424704.</span></p>
<p style="top:306.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Accessed 12 June 2016.</span></p>
<p style="top:316.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">24.</span></p>
<p style="top:316.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bae DK, Yoon KH, Song SJ. Cartilage healing after microfracture in</span></p>
<p style="top:325.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteoarthritic knees. Arthroscopy. 2006;22(4):367</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">74. doi:10.1016/j.arthro.</span></p>
<p style="top:334.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2006.01.015.</span></p>
<p style="top:343.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">25.</span></p>
<p style="top:343.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Brown WE, Potter HG, Marx RG, Wickiewicz TL, Warren RF. Magnetic</span></p>
<p style="top:352.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">resonance imaging appearance of cartilage repair in the knee. Clin Orthop</span></p>
<p style="top:361.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Relat Res. 2004;(422):214-23. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:370.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/15187860. Accessed 12 June 2016.</span></p>
<p style="top:379.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">26.</span></p>
<p style="top:379.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Minas T, Gomoll AH, Rosenberger R, Royce RO, Bryant T. Increased failure</span></p>
<p style="top:388.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">rate of autologous chondrocyte implantation after previous treatment with</span></p>
<p style="top:397.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">marrow stimulation techniques. Am J Sports Med. 2009;37(5):902</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8.</span></p>
<p style="top:406.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1177/0363546508330137.</span></p>
<p style="top:416.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">27.</span></p>
<p style="top:416.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bartha L, Vajda A, Duska Z, Rahmeh H, Hangody L. Autologous osteochondral</span></p>
<p style="top:425.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mosaicplasty grafting. J Orthop Sports Phys Ther. 2006;36(10):739</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">50.</span></p>
<p style="top:434.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.2519/jospt.2006.2182.</span></p>
<p style="top:443.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">28.</span></p>
<p style="top:443.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Feczk&#xf3; P, Hangody L, Varga J, et al. Experimental results of donor site filling</span></p>
<p style="top:452.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">for autologous osteochondral mosaicplasty. Arthroscopy. 2003;19(7):755</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">61.</span></p>
<p style="top:461.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/12966384. Accessed</span></p>
<p style="top:470.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12 June 2016.</span></p>
<p style="top:479.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">29.</span></p>
<p style="top:479.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bentley G, Bhamra JS, Gikas PD, Skinner JA, Carrington R, Briggs TW.</span></p>
<p style="top:488.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Repair of osteochondral defects in joints</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2014;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">how to achieve success.</span></p>
<p style="top:497.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Injury. 2013;44 Suppl 1:S3</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">10. doi:10.1016/S0020-1383(13)70003-2.</span></p>
<p style="top:506.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">30.</span></p>
<p style="top:506.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Wood JJ, Malek MA, Frassica FJ, et al. Autologous cultured chondrocytes:</span></p>
<p style="top:515.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adverse events reported to the United States Food and Drug</span></p>
<p style="top:524.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Administration. J Bone Joint Surg Am. 2006;88(3):503</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. doi:10.2106/</span></p>
<p style="top:533.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">JBJS.E.00103.</span></p>
<p style="top:543.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">31.</span></p>
<p style="top:543.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Peterson L, Minas T, Brittberg M, Nilsson A, Sj&#xf6;gren-Jansson E, Lindahl A.</span></p>
<p style="top:552.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Two- to 9-year outcome after autologous chondrocyte transplantation</span></p>
<p style="top:561.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of the knee. Clin Orthop Relat Res. 2000;(374):212-34. Available at:</span></p>
<p style="top:570.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">http://www.ncbi.nlm.nih.gov/pubmed/10818982. Accessed 12 June 2016.</span></p>
<p style="top:579.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">32.</span></p>
<p style="top:579.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Benya PD, Shaffer JD. Dedifferentiated chondrocytes reexpress the</span></p>
<p style="top:588.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiated collagen phenotype when cultured in agarose gels.</span></p>
<p style="top:597.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Cell. 1982;30(1):215</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">24. Available at: http://www.ncbi.nlm.nih.gov/pubmed/</span></p>
<p style="top:606.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7127471. Accessed 12 June 2016.</span></p>
<p style="top:615.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">33.</span></p>
<p style="top:615.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Takata N, Furumatsu T, Abe N, Naruse K, Ozaki T. Comparison between</span></p>
<p style="top:624.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">loose fragment chondrocytes and condyle fibrochondrocytes in cellular</span></p>
<p style="top:633.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">proliferation and redifferentiation. J Orthop Sci. 2011;16(5):589</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">97. doi:10.1007/</span></p>
<p style="top:642.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">s00776-011-0128-1.</span></p>
<p style="top:651.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">34.</span></p>
<p style="top:651.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Keramaris NC, Kanakaris NK, Tzioupis C, Kontakis G, Giannoudis PV.</span></p>
<p style="top:660.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Translational research: from benchside to bedside. Injury. 2008;39(6):643</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">50.</span></p>
<p style="top:669.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.injury.2008.01.051.</span></p>
<p style="top:679.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">35.</span></p>
<p style="top:679.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Woolf SH. The meaning of translational research and why it matters.</span></p>
<p style="top:688.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">JAMA. 2008;299(2):211</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">3. doi:10.1001/jama.2007.26.</span></p>
<p style="top:698.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">36.</span></p>
<p style="top:698.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bartlett W, Skinner JA, Gooding CR, et al. Autologous chondrocyte</span></p>
<p style="top:707.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">implantation versus matrix-induced autologous chondrocyte implantation</span></p>
<p style="top:716.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">for osteochondral defects of the knee: a prospective, randomised study.</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Bone Joint Surg Br. 2005;87(5):640</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">5. doi:10.1302/0301-620X.87B5.15905.</span></p>
<p style="top:89.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">37.</span></p>
<p style="top:89.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Bhosale AM, Richardson JB. Articular cartilage: structure, injuries and review</span></p>
<p style="top:98.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of management. Br Med Bull. 2008;87:77</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">95. doi:10.1093/bmb/ldn025.</span></p>
<p style="top:107.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">38.</span></p>
<p style="top:107.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Koga H, Engebretsen L, Brinchmann JE, Muneta T, Sekiya I. Mesenchymal</span></p>
<p style="top:116.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cell-based therapy for cartilage repair: a review. Knee Surg Sports</span></p>
<p style="top:125.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Traumatol Arthrosc. 2009;17(11):1289</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">97. doi:10.1007/s00167-009-0782-4.</span></p>
<p style="top:135.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">39.</span></p>
<p style="top:135.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Kon E, Verdonk P, Condello V, et al. Matrix-assisted autologous chondrocyte</span></p>
<p style="top:144.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplantation for the repair of cartilage defects of the knee: systematic</span></p>
<p style="top:153.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">clinical data review and study quality analysis. Am J Sports Med. 2009;37</span></p>
<p style="top:162.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Suppl 1:156S</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">66S. doi:10.1177/0363546509351649.</span></p>
<p style="top:171.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">40.</span></p>
<p style="top:171.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Lubis AM, Lubis VK. Adult bone marrow stem cells in cartilage therapy.</span></p>
<p style="top:180.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Acta Med Indones. 2012;44(1):62</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:189.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/22451188. Accessed 12 June 2016.</span></p>
<p style="top:198.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41.</span></p>
<p style="top:198.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Magnussen RA, Dunn WR, Carey JL, Spindler KP. Treatment of focal articular</span></p>
<p style="top:207.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage defects in the knee: a systematic review. Clin Orthop Relat Res.</span></p>
<p style="top:216.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2008;466(4):952</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">62. doi:10.1007/s11999-007-0097-z.</span></p>
<p style="top:226.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">42.</span></p>
<p style="top:226.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Matsumoto T, Okabe T, Ikawa T, et al. Articular cartilage repair with autologous</span></p>
<p style="top:235.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow mesenchymal cells. J Cell Physiol. 2010;225(2):291</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">5.</span></p>
<p style="top:244.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1002/jcp.22223.</span></p>
<p style="top:253.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">43.</span></p>
<p style="top:253.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Maumus M, Gu&#xe9;rit D, Toupet K, Jorgensen C, No&#xeb;l D. Mesenchymal stem</span></p>
<p style="top:262.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cell-based therapies in regenerative medicine: applications in rheumatology.</span></p>
<p style="top:271.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Stem Cell Res Ther. 2011;2(2):14. doi:10.1186/scrt55.</span></p>
<p style="top:280.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">44.</span></p>
<p style="top:280.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Pastides P, Chimutengwende-Gordon M, Maffulli N, Khan W. Stem cell</span></p>
<p style="top:289.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">therapy for human cartilage defects: a systematic review. Osteoarthritis</span></p>
<p style="top:298.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Cartilage. 2013;21(5):646</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">54. doi:10.1016/j.joca.2013.02.008.</span></p>
<p style="top:307.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">45.</span></p>
<p style="top:307.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ye K, Di Bella C, Myers DE, Choong PFM. The osteochondral dilemma: review</span></p>
<p style="top:316.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of current management and future trends. ANZ J Surg. 2014;84(4):211</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:325.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1111/ans.12108.</span></p>
<p style="top:335.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">46.</span></p>
<p style="top:335.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zengerink M, Struijs PAA, Tol JL, van Dijk CN. Treatment of osteochondral</span></p>
<p style="top:344.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">lesions of the talus: a systematic review. Knee Surg Sports Traumatol</span></p>
<p style="top:353.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arthrosc. 2010;18(2):238</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">46. doi:10.1007/s00167-009-0942-6.</span></p>
<p style="top:362.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">47.</span></p>
<p style="top:362.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Liberati A, Altman DG, Tetzlaff J, et al. PRISMA statement for reporting</span></p>
<p style="top:371.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">systematic reviews and meta-analyses of studies that evaluate healthcare</span></p>
<p style="top:380.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">interventions: explanation and elaboration. BMJ. 2009;339:b2700. Available</span></p>
<p style="top:389.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">at: http://www.ncbi.nlm.nih.gov/pubmed/19622552. Accessed 12 June 2016.</span></p>
<p style="top:398.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">48.</span></p>
<p style="top:398.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zhang B, Yang S, Sun Z, et al. Human mesenchymal stem cells induced by</span></p>
<p style="top:407.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">growth differentiation factor 5: an improved self-assembly tissue</span></p>
<p style="top:416.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">engineering method for cartilage repair. Tissue Eng Part C Methods.</span></p>
<p style="top:425.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2011;17(12):1189</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">99. doi:10.1089/ten.tec.2011.0011.</span></p>
<p style="top:435.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">49.</span></p>
<p style="top:435.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Nam HY, Karunanithi P, Loo WC, et al. The effects of staged intra-articular</span></p>
<p style="top:444.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">injection of cultured autologous mesenchymal stromal cells on the repair</span></p>
<p style="top:453.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of damaged cartilage: a pilot study in caprine model. Arthritis Res Ther.</span></p>
<p style="top:462.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;15(5):R129. doi:10.1186/ar4309.</span></p>
<p style="top:471.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">50.</span></p>
<p style="top:471.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Li Z, Kupcsik L, Yao S-J, Alini M, Stoddart MJ. Chondrogenesis of human</span></p>
<p style="top:480.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow mesenchymal stem cells in fibrin-polyurethane composites.</span></p>
<p style="top:489.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tissue Eng Part A. 2009;15(7):1729</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">37. doi:10.1089/ten.tea.2008.0247.</span></p>
<p style="top:498.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">51.</span></p>
<p style="top:498.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Erickson IE, Kestle SR, Zellars KH, Dodge GR, Burdick JA, Mauck RL. Improved</span></p>
<p style="top:507.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage repair via in vitro pre-maturation of MSC-seeded hyaluronic acid</span></p>
<p style="top:516.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">hydrogels. Biomed Mater. 2012;7(2):24110. doi:10.1088/1748-6041/7/2/024110.</span></p>
<p style="top:526.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">52.</span></p>
<p style="top:526.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Hui TY, Cheung KMC, Cheung WL, Chan D, Chan BP. In vitro chondrogenic</span></p>
<p style="top:535.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiation of human mesenchymal stem cells in collagen microspheres:</span></p>
<p style="top:544.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">influence of cell seeding density and collagen concentration. Biomaterials.</span></p>
<p style="top:553.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2008;29(22):3201</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12. doi:10.1016/j.biomaterials.2008.04.001.</span></p>
<p style="top:562.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">53.</span></p>
<p style="top:562.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Huang C-YC, Reuben PM, D</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ippolito G, Schiller PC, Cheung HS.</span></p>
<p style="top:571.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chondrogenesis of human bone marrow-derived mesenchymal stem cells</span></p>
<p style="top:580.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in agarose culture. Anat Rec A Discov Mol Cell Evol Biol. 2004;278(1):428</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">36.</span></p>
<p style="top:589.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1002/ar.a.20010.</span></p>
<p style="top:598.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">54.</span></p>
<p style="top:598.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Wang ZJ, An RZ, Zhao JY, et al. Repair of articular cartilage defects by tissue-</span></p>
<p style="top:607.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">engineered cartilage constructed with adipose-derived stem cells and</span></p>
<p style="top:616.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">acellular cartilaginous matrix in rabbits. Genet Mol Res. 2014;13(2):4599</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">606.</span></p>
<p style="top:625.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.4238/2014.June.18.2.</span></p>
<p style="top:634.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">55.</span></p>
<p style="top:634.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Raheja LF, Galuppo LD, Bowers-Lepore J, Dowd JP, Tablin F, Yellowley CE.</span></p>
<p style="top:643.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Treatment of bilateral medial femoral condyle articular cartilage fissures in a</span></p>
<p style="top:652.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">horse using bone marrow-derived multipotent mesenchymal stromal cells.</span></p>
<p style="top:661.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Equine Vet Sci. 2011;31(3):147</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">54. doi:10.1016/j.jevs.2010.12.009.</span></p>
<p style="top:671.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">56.</span></p>
<p style="top:671.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Wu G, Cui Y, Wang Y, et al. Repair of cartilage defects in BMSCs via CDMP1</span></p>
<p style="top:680.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">gene transfection. Genet Mol Res Mol Res. 2014;13(131):291</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">301. doi:10.4238/</span></p>
<p style="top:689.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2014.January.17.14.</span></p>
<p style="top:698.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">57.</span></p>
<p style="top:698.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Mokbel AN, El Tookhy OS, Shamaa AA, Rashed LA, Sabry D, El Sayed AM.</span></p>
<p style="top:707.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Homing and reparative effect of intra-articular injection of autologus</span></p>
<p style="top:716.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells in osteoarthritic animal model. BMC Musculoskelet</span></p>
<p style="top:725.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Disord. 2011;12:259. doi:10.1186/1471-2474-12-259.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 22 of 30</span></p>


<p style="top:89.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">58.</span></p>
<p style="top:89.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Masuoka K, Asazuma T, Hattori H, et al. Tissue engineering of articular</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage with autologous cultured adipose tissue-derived stromal cells</span></p>
<p style="top:107.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">using atelocollagen honeycomb-shaped scaffold with a membrane sealing</span></p>
<p style="top:116.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in rabbits. J Biomed Mater Res B Appl Biomater. 2006;79(1):25</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">34. doi:10.</span></p>
<p style="top:125.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1002/jbm.b.30507.</span></p>
<p style="top:134.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">59.</span></p>
<p style="top:134.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zhang K, Zhang Y, Yan S, et al. Repair of an articular cartilage defect using</span></p>
<p style="top:143.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adipose-derived stem cells loaded on a polyelectrolyte complex scaffold</span></p>
<p style="top:152.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">based on poly(l-glutamic acid) and chitosan. Acta Biomater. 2013;9(7):7276</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">88.</span></p>
<p style="top:161.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.actbio.2013.03.025.</span></p>
<p style="top:171.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">60.</span></p>
<p style="top:171.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zhu S, Chen P, Wu Y, et al. Programmed application of transforming growth</span></p>
<p style="top:180.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">factor</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313"> &#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">3 and Rac1 inhibitor NSC23766 committed hyaline cartilage</span></p>
<p style="top:189.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiation of adipose-derived stem cells for osteochondral defect repair.</span></p>
<p style="top:198.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Stem Cells Transl Med. 2014;3(10):1242</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">51. doi:10.5966/sctm.2014-0042.</span></p>
<p style="top:207.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">61.</span></p>
<p style="top:207.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Murata D, Tokunaga S, Tamura T, et al. A preliminary study of osteochondral</span></p>
<p style="top:216.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">regeneration using a scaffold-free three-dimensional construct of porcine</span></p>
<p style="top:225.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adipose tissue-derived mesenchymal stem cells. J Orthop Surg Res. 2015;10:35.</span></p>
<p style="top:234.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1186/s13018-015-0173-0.</span></p>
<p style="top:243.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">62.</span></p>
<p style="top:243.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Cui L, Wu Y, Cen L, et al. Repair of articular cartilage defect in non-weight</span></p>
<p style="top:252.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bearing areas using adipose derived stem cells loaded polyglycolic acid mesh.</span></p>
<p style="top:261.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Biomaterials. 2009;30(14):2683</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">93. doi:10.1016/j.biomaterials.2009.01.045.</span></p>
<p style="top:270.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">63.</span></p>
<p style="top:270.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Lu C-H, Yeh T-S, Yeh C-L, et al. Regenerating cartilages by Engineered</span></p>
<p style="top:279.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">ASCs: prolonged TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">3/BMP-6 expression improved articular cartilage</span></p>
<p style="top:288.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">formation and restored zonal structure. Mol Ther. 2014;22(1):186</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">95.</span></p>
<p style="top:297.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1038/mt.2013.165.</span></p>
<p style="top:307.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64.</span></p>
<p style="top:307.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Dragoo JL, Carlson G, McCormick F, et al. Healing full-thickness cartilage</span></p>
<p style="top:316.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects using adipose-derived stem cells. Tissue Eng. 2007;13(7):1615</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">21.</span></p>
<p style="top:325.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.2006.0249.</span></p>
<p style="top:334.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">65.</span></p>
<p style="top:334.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Portron S, Merceron C, Gauthier O, et al. Effects of in vitro low oxygen</span></p>
<p style="top:343.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">tension preconditioning of adipose stromal cells on their in vivo</span></p>
<p style="top:352.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenic potential: application in cartilage tissue repair. PLoS One.</span></p>
<p style="top:361.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;8(4):e62368. doi:10.1371/journal.pone.0062368. Abhay Pandit, ed.</span></p>
<p style="top:370.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">66.</span></p>
<p style="top:370.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Im G-I, Lee JH. Repair of osteochondral defects with adipose stem cells and</span></p>
<p style="top:379.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">a dual growth factor-releasing scaffold in rabbits. J Biomed Mater Res B</span></p>
<p style="top:388.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Appl Biomater. 2010;92(2):552</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">60. doi:10.1002/jbm.b.31552.</span></p>
<p style="top:398.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">67.</span></p>
<p style="top:398.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Kang H, Peng J, Lu S, et al. In vivo cartilage repair using adipose-derived</span></p>
<p style="top:407.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cell-loaded decellularized cartilage ECM scaffolds. J Tissue Eng Regen</span></p>
<p style="top:416.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Med. 2014;8(6):442</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">53. doi:10.1002/term.1538.</span></p>
<p style="top:425.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">68.</span></p>
<p style="top:425.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Gong L, Zhou X, Wu Y, et al. Proteomic analysis profile of engineered</span></p>
<p style="top:434.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">articular cartilage with chondrogenic differentiated adipose tissue-</span></p>
<p style="top:443.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived stem cells loaded polyglycolic acid mesh for weight-bearing</span></p>
<p style="top:452.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">area defect repair. Tissue Eng Part A. 2014;20(3-4):575</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">87. doi:10.1089/</span></p>
<p style="top:461.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">ten.TEA.2013.0205.</span></p>
<p style="top:470.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">69.</span></p>
<p style="top:470.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">de Girolamo L, Niada S, Arrigoni E, et al. Repair of osteochondral defects in</span></p>
<p style="top:479.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">the minipig model by OPF hydrogel loaded with adipose-derived</span></p>
<p style="top:488.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells. Regen Med. 2015;10(2):135</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">51. doi:10.2217/rme.14.77.</span></p>
<p style="top:497.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">70.</span></p>
<p style="top:497.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Pei M, He F, Li J, Tidwell JE, Jones AC, McDonough EB. Repair of large</span></p>
<p style="top:506.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">animal partial-thickness cartilage defects through intraarticular injection of</span></p>
<p style="top:515.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">matrix-rejuvenated synovium-derived stem cells. Tissue Eng Part A.</span></p>
<p style="top:524.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;19(9-10):1144</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">54. doi:10.1089/ten.TEA.2012.0351.</span></p>
<p style="top:534.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">71.</span></p>
<p style="top:534.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Lee J-C, Lee SY, Min HJ, et al. Synovium-derived mesenchymal stem cells</span></p>
<p style="top:543.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">encapsulated in a novel injectable gel can repair osteochondral defects in a</span></p>
<p style="top:552.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">rabbit model. Tissue Eng Part A. 2012;18(19-20):2173</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">86. doi:10.1089/ten.</span></p>
<p style="top:561.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">TEA.2011.0643.</span></p>
<p style="top:570.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">72.</span></p>
<p style="top:570.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Nakamura T, Sekiya I, Muneta T, et al. Arthroscopic, histological and MRI</span></p>
<p style="top:579.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">analyses of cartilage repair after a minimally invasive method of</span></p>
<p style="top:588.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplantation of allogeneic synovial mesenchymal stromal cells into</span></p>
<p style="top:597.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage defects in pigs. Cytotherapy. 2012;14(3):327</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">38. doi:10.3109/</span></p>
<p style="top:606.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">14653249.2011.638912.</span></p>
<p style="top:615.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">73.</span></p>
<p style="top:615.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Koga H, Shimaya M, Muneta T, et al. Local adherent technique for</span></p>
<p style="top:624.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplanting mesenchymal stem cells as a potential treatment of cartilage</span></p>
<p style="top:633.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defect. Arthritis Res Ther. 2008;10(4):R84. doi:10.1186/ar2460.</span></p>
<p style="top:643.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">74.</span></p>
<p style="top:643.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Lee J-C, Min HJ, Lee S, Seong SC, Lee MC. Effect of chondroitinase ABC</span></p>
<p style="top:651.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">on adhesion and behavior of synovial membrane-derived mesenchymal</span></p>
<p style="top:660.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells in rabbit partial-thickness chondral defects. J Orthop Res.</span></p>
<p style="top:669.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;31(8):1293</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">301. doi:10.1002/jor.22353.</span></p>
<p style="top:679.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">75.</span></p>
<p style="top:679.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Lee J-C, Min HJ, Park HJ, Lee S, Seong SC, Lee MC. Synovial membrane-</span></p>
<p style="top:688.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived mesenchymal stem cells supported by platelet-rich plasma can repair</span></p>
<p style="top:697.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral defects in a rabbit model. Arthroscopy. 2013;29(6):1034</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">46.</span></p>
<p style="top:706.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.arthro.2013.02.026.</span></p>
<p style="top:716.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">76.</span></p>
<p style="top:716.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Perka C, Schultz O, Spitzer R-S, Lindenhayn K. The influence of transforming</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">growth factor</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313"> &#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1 on mesenchymal cell repair of full-thickness cartilage</span></p>
<p style="top:89.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects. J Biomed Mater Res. 2000;52(3):543</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">52. doi:10.1002/1097-</span></p>
<p style="top:98.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">4636(20001205)52:3&lt;543::AID-JBM13&gt;3.0.CO;2-2.</span></p>
<p style="top:107.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">77.</span></p>
<p style="top:107.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Hui JHP, Chen F, Thambyah A, Lee EH. Treatment of chondral lesions in</span></p>
<p style="top:116.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">advanced osteochondritis dissecans: a comparative study of the efficacy of</span></p>
<p style="top:125.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrocytes, mesenchymal stem cells, periosteal graft, and mosaicplasty</span></p>
<p style="top:134.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">(osteochondral autograft) in animal models. J Pediatr Orthop. 24(4):427-33.</span></p>
<p style="top:143.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/15205626. Accessed</span></p>
<p style="top:152.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12 June 2016.</span></p>
<p style="top:162.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">78.</span></p>
<p style="top:162.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Gelse K, von der Mark K, Aigner T, Park J, Schneider H. Articular cartilage</span></p>
<p style="top:171.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">repair by gene therapy using growth factor-producing mesenchymal cells.</span></p>
<p style="top:180.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arthritis Rheum. 2003;48(2):430</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41. doi:10.1002/art.10759.</span></p>
<p style="top:189.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">79.</span></p>
<p style="top:189.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zhang S, Jiang YZ, Zhang W, et al. Neonatal desensitization supports</span></p>
<p style="top:198.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">long-term survival and functional integration of human embryonic stem</span></p>
<p style="top:207.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cell-derived mesenchymal stem cells in rat joint cartilage without</span></p>
<p style="top:216.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">immunosuppression. Stem Cells Dev. 2013;22(1):90</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">101. doi:10.1089/</span></p>
<p style="top:225.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">scd.2012.0116.</span></p>
<p style="top:234.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">80.</span></p>
<p style="top:234.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Wakitani S, Aoki H, Harada Y, et al. Embryonic stem cells form articular</span></p>
<p style="top:243.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage, not teratomas, in osteochondral defects of rat joints. Cell</span></p>
<p style="top:252.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Transplant. 2004;13(4):331</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">6. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:261.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/15468674. Accessed 12 June 2016.</span></p>
<p style="top:270.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">81.</span></p>
<p style="top:270.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chung J, Song M, Ha C-W, Kim J-A, Lee C-H, Park Y-B. Comparison of</span></p>
<p style="top:279.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">articular cartilage repair with different hydrogel-human umbilical cord</span></p>
<p style="top:289.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">blood-derived mesenchymal stem cell composites in a rat model. Stem Cell</span></p>
<p style="top:298.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Res Ther. 2014;5(2):39. doi:10.1186/scrt427.</span></p>
<p style="top:307.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">82.</span></p>
<p style="top:307.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Nawata M, Wakitani S, Nakaya H, et al. Use of bone morphogenetic protein</span></p>
<p style="top:316.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2 and diffusion chambers to engineer cartilage tissue for the repair of</span></p>
<p style="top:325.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects in articular cartilage. Arthritis Rheum. 2005;52(1):155</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">63. doi:10.</span></p>
<p style="top:334.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1002/art.20713.</span></p>
<p style="top:343.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">83.</span></p>
<p style="top:343.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Grande DA, Southerland SS, Manji R, Pate DW, Schwartz RE, Lucas PA. Repair</span></p>
<p style="top:352.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of articular cartilage defects using mesenchymal stem cells. Tissue Eng.</span></p>
<p style="top:361.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1995;1(4):345</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">53. doi:10.1089/ten.1995.1.345.</span></p>
<p style="top:370.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">84.</span></p>
<p style="top:370.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tay LX, Ahmad RE, Dashtdar H, et al. Treatment outcomes of alginate-</span></p>
<p style="top:379.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">embedded allogenic mesenchymal stem cells versus autologous</span></p>
<p style="top:388.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrocytes for the repair of focal articular cartilage defects in a</span></p>
<p style="top:397.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">rabbit model. Am J Sports Med. 2012;40(1):83</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">90. doi:10.1177/</span></p>
<p style="top:406.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">0363546511420819.</span></p>
<p style="top:416.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">85.</span></p>
<p style="top:416.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Dashtdar H, Rothan HA, Tay T, et al. A preliminary study comparing the use</span></p>
<p style="top:425.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of allogenic chondrogenic pre-differentiated and undifferentiated</span></p>
<p style="top:434.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells for the repair of full thickness articular cartilage</span></p>
<p style="top:443.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects in rabbits. J Orthop Res. 2011;29(9):1336</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">42. doi:10.1002/jor.21413.</span></p>
<p style="top:452.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">86.</span></p>
<p style="top:452.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Igarashi T, Iwasaki N, Kawamura D, et al. Repair of articular cartilage defects</span></p>
<p style="top:461.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with a novel injectable in situ forming material in a canine model. J Biomed</span></p>
<p style="top:470.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Mater Res A. 2012;100(1):180</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. doi:10.1002/jbm.a.33248.</span></p>
<p style="top:479.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">87.</span></p>
<p style="top:479.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ho STB, Hutmacher DW, Ekaputra AK, Hitendra D, Hui JH. The evaluation of</span></p>
<p style="top:488.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">a biphasic osteochondral implant coupled with an electrospun membrane</span></p>
<p style="top:497.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in a large animal model. Tissue Eng Part A. 2010;16(4):1123</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41. doi:10.1089/</span></p>
<p style="top:506.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">ten.TEA.2009.0471.</span></p>
<p style="top:516.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">88.</span></p>
<p style="top:516.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Oshima Y, Harwood FL, Coutts RD, Kubo T, Amiel D. Variation of</span></p>
<p style="top:525.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal cells in polylactic acid scaffold in an osteochondral repair</span></p>
<p style="top:534.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">model. Tissue Eng Part C Methods. 2009;15(4):595</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">604. doi:10.1089/</span></p>
<p style="top:543.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">ten.TEC.2008.0487.</span></p>
<p style="top:552.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">89.</span></p>
<p style="top:552.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Al Faqeh H, Nor Hamdan BMY, Chen HC, Aminuddin BS, Ruszymah BHI. The</span></p>
<p style="top:561.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">potential of intra-articular injection of chondrogenic-induced bone marrow</span></p>
<p style="top:570.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells to retard the progression of osteoarthritis in a sheep model. Exp</span></p>
<p style="top:579.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Gerontol. 2012;47(6):458</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64. doi:10.1016/j.exger.2012.03.018.</span></p>
<p style="top:588.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">90.</span></p>
<p style="top:588.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Iwai R, Fujiwara M, Wakitani S, Takagi M. Ex vivo cartilage defect model for</span></p>
<p style="top:597.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">the evaluation of cartilage regeneration using mesenchymal stem cells.</span></p>
<p style="top:606.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Biosci Bioeng. 2011;111(3):357</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64. doi:10.1016/j.jbiosc.2010.11.001.</span></p>
<p style="top:615.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">91.</span></p>
<p style="top:615.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Nishimori M, Deie M, Kanaya A, Exham H, Adachi N, Ochi M. Repair of</span></p>
<p style="top:624.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chronic osteochondral defects in the rat. A bone marrow-stimulating</span></p>
<p style="top:633.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">procedure enhanced by cultured allogenic bone marrow mesenchymal</span></p>
<p style="top:642.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stromal cells. J Bone Joint Surg Br. 2006;88(9):1236</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">44. doi:10.1302/</span></p>
<p style="top:651.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">0301-620X.88B9.17810.</span></p>
<p style="top:661.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">92.</span></p>
<p style="top:661.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Espinosa M, Vaisman A, Nazal N, Figueroa D, Gallegos M, Conget P.</span></p>
<p style="top:670.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Intraarticular administration of dexamethasone after mesenchymal stem</span></p>
<p style="top:679.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells implantation does not improve significantly the treatment of</span></p>
<p style="top:688.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">preestablished full-thickness chondral defect in a rabbit model. Cartilage.</span></p>
<p style="top:697.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;4(2):144</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">52. doi:10.1177/1947603512472696.</span></p>
<p style="top:707.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">93.</span></p>
<p style="top:707.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Deng T, Lv J, Pang J, Liu B, Ke J. Construction of tissue-engineered</span></p>
<p style="top:716.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral composites and repair of large joint defects in rabbit.</span></p>
<p style="top:725.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Tissue Eng Regen Med. 2014;8(7):546</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">56. doi:10.1002/term.1556.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 23 of 30</span></p>


<p style="top:89.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">94.</span></p>
<p style="top:89.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Wan W, Li Q, Gao H, et al. BMSCs laden injectable amino-diethoxypropane</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">modified alginate-chitosan hydrogel for hyaline cartilage reconstruction.</span></p>
<p style="top:107.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Mater Chem B. 2015;3(9):1990</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2005. doi:10.1039/C4TB01394H.</span></p>
<p style="top:116.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">95.</span></p>
<p style="top:116.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Saw K-Y, Hussin P, Loke S-C, et al. Articular cartilage regeneration with</span></p>
<p style="top:125.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous marrow aspirate and hyaluronic acid: an experimental study</span></p>
<p style="top:134.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in a goat model. Arthroscopy. 2009;25(12):1391</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">400. doi:10.1016/j.arthro.</span></p>
<p style="top:143.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2009.07.011.</span></p>
<p style="top:153.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">96.</span></p>
<p style="top:153.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">McIlwraith CW, Frisbie DD, Rodkey WG, et al. Evaluation of intra-articular</span></p>
<p style="top:162.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells to augment healing of microfractured chondral</span></p>
<p style="top:171.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects. Arthroscopy. 2011;27(11):1552</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">61. doi:10.1016/j.arthro.2011.06.002.</span></p>
<p style="top:180.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">97.</span></p>
<p style="top:180.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Mokbel A, El-Tookhy O, Shamaa AA, Sabry D, Rashed L, Mostafa A. Homing</span></p>
<p style="top:189.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">and efficacy of intra-articular injection of autologous mesenchymal stem</span></p>
<p style="top:198.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells in experimental chondral defects in dogs. Clin Exp Rheumatol. 29(2):</span></p>
<p style="top:207.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">275-84. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21385540.</span></p>
<p style="top:216.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Accessed 12 June 2016.</span></p>
<p style="top:225.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">98.</span></p>
<p style="top:225.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Fortier LA, Potter HG, Rickey EJ, et al. Concentrated bone marrow aspirate</span></p>
<p style="top:234.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">improves full-thickness cartilage repair compared with microfracture in the</span></p>
<p style="top:243.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">equine model. J Bone Joint Surg Am. 2010;92(10):1927</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">37. doi:10.2106/JBJS.</span></p>
<p style="top:252.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">I.01284.</span></p>
<p style="top:261.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">99.</span></p>
<p style="top:261.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zhao Q, Wang S, Tian J, et al. Combination of bone marrow concentrate</span></p>
<p style="top:270.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">and PGA scaffolds enhance bone marrow stimulation in rabbit articular</span></p>
<p style="top:279.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage repair. J Mater Sci Mater Med. 2013;24(3):793</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">801. doi:10.1007/</span></p>
<p style="top:288.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">s10856-012-4841-x.</span></p>
<p style="top:298.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">100. Sun J, Hou X-K, Li X, et al. Mosaicplasty associated with gene enhanced</span></p>
<p style="top:307.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">tissue engineering for the treatment of acute osteochondral defects in a</span></p>
<p style="top:316.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">goat model. Arch Orthop Trauma Surg. 2009;129(6):757</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">71. doi:10.1007/</span></p>
<p style="top:325.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">s00402-008-0761-0.</span></p>
<p style="top:334.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">101. Leng P, Ding C, Zhang H, Wang Y. Reconstruct large osteochondral defects</span></p>
<p style="top:343.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of the knee with hIGF-1 gene enhanced Mosaicplasty. Knee. 2012;19(6):804</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">11.</span></p>
<p style="top:352.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.knee.2012.03.009.</span></p>
<p style="top:361.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">102. Ma X, Sun Y, Cheng X, et al. Repair of osteochondral defects by</span></p>
<p style="top:370.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mosaicplasty and allogeneic BMSCs transplantation. Int J Clin Exp Med.</span></p>
<p style="top:379.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2015;8(4):6053</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/</span></p>
<p style="top:388.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">26131203. Accessed 12 June 2016.</span></p>
<p style="top:397.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">103. Vega A, Mart&#xed;n-Ferrero MA, Del Canto F, et al. Treatment of knee</span></p>
<p style="top:406.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a</span></p>
<p style="top:415.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">randomized controlled trial. Transplantation. 2015;99(8):1681</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">90. doi:10.1097/</span></p>
<p style="top:424.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">TP.0000000000000678.</span></p>
<p style="top:434.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">104. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased</span></p>
<p style="top:443.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">knee cartilage volume in degenerative joint disease using percutaneously</span></p>
<p style="top:452.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">implanted, autologous mesenchymal stem cells. Pain Physician. 11(3):343-53.</span></p>
<p style="top:461.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/18523506. Accessed</span></p>
<p style="top:470.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">13 June 2016.</span></p>
<p style="top:479.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">105. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal</span></p>
<p style="top:488.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cell therapy for knee osteoarthritis. Preliminary report of four patients.</span></p>
<p style="top:497.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Int J Rheum Dis. 2011;14(2):211</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">5. doi:10.1111/j.1756-185X.2011.01599.x.</span></p>
<p style="top:506.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">106. Pak J. Regeneration of human bones in hip osteonecrosis and human</span></p>
<p style="top:515.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem</span></p>
<p style="top:524.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells: a case series. J Med Case Rep. 2011;5:296. doi:10.1186/1752-1947-5-296.</span></p>
<p style="top:533.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">107. Koh YG, Choi YJ, Kwon OR, Kim YS. Second-look arthroscopic evaluation</span></p>
<p style="top:542.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of cartilage lesions after mesenchymal stem cell implantation in</span></p>
<p style="top:551.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteoarthritic knees. Am J Sports Med. 2014;42(7):1628</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">37. doi:10.1177/</span></p>
<p style="top:560.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">0363546514529641.</span></p>
<p style="top:570.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">108. Kim YS, Choi YJ, Suh DS, et al. Mesenchymal stem cell implantation in</span></p>
<p style="top:579.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteoarthritic knees: is fibrin glue effective as a scaffold? Am J Sports Med.</span></p>
<p style="top:588.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2015;43(1):176</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">85. doi:10.1177/0363546514554190.</span></p>
<p style="top:597.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">109. Emadedin M, Aghdami N, Taghiyar L, et al. Intra-articular injection of</span></p>
<p style="top:606.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous mesenchymal stem cells in six patients with knee osteoarthritis.</span></p>
<p style="top:615.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arch Iran Med. 2012;15(7):422-8. doi:012157/AIM.0010.</span></p>
<p style="top:624.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">110. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem</span></p>
<p style="top:633.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells for the treatment of osteoarthritis of the knee: a proof-of-concept</span></p>
<p style="top:642.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">clinical trial. Stem Cells. 2014;32(5):1254</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">66. doi:10.1002/stem.1634.</span></p>
<p style="top:652.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">111. Orozco L, Munar A, Soler R, et al. Treatment of knee osteoarthritis with</span></p>
<p style="top:661.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous mesenchymal stem cells: a pilot study. Transplantation.</span></p>
<p style="top:669.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;95(12):1535</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41. doi:10.1097/TP.0b013e318291a2da.</span></p>
<p style="top:679.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">112. Emadedin M, Ghorbani Liastani M, Fazeli R, et al. Long-term follow-up of</span></p>
<p style="top:688.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">intra-articular injection of autologous mesenchymal stem cells in patients</span></p>
<p style="top:697.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with knee, ankle, or hip osteoarthritis. Arch Iran Med. 2015;18(6):336-44.</span></p>
<p style="top:706.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:015186/AIM.003.</span></p>
<p style="top:716.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">113. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous culture expanded bone marrow mesenchymal cell</span></p>
<p style="top:89.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplantation for repair of cartilage defects in osteoarthritic knees.</span></p>
<p style="top:98.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Osteoarthritis Cartilage. 2002;10(3):199</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">206. doi:10.1053/joca.2001.0504.</span></p>
<p style="top:107.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">114. Koh Y-G, Choi Y-J. Infrapatellar fat pad-derived mesenchymal stem cell</span></p>
<p style="top:116.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">therapy for knee osteoarthritis. Knee. 2012;19(6):902</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. doi:10.1016/j.knee.</span></p>
<p style="top:125.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2012.04.001.</span></p>
<p style="top:135.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">115. Wong KL, Lee KBL, Tai BC, Law P, Lee EH, Hui JHP. Injectable cultured</span></p>
<p style="top:144.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow-derived mesenchymal stem cells in varus knees with</span></p>
<p style="top:153.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage defects undergoing high tibial osteotomy: a prospective,</span></p>
<p style="top:162.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">randomized controlled clinical trial with 2 years</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> follow-up. Arthroscopy.</span></p>
<p style="top:171.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;29(12):2020</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8. doi:10.1016/j.arthro.2013.09.074.</span></p>
<p style="top:180.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">116. Giannini S, Buda R, Vannini F, Cavallo M, Grigolo B. One-step bone marrow-</span></p>
<p style="top:189.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived cell transplantation in talar osteochondral lesions. Clin Orthop Relat</span></p>
<p style="top:198.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Res. 2009;467(12):3307</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">20. doi:10.1007/s11999-009-0885-8.</span></p>
<p style="top:207.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">117. Giannini S, Buda R, Cavallo M, et al. Cartilage repair evolution in post-</span></p>
<p style="top:216.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">traumatic osteochondral lesions of the talus: from open field autologous</span></p>
<p style="top:225.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrocyte to bone-marrow-derived cells transplantation. Injury.</span></p>
<p style="top:234.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;41(11):1196</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">203. doi:10.1016/j.injury.2010.09.028.</span></p>
<p style="top:243.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">118. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S.</span></p>
<p style="top:253.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Autologous bone marrow stromal cell transplantation for repair of full-</span></p>
<p style="top:262.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">thickness articular cartilage defects in human patellae: two case reports. Cell</span></p>
<p style="top:270.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Transplant. 2004;13(5):595</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">600. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:279.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/15565871. Accessed 13 June 2016.</span></p>
<p style="top:289.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">119. Saw K-Y, Anz A, Merican S, et al. Articular cartilage regeneration with</span></p>
<p style="top:298.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous peripheral blood progenitor cells and hyaluronic acid after</span></p>
<p style="top:307.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">arthroscopic subchondral drilling: a report of 5 cases with histology.</span></p>
<p style="top:316.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arthroscopy. 2011;27(4):493</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">506. doi:10.1016/j.arthro.2010.11.054.</span></p>
<p style="top:325.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">120. Nejadnik H, Hui JH, Feng Choong EP, Tai B-C, Lee EH. Autologous bone</span></p>
<p style="top:334.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">marrow-derived mesenchymal stem cells versus autologous chondrocyte</span></p>
<p style="top:343.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">implantation: an observational cohort study. Am J Sports Med.</span></p>
<p style="top:352.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;38(6):1110</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">6. doi:10.1177/0363546509359067.</span></p>
<p style="top:361.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">121. Saw K-Y, Anz A, Siew-Yoke Jee C, et al. Articular cartilage regeneration with</span></p>
<p style="top:370.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous peripheral blood stem cells versus hyaluronic acid: a</span></p>
<p style="top:379.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">randomized controlled trial. Arthroscopy. 2013;29(4):684</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">94. doi:10.1016/j.</span></p>
<p style="top:388.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">arthro.2012.12.008.</span></p>
<p style="top:398.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">122. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H. Repair of</span></p>
<p style="top:407.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">articular cartilage defects in the patello-femoral joint with autologous bone</span></p>
<p style="top:416.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">marrow mesenchymal cell transplantation: three case reports involving nine</span></p>
<p style="top:425.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects in five knees. J Tissue Eng Regen Med. 1(1):74-9. doi:10.1002/term.8.</span></p>
<p style="top:434.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">123. Lee KBL, Wang VTZ, Chan YH, Hui JHP. A novel, minimally-invasive</span></p>
<p style="top:443.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">technique of cartilage repair in the human knee using arthroscopic</span></p>
<p style="top:452.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">microfracture and injections of mesenchymal stem cells and hyaluronic</span></p>
<p style="top:461.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">acid</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2014;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">a prospective comparative study on safety and short-term efficacy.</span></p>
<p style="top:470.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ann Acad Med Singapore. 2012;41(11):511</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. Available at: http://www.ncbi.</span></p>
<p style="top:479.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">nlm.nih.gov/pubmed/23235728. Accessed 16 June 2016.</span></p>
<p style="top:488.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">124. Kuroda R, Ishida K, Matsumoto T, et al. Treatment of a full-thickness articular</span></p>
<p style="top:497.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage defect in the femoral condyle of an athlete with autologous bone-</span></p>
<p style="top:506.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">marrow stromal cells. Osteoarthritis Cartilage. 2007;15(2):226</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">31. doi:10.</span></p>
<p style="top:515.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1016/j.joca.2006.08.008.</span></p>
<p style="top:525.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">125. Haleem AM, El Singergy AA, Sabry D, et al. The clinical use of human</span></p>
<p style="top:534.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">culture-expanded autologous bone marrow mesenchymal stem cells</span></p>
<p style="top:543.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplanted on platelet-rich fibrin glue in the treatment of articular</span></p>
<p style="top:552.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage defects: a pilot study and preliminary results. Cartilage.</span></p>
<p style="top:561.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;1(4):253</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">61. doi:10.1177/1947603510366027.</span></p>
<p style="top:570.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">126. Kasemkijwattana C, Hongeng S, Kesprayura S, Rungsinaporn V, Chaipinyo K,</span></p>
<p style="top:579.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chansiri K. Autologous bone marrow mesenchymal stem cells implantation</span></p>
<p style="top:588.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">for cartilage defects: two cases report. J Med Assoc Thai. 2011;94(3):395</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">400.</span></p>
<p style="top:597.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/21560849. Accessed 13</span></p>
<p style="top:606.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">June 2016.</span></p>
<p style="top:615.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">127. Gigante A, Cecconi S, Calcagno S, Busilacchi A, Enea D. Arthroscopic knee</span></p>
<p style="top:624.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage repair with covered microfracture and bone marrow concentrate.</span></p>
<p style="top:633.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arthrosc Tech. 2012;1(2):e175</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">80. doi:10.1016/j.eats.2012.07.001.</span></p>
<p style="top:642.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">128. Shetty AA, Kim SJ, Shetty V, et al. Autologous bone-marrow mesenchymal</span></p>
<p style="top:651.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cell induced chondrogenesis: single-stage arthroscopic cartilage repair.</span></p>
<p style="top:660.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tissue Eng Regen Med. 2014;11(3):247</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">53. doi:10.1007/s13770-014-0061-4.</span></p>
<p style="top:670.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">129. Akgun I, Unlu MC, Erdal OA, et al. Matrix-induced autologous mesenchymal</span></p>
<p style="top:679.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cell implantation versus matrix-induced autologous chondrocyte</span></p>
<p style="top:688.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">implantation in the treatment of chondral defects of the knee: a 2-year</span></p>
<p style="top:697.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">randomized study. Arch Orthop Trauma Surg. 2015;135(2):251</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">63. doi:10.</span></p>
<p style="top:706.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1007/s00402-014-2136-z.</span></p>
<p style="top:716.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">130. Buda R, Vannini F, Cavallo M, Grigolo B, Cenacchi A, Giannini S.</span></p>
<p style="top:725.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Osteochondral lesions of the knee: a new one-step repair technique with</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 24 of 30</span></p>


<p style="top:89.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone-marrow-derived cells. J Bone Joint Surg Am. 2010;92 Suppl 2:2</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">11.</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.2106/JBJS.J.00813.</span></p>
<p style="top:107.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">131. Enea D, Cecconi S, Calcagno S, et al. Single-stage cartilage repair in the</span></p>
<p style="top:116.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">knee with microfracture covered with a resorbable polymer-based matrix</span></p>
<p style="top:125.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">and autologous bone marrow concentrate. Knee. 2013;20(6):562</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9.</span></p>
<p style="top:134.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.knee.2013.04.003.</span></p>
<p style="top:144.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">132. Gobbi A, Chaurasia S, Karnatzikos G, Nakamura N. Matrix-induced</span></p>
<p style="top:153.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous chondrocyte implantation versus multipotent stem cells for the</span></p>
<p style="top:162.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">treatment of large patellofemoral chondral lesions: a nonrandomized</span></p>
<p style="top:171.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">prospective trial. Cartilage. 2015;6(2):82</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">97. doi:10.1177/1947603514563597.</span></p>
<p style="top:180.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">133. Sekiya I, Muneta T, Horie M, Koga H. Arthroscopic transplantation of synovial</span></p>
<p style="top:189.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells improves clinical outcomes in knees with cartilage defects. Clin</span></p>
<p style="top:198.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Orthop Relat Res. 2015;473(7):2316</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">26. doi:10.1007/s11999-015-4324-8.</span></p>
<p style="top:207.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">134. Katayama R, Wakitani S, Tsumaki N, et al. Repair of articular cartilage defects</span></p>
<p style="top:216.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in rabbits using CDMP1 gene-transfected autologous mesenchymal cells</span></p>
<p style="top:225.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived from bone marrow. Rheumatology (Oxford). 2004;43(8):980</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">5.</span></p>
<p style="top:234.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1093/rheumatology/keh240.</span></p>
<p style="top:244.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">135. Insall JN. Intra-articular surgery for degenerative arthritis of the knee. A report</span></p>
<p style="top:253.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of the work of the late K. H. Pridie. J Bone Joint Surg Br. 1967;49(2):211</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">28.</span></p>
<p style="top:262.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/6026508. Accessed</span></p>
<p style="top:271.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8 July 2016.</span></p>
<p style="top:280.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">136. Meachim G, Roberts C. Repair of the joint surface from subarticular tissue in</span></p>
<p style="top:289.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">the rabbit knee. J Anat. 1971;109(Pt 2):317</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">27. Available at: http://www.ncbi.</span></p>
<p style="top:298.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">nlm.nih.gov/pubmed/5558237. Accessed 8 July 2016.</span></p>
<p style="top:307.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">137. Dzioba RB. The classification and treatment of acute articular cartilage</span></p>
<p style="top:316.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">lesions. Arthroscopy. 1988;4(2):72</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">80. Available at: http://www.ncbi.nlm.nih.</span></p>
<p style="top:325.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">gov/pubmed/3395420. Accessed 8 July 2016.</span></p>
<p style="top:334.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">138. Insall J. The Pridie debridement operation for osteoarthritis of the knee. Clin</span></p>
<p style="top:343.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Orthop Relat Res. 1974;(101):61-7. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:352.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/4837919. Accessed 8 July 2016.</span></p>
<p style="top:362.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">139. Ficat RP, Ficat C, Gedeon P, Toussaint JB. Spongialization: a new treatment</span></p>
<p style="top:371.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">for diseased patellae. Clin Orthop Relat Res. 1979;(144):74-83. Available at:</span></p>
<p style="top:380.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">http://www.ncbi.nlm.nih.gov/pubmed/535254. Accessed 8 July 2016.</span></p>
<p style="top:389.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">140. Johnson LL. Arthroscopic abrasion arthroplasty historical and pathologic</span></p>
<p style="top:398.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">perspective: present status. Arthroscopy. 1986;2(1):54</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">69. Available at: http://</span></p>
<p style="top:407.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">www.ncbi.nlm.nih.gov/pubmed/3954840. Accessed 8 July 2016.</span></p>
<p style="top:416.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">141. Friedman MJ, Berasi CC, Fox JM, Del Pizzo W, Snyder SJ, Ferkel RD.</span></p>
<p style="top:425.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Preliminary results with abrasion arthroplasty in the osteoarthritic knee. Clin</span></p>
<p style="top:434.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Orthop Relat Res. (182):200-5. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:443.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/6692614. Accessed 8 July 2016.</span></p>
<p style="top:453.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">142. Ogilvie-Harris DJ, Fitsialos DP. Arthroscopic management of the degenerative</span></p>
<p style="top:462.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">knee. Arthrosc J Arthrosc Relat Surg. 1991;7(2):151</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. doi:10.1016/0749-</span></p>
<p style="top:471.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8063(91)90101-3.</span></p>
<p style="top:480.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">143. Baumgaertner MR, Cannon WD, Vittori JM, Schmidt ES, Maurer RC.</span></p>
<p style="top:489.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arthroscopic debridement of the arthritic knee. Clin Orthop Relat Res.</span></p>
<p style="top:498.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1990;(253):197-202. Available at: http://www.ncbi.nlm.nih.gov/pubmed/</span></p>
<p style="top:507.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2317974. Accessed 10 July 2016.</span></p>
<p style="top:516.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">144. Rand JA. Role of arthroscopy in osteoarthritis of the knee. Arthroscopy.</span></p>
<p style="top:525.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1991;7(4):358</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">63. Available at: http://www.ncbi.nlm.nih.gov/pubmed/</span></p>
<p style="top:534.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1755883. Accessed 10 July 2016.</span></p>
<p style="top:544.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">145. Bert JM. Role of abrasion arthroplasty and debridement in the management</span></p>
<p style="top:553.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of osteoarthritis of the knee. Rheum Dis Clin North Am. 1993;19(3):725</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">39.</span></p>
<p style="top:562.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/8210584. Accessed 10</span></p>
<p style="top:571.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">July 2016.</span></p>
<p style="top:580.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">146. Nehrer S, Spector M, Minas T. Histologic analysis of tissue after failed</span></p>
<p style="top:589.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage repair procedures. Clin Orthop Relat Res. 1999;(365):149-62.</span></p>
<p style="top:598.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/10627699. Accessed</span></p>
<p style="top:607.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">10 July 2016.</span></p>
<p style="top:616.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">147. Dandy DJ. Abrasion chondroplasty. Arthrosc J Arthrosc Relat Surg.</span></p>
<p style="top:625.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1986;2(1):51</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">3. doi:10.1016/S0749-8063(86)80011-1.</span></p>
<p style="top:634.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">148. Mithoefer K, Williams RJ, Warren RF, et al. The microfracture technique</span></p>
<p style="top:643.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">for the treatment of articular cartilage lesions in the knee. A prospective</span></p>
<p style="top:652.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cohort study. J Bone Joint Surg Am. 2005;87(9):1911</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">20. doi:10.2106/</span></p>
<p style="top:661.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">JBJS.D.02846.</span></p>
<p style="top:671.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">149. Steadman JR, Briggs KK, Rodrigo JJ, et al. Outcomes of microfracture for</span></p>
<p style="top:680.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">traumatic chondral defects of the knee: average 11-year follow-up. Arthrosc</span></p>
<p style="top:689.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Arthrosc Relat Surg. 2003;19(5):477</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">84. doi:10.1053/jars.2003.50112.</span></p>
<p style="top:698.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">150. Uematsu K, Hattori K, Ishimoto Y, et al. Cartilage regeneration using</span></p>
<p style="top:707.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells and a three-dimensional poly-lactic-glycolic acid</span></p>
<p style="top:716.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">(PLGA) scaffold. Biomaterials. 2005;26(20):4273</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1016/j.biomaterials.</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2004.10.037.</span></p>
<p style="top:89.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">151. Duan X, Zhu X, Dong X, et al. Repair of large osteochondral defects in a beagle</span></p>
<p style="top:98.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">model with a novel type I collagen/glycosaminoglycan-porous titanium</span></p>
<p style="top:107.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">biphasic scaffold. Mater Sci Eng C Mater Biol Appl. 2013;33(7):3951</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:116.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.msec.2013.05.040.</span></p>
<p style="top:125.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">152. Oshima Y, Watanabe N, Matsuda K, Takai S, Kawata M, Kubo T. Fate of</span></p>
<p style="top:134.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplanted bone-marrow-derived mesenchymal cells during</span></p>
<p style="top:143.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral repair using transgenic rats to simulate autologous</span></p>
<p style="top:152.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplantation. Osteoarthritis Cartilage. 2004;12(10):811</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. doi:10.1016/j.</span></p>
<p style="top:161.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">joca.2004.06.014.</span></p>
<p style="top:171.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">153. Betsch M, Schneppendahl J, Thuns S, et al. Bone marrow aspiration</span></p>
<p style="top:180.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">concentrate and platelet rich plasma for osteochondral repair in a porcine</span></p>
<p style="top:189.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral defect model. PLoS One. 2013;8(8):e71602. doi:10.1371/</span></p>
<p style="top:198.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">journal.pone.0071602.</span></p>
<p style="top:207.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">154. Solchaga LA, Gao J, Dennis JE, et al. Treatment of osteochondral defects</span></p>
<p style="top:216.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with autologous bone marrow in a hyaluronan-based delivery vehicle.</span></p>
<p style="top:225.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tissue Eng. 2002;8(2):333</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">47. doi:10.1089/107632702753725085.</span></p>
<p style="top:234.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">155. Gille J, Schuseil E, Wimmer J, Gellissen J, Schulz AP, Behrens P. Mid-term</span></p>
<p style="top:243.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">results of autologous matrix-induced chondrogenesis for treatment of focal</span></p>
<p style="top:252.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage defects in the knee. Knee Surg Sports Traumatol Arthrosc.</span></p>
<p style="top:261.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;18(11):1456</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64. doi:10.1007/s00167-010-1042-3.</span></p>
<p style="top:270.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">156. Dhollander AAM, De Neve F, Almqvist KF, et al. Autologous matrix-induced</span></p>
<p style="top:279.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenesis combined with platelet-rich plasma gel: technical</span></p>
<p style="top:288.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">description and a five pilot patients report. Knee Surg Sports Traumatol</span></p>
<p style="top:297.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arthrosc. 2011;19(4):536</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">42. doi:10.1007/s00167-010-1337-4.</span></p>
<p style="top:307.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">157. Kusano T, Jakob RP, Gautier E, Magnussen RA, Hoogewoud H, Jacobi M.</span></p>
<p style="top:316.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Treatment of isolated chondral and osteochondral defects in the knee by</span></p>
<p style="top:325.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous matrix-induced chondrogenesis (AMIC). Knee Surg Sports</span></p>
<p style="top:334.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Traumatol Arthrosc. 2012;20(10):2109</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">15. doi:10.1007/s00167-011-1840-2.</span></p>
<p style="top:343.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">158. Zantop T, Petersen W, Murrell GA, et al. Arthroscopic implantation of a</span></p>
<p style="top:352.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">matrix to cover large chondral defect during microfracture. Arthrosc J</span></p>
<p style="top:361.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arthrosc Relat Surg. 2009;25(11):1354</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">60. doi:10.1016/j.arthro.2009.04.077.</span></p>
<p style="top:370.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">159. Siclari A, Mascaro G, Gentili C, Cancedda R, Boux E. A cell-free scaffold-</span></p>
<p style="top:379.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">based cartilage repair provides improved function hyaline-like repair at</span></p>
<p style="top:388.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">one year. Clin Orthop Relat Res. 2012;470(3):910</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1007/</span></p>
<p style="top:397.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">s11999-011-2107-4.</span></p>
<p style="top:407.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">160. Huade Li H, Qiang Zheng Q, Yuxiang Xiao Y, Jie Feng J, Zhongli Shi Z,</span></p>
<p style="top:416.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zhijun PZ. Rat cartilage repair using nanophase PLGA/HA composite and</span></p>
<p style="top:425.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells. J Bioact Compat Polym. 2009;24(1):83</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">99.</span></p>
<p style="top:434.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1177/0883911508100655.</span></p>
<p style="top:443.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">161. Yan H, Yu C. Repair of full-thickness cartilage defects with cells of different</span></p>
<p style="top:452.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">origin in a rabbit model. Arthroscopy. 2007;23(2):178</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">87. doi:10.1016/</span></p>
<p style="top:461.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.arthro.2006.09.005.</span></p>
<p style="top:470.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">162. Charles Huang C-Y, Reuben PM, D</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ippolito G, Schiller PC, Cheung HS.</span></p>
<p style="top:479.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chondrogenesis of human bone marrow-derived mesenchymal stem cells</span></p>
<p style="top:488.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in agarose culture. Anat Rec. 2004;278A(1):428</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">36. doi:10.1002/ar.a.20010.</span></p>
<p style="top:497.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">163. Koga H, Muneta T, Nagase T, et al. Comparison of mesenchymal tissues-</span></p>
<p style="top:506.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived stem cells for in vivo chondrogenesis: suitable conditions for cell</span></p>
<p style="top:515.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">therapy of cartilage defects in rabbit. Cell Tissue Res. 2008;333(2):207</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">15.</span></p>
<p style="top:524.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1007/s00441-008-0633-5.</span></p>
<p style="top:534.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">164. Erickson IE, Kestle SR, Zellars KH, et al. High mesenchymal stem cell seeding</span></p>
<p style="top:543.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">densities in hyaluronic acid hydrogels produce engineered cartilage with</span></p>
<p style="top:552.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">native tissue properties. Acta Biomater. 2012;8(8):3027</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">34. doi:10.1016/j.</span></p>
<p style="top:561.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">actbio.2012.04.033.</span></p>
<p style="top:570.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">165. What are induced pluripotent stem cells? [Stem Cell Information]. Available</span></p>
<p style="top:579.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">at: https://stemcells.nih.gov/info/basics.htm. Accessed June 2016.</span></p>
<p style="top:588.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">166. Wei Y, Zeng W, Wan R, et al. Chondrogenic differentiation of induced</span></p>
<p style="top:597.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pluripotent stem cells from osteoarthritic chondrocytes in alginate matrix.</span></p>
<p style="top:606.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Eur Cell Mater. 2012;23:1</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:615.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/22241609. Accessed 12 Aug 2016.</span></p>
<p style="top:624.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">167. Medvedev SP, Grigor</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">eva EV, Shevchenko AI, et al. Human induced pluripotent</span></p>
<p style="top:633.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells derived from fetal neural stem cells successfully undergo directed</span></p>
<p style="top:643.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiation into cartilage. Stem Cells Dev. 2011;20(6):1099</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">112. doi:10.1089/</span></p>
<p style="top:651.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">scd.2010.0249.</span></p>
<p style="top:661.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">168. Millan C, Cavalli E, Groth T, Maniura-Weber K, Zenobi-Wong M. Engineered</span></p>
<p style="top:670.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">microtissues formed by schiff base crosslinking restore the chondrogenic</span></p>
<p style="top:679.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">potential of aged mesenchymal stem cells. Adv Healthc Mater.</span></p>
<p style="top:688.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2015;4(9):1348</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">58. doi:10.1002/adhm.201500102.</span></p>
<p style="top:698.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">169. Popa EG, Caridade SG, Mano JF, Reis RL, Gomes ME. Chondrogenic potential</span></p>
<p style="top:707.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of injectable</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313"> &#x3ba;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">-carrageenan hydrogel with encapsulated adipose stem cells</span></p>
<p style="top:716.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">for cartilage tissue-engineering applications. J Tissue Eng Regen Med.</span></p>
<p style="top:725.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2015;9(5):550</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">63. doi:10.1002/term.1683.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 25 of 30</span></p>


<p style="top:89.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">170. Huang Z, Nooeaid P, Kohl B, et al. Chondrogenesis of human bone marrow</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stromal cells in highly porous alginate-foams supplemented</span></p>
<p style="top:107.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with chondroitin sulfate. Mater Sci Eng C Mater Biol Appl. 2015;50:160</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">72.</span></p>
<p style="top:116.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.msec.2015.01.082.</span></p>
<p style="top:125.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">171. Narcisi R, Cleary MA, Brama PAJ, et al. Long-term expansion, enhanced</span></p>
<p style="top:134.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenic potential, and suppression of endochondral ossification of</span></p>
<p style="top:143.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adult human MSCs via WNT signaling modulation. Stem Cell Reports.</span></p>
<p style="top:152.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2015;4(3):459</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">72. doi:10.1016/j.stemcr.2015.01.017.</span></p>
<p style="top:162.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">172. Castro NJ, O</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Brien J, Zhang LG. Integrating biologically inspired</span></p>
<p style="top:171.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">nanomaterials and table-top stereolithography for 3D printed biomimetic</span></p>
<p style="top:180.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral scaffolds. Nanoscale. 2015;7(33):14010</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">22. doi:10.1039/</span></p>
<p style="top:189.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">c5nr03425f.</span></p>
<p style="top:198.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">173. Rey-Rico A, Venkatesan JK, Sohier J, Moroni L, Cucchiarini M, Madry H.</span></p>
<p style="top:207.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Adapted chondrogenic differentiation of human mesenchymal stem cells</span></p>
<p style="top:216.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">via controlled release of TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1 from poly(ethylene oxide)-terephtalate/</span></p>
<p style="top:225.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">poly(butylene terepthalate) multiblock scaffolds. J Biomed Mater Res A.</span></p>
<p style="top:234.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2015;103(1):371</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">83. doi:10.1002/jbm.a.35181.</span></p>
<p style="top:243.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">174. Kim J, Lin B, Kim S, Choi B, Evseenko D, Lee M. TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1 conjugated</span></p>
<p style="top:252.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chitosan collagen hydrogels induce chondrogenic differentiation of</span></p>
<p style="top:261.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">human synovium-derived stem cells. J Biol Eng. 2015;9:1. doi:10.1186/</span></p>
<p style="top:270.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1754-1611-9-1.</span></p>
<p style="top:279.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">175. Dang PN, Solorio LD, Alsberg E. Driving cartilage formation in high-density</span></p>
<p style="top:289.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">human adipose-derived stem cell aggregate and sheet constructs without</span></p>
<p style="top:298.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">exogenous growth factor delivery. Tissue Eng Part A. 2014;20(23-24):3163</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">75.</span></p>
<p style="top:306.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.tea.2012.0551.</span></p>
<p style="top:316.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">176. Focaroli S, Teti G, Salvatore V, et al. Chondrogenic differentiation of human</span></p>
<p style="top:325.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adipose mesenchimal stem cells: influence of a biomimetic gelatin genipin</span></p>
<p style="top:334.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">crosslinked porous scaffold. Microsc Res Tech. 2014;77(11):928</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">34.</span></p>
<p style="top:343.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1002/jemt.22417.</span></p>
<p style="top:352.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">177. Leijten J, Georgi N, Moreira Teixeira L, van Blitterswijk CA, Post JN,</span></p>
<p style="top:361.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Karperien M. Metabolic programming of mesenchymal stromal cells by</span></p>
<p style="top:370.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">oxygen tension directs chondrogenic cell fate. Proc Natl Acad Sci U S A.</span></p>
<p style="top:379.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2014;111(38):13954</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1073/pnas.1410977111.</span></p>
<p style="top:388.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">178. Jagielski M, Wolf J, Marzahn U, et al. The influence of IL-10 and TNF</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313">&#x3b1;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> on</span></p>
<p style="top:397.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenesis of human mesenchymal stromal cells in three-dimensional</span></p>
<p style="top:406.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cultures. Int J Mol Sci. 2014;15(9):15821</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">44. doi:10.3390/ijms150915821.</span></p>
<p style="top:416.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">179. Frisch J, Venkatesan J, Rey-Rico A, et al. Influence of insulin-like growth</span></p>
<p style="top:425.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">factor I overexpression via recombinant adeno-associated vector gene</span></p>
<p style="top:434.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transfer upon the biological activities and differentiation potential of human</span></p>
<p style="top:443.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther.</span></p>
<p style="top:452.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2014;5(4):103. doi:10.1186/scrt491.</span></p>
<p style="top:461.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">180. Meng F, He A, Zhang Z, et al. Chondrogenic differentiation of ATDC5 and</span></p>
<p style="top:470.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">hMSCs could be induced by a novel scaffold-tricalcium phosphate-collagen-</span></p>
<p style="top:479.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">hyaluronan without any exogenous growth factors in vitro. J Biomed Mater</span></p>
<p style="top:488.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Res Part A. 2014;102(8):2725</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">35. doi:10.1002/jbm.a.34948.</span></p>
<p style="top:497.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">181. Ye K, Felimban R, Traianedes K, et al. Chondrogenesis of infrapatellar fat pad</span></p>
<p style="top:506.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived adipose stem cells in 3D printed chitosan scaffold. PLoS One.</span></p>
<p style="top:515.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2014;9(6):e99410. doi:10.1371/journal.pone.0099410. Reilly G, ed.</span></p>
<p style="top:525.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">182. Bhumiratana S, Eton RE, Oungoulian SR, Wan LQ, Ateshian GA, Vunjak-</span></p>
<p style="top:534.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Novakovic G. Large, stratified, and mechanically functional human cartilage</span></p>
<p style="top:543.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">grown in vitro by mesenchymal condensation. Proc Natl Acad Sci.</span></p>
<p style="top:552.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2014;111(19):6940</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">5. doi:10.1073/pnas.1324050111.</span></p>
<p style="top:561.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">183. Mhanna R, &#xd6;zt&#xfc;rk E, Vallmajo-Martin Q, Millan C, M&#xfc;ller M, Zenobi-Wong M.</span></p>
<p style="top:570.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">GFOGER-modified MMP-sensitive polyethylene glycol hydrogels induce</span></p>
<p style="top:579.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenic differentiation of human mesenchymal stem cells. Tissue Eng</span></p>
<p style="top:588.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Part A. 2014;20(7-8):1165</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">74. doi:10.1089/ten.TEA.2013.0519.</span></p>
<p style="top:597.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">184. Sato Y, Wakitani S, Takagi M. Xeno-free and shrinkage-free preparation of</span></p>
<p style="top:606.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">scaffold-free cartilage-like disc-shaped cell sheet using human bone marrow</span></p>
<p style="top:615.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells. J Biosci Bioeng. 2013;116(6):734</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1016/</span></p>
<p style="top:624.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.jbiosc.2013.05.019.</span></p>
<p style="top:633.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">185. Guenther D, Oks A, Ettinger M, et al. Enhanced migration of human</span></p>
<p style="top:642.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow stromal cells in modified collagen hydrogels. Int Orthop.</span></p>
<p style="top:651.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;37(8):1605</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">11. doi:10.1007/s00264-013-1894-5.</span></p>
<p style="top:661.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">186. Yang X, Shang H, Katz A, Li X. A modified aggregate culture for</span></p>
<p style="top:670.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenesis of human adipose-derived stem cells genetically</span></p>
<p style="top:679.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">modified with growth and differentiation factor 5. Biores Open Access.</span></p>
<p style="top:688.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;2(4):258</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">65. doi:10.1089/biores.2013.0014.</span></p>
<p style="top:698.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">187. Saha S, Kirkham J, Wood D, Curran S, Yang XB. Informing future cartilage</span></p>
<p style="top:707.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">repair strategies: a comparative study of three different human cell types</span></p>
<p style="top:716.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">for cartilage tissue engineering. Cell Tissue Res. 2013;352(3):495</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">507.</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1007/s00441-013-1586-x.</span></p>
<p style="top:89.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">188. Neumann AJ, Alini M, Archer CW, Stoddart MJ. Chondrogenesis of human</span></p>
<p style="top:98.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow-derived mesenchymal stem cells is modulated by complex</span></p>
<p style="top:107.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mechanical stimulation and adenoviral-mediated overexpression of bone</span></p>
<p style="top:116.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">morphogenetic protein 2. Tissue Eng Part A. 2013;19(11-12):1285</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">94.</span></p>
<p style="top:125.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.TEA.2012.0411.</span></p>
<p style="top:134.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">189. Kim D-H, Kim D-D, Yoon I-S. Proliferation and chondrogenic differentiation</span></p>
<p style="top:143.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of human adipose-derived mesenchymal stem cells in sodium alginate</span></p>
<p style="top:152.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">beads with or without hyaluronic acid. J Pharm Investig. 2013;43(2):145</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">51.</span></p>
<p style="top:161.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1007/s40005-013-0059-2.</span></p>
<p style="top:171.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">190. Chen X, Zhang F, He X, et al. Chondrogenic differentiation of umbilical</span></p>
<p style="top:180.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cord-derived mesenchymal stem cells in type I collagen-hydrogel for</span></p>
<p style="top:189.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage engineering. Injury. 2013;44(4):540</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1016/j.injury.2012.09.024.</span></p>
<p style="top:198.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">191. Pei M, Zhang Y, Li J, Chen D. Antioxidation of decellularized stem</span></p>
<p style="top:207.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cell matrix promotes human synovium-derived stem cell-based</span></p>
<p style="top:216.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenesis. Stem Cells Dev. 2013;22(6):889</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">900. doi:10.1089/</span></p>
<p style="top:225.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">scd.2012.0495.</span></p>
<p style="top:234.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">192. Petrou M, Niemeyer P, Stoddart MJ, et al. Mesenchymal stem cell</span></p>
<p style="top:243.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenesis: composite growth factor-bioreactor synergism for</span></p>
<p style="top:252.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">human stem cell chondrogenesis. Regen Med. 2013;8(2):157</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">70.</span></p>
<p style="top:261.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.2217/rme.13.3.</span></p>
<p style="top:270.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">193. Cheng N-C, Estes BT, Young T-H, Guilak F. Genipin-crosslinked cartilage-</span></p>
<p style="top:279.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived matrix as a scaffold for human adipose-derived stem cell</span></p>
<p style="top:288.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenesis. Tissue Eng Part A. 2013;19(3-4):484</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">96. doi:10.1089/</span></p>
<p style="top:297.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">ten.tea.2012.0384.</span></p>
<p style="top:307.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">194. L&#xf3;pez-Ruiz E, Per&#xe1;n M, Cobo-Molinos J, et al. Chondrocytes extract from</span></p>
<p style="top:316.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">patients with osteoarthritis induces chondrogenesis in infrapatellar fat pad-</span></p>
<p style="top:325.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived stem cells. Osteoarthr Cartil. 2013;21(1):246</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">58. doi:10.1016/</span></p>
<p style="top:334.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.joca.2012.10.007.</span></p>
<p style="top:343.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">195. Spoliti M, Iudicone P, Leone R, De Rosa A, Rossetti FR, Pierelli L. In vitro</span></p>
<p style="top:352.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">release and expansion of mesenchymal stem cells by a hyaluronic acid</span></p>
<p style="top:361.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">scaffold used in combination with bone marrow. Muscles Ligaments</span></p>
<p style="top:370.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tendons J. 2012;2(4):289</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">94. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:379.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/23738312. Accessed June 22, 2016.</span></p>
<p style="top:388.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">196. Mifune Y, Matsumoto T, Murasawa S, et al. Therapeutic superiority for</span></p>
<p style="top:397.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage repair by CD271-positive marrow stromal cell transplantation. Cell</span></p>
<p style="top:406.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Transplant. 2013;22(7):1201</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">11. doi:10.3727/096368912X657378.</span></p>
<p style="top:416.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">197. Ousema PH, Moutos FT, Estes BT, et al. The inhibition by interleukin 1 of</span></p>
<p style="top:425.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">MSC chondrogenesis and the development of biomechanical properties in</span></p>
<p style="top:434.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">biomimetic 3D woven PCL scaffolds. Biomaterials. 2012;33(35):8967</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">74.</span></p>
<p style="top:443.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.biomaterials.2012.08.045.</span></p>
<p style="top:452.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">198. Li F, Chen Y-Z, Miao Z-N, Zheng S, Jin J. Human placenta-derived</span></p>
<p style="top:461.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells with silk fibroin biomaterial in the repair of</span></p>
<p style="top:470.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">articular cartilage defects. 2012.</span></p>
<p style="top:479.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">199. Popa E, Reis R, Gomes M. Chondrogenic phenotype of different cells</span></p>
<p style="top:488.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">encapsulated in</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313"> &#x3ba;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">-carrageenan hydrogels for cartilage regeneration</span></p>
<p style="top:497.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">strategies. Biotechnol Appl Biochem. 59(2):132-41. doi:10.1002/bab.1007.</span></p>
<p style="top:506.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">200. Suzuki S, Muneta T, Tsuji K, et al. Properties and usefulness of aggregates of</span></p>
<p style="top:515.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">synovial mesenchymal stem cells as a source for cartilage regeneration.</span></p>
<p style="top:524.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Arthritis Res Ther. 2012;14(3):R136. doi:10.1186/ar3869.</span></p>
<p style="top:534.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">201. Musumeci G, Lo Furno D, Loreto C, et al. Mesenchymal stem cells from</span></p>
<p style="top:543.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adipose tissue which have been differentiated into chondrocytes in three-</span></p>
<p style="top:552.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">dimensional culture express lubricin. Exp Biol Med. 2011;236(11):1333</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41.</span></p>
<p style="top:561.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1258/ebm.2011.011183.</span></p>
<p style="top:570.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">202. Yoon I-S, Chung CW, Sung J-H, et al. Proliferation and chondrogenic</span></p>
<p style="top:579.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiation of human adipose-derived mesenchymal stem cells in</span></p>
<p style="top:588.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">porous hyaluronic acid scaffold. J Biosci Bioeng. 2011;112(4):402</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8.</span></p>
<p style="top:597.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.jbiosc.2011.06.018.</span></p>
<p style="top:606.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">203. Liu TM, Guo XM, Tan HS, Hui JH, Lim B, Lee EH. Zinc-finger protein 145,</span></p>
<p style="top:615.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">acting as an upstream regulator of SOX9, improves the differentiation</span></p>
<p style="top:624.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">potential of human mesenchymal stem cells for cartilage regeneration and</span></p>
<p style="top:633.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">repair. Arthritis Rheum. 2011;63(9):2711</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">20. doi:10.1002/art.30430.</span></p>
<p style="top:643.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">204. Im G-I, Kim H-J, Lee JH. Chondrogenesis of adipose stem cells in a porous</span></p>
<p style="top:651.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">PLGA scaffold impregnated with plasmid DNA containing SOX trio (SOX-5,</span></p>
<p style="top:660.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">-6 and -9) genes. Biomaterials. 2011;32(19):4385</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">92. doi:10.1016/j.</span></p>
<p style="top:669.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">biomaterials.2011.02.054.</span></p>
<p style="top:679.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">205. Chen W-C, Yao C-L, Chu I-M, Wei Y-H. Compare the effects of chondrogenesis</span></p>
<p style="top:688.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">by culture of human mesenchymal stem cells with various type of the</span></p>
<p style="top:697.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondroitin sulfate C. J Biosci Bioeng. 2011;111(2):226</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">31. doi:10.1016/</span></p>
<p style="top:706.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.jbiosc.2010.10.002.</span></p>
<p style="top:716.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">206. Garc&#xed;a-&#xc1;lvarez F, Alegre-Aguar&#xf3;n E, Desportes P, et al. Chondrogenic</span></p>
<p style="top:725.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiation in femoral bone marrow-derived mesenchymal cells (MSC)</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 26 of 30</span></p>


<p style="top:89.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">from elderly patients suffering osteoarthritis or femoral fracture. Arch</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Gerontol Geriatr. 52(2):239-42. doi:10.1016/j.archger.2010.03.026.</span></p>
<p style="top:107.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">207. Abrahamsson CK, Yang F, Park H, et al. Chondrogenesis and mineralization</span></p>
<p style="top:116.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">during in vitro culture of human mesenchymal stem cells on three-</span></p>
<p style="top:125.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">dimensional woven scaffolds. Tissue Eng Part A. 2010;16(12):3709</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">18.</span></p>
<p style="top:134.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.TEA.2010.0190.</span></p>
<p style="top:144.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">208. Baumgartner L, Arnhold S, Brixius K, Addicks K, Bloch W. Human</span></p>
<p style="top:153.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells: influence of oxygen pressure on proliferation and</span></p>
<p style="top:162.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenic differentiation in fibrin glue in vitro. J Biomed Mater Res Part</span></p>
<p style="top:171.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">A. 2009;9999A(3):NA-NA. doi:10.1002/jbm.a.32577.</span></p>
<p style="top:180.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">209. Kim H-J, Lee J-H, Im G-I. Chondrogenesis using mesenchymal stem cells</span></p>
<p style="top:189.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">and PCL scaffolds. J Biomed Mater Res Part A. 2009;9999A(2):NA-NA.</span></p>
<p style="top:198.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1002/jbm.a.32414.</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">210. Kobayashi T, Ochi M, Yanada S, et al. Augmentation of degenerated human</span></p>
<p style="top:216.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage in vitro using magnetically labeled mesenchymal stem cells and an</span></p>
<p style="top:225.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">external magnetic device. Arthroscopy. 2009;25(12):1435</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41. doi:10.1016/</span></p>
<p style="top:234.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.arthro.2009.06.009.</span></p>
<p style="top:243.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">211. Hildner F, Concaro S, Peterbauer A, et al. Human adipose-derived stem</span></p>
<p style="top:252.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells contribute to chondrogenesis in coculture with human articular</span></p>
<p style="top:261.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrocytes. Tissue Eng Part A. 2009;15(12):3961</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1089/</span></p>
<p style="top:270.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">ten.TEA.2009.0002.</span></p>
<p style="top:280.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">212. Angele P, M&#xfc;ller R, Schumann D, et al. Characterization of esterified</span></p>
<p style="top:289.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">hyaluronan-gelatin polymer composites suitable for chondrogenic</span></p>
<p style="top:298.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiation of mesenchymal stem cells. J Biomed Mater Res Part A.</span></p>
<p style="top:307.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2009;91A(2):416</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">27. doi:10.1002/jbm.a.32236.</span></p>
<p style="top:316.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">213. Lee S, Kim JH, Jo CH, Seong SC, Lee JC, Lee MC. Effect of serum and growth</span></p>
<p style="top:325.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">factors on chondrogenic differentiation of synovium-derived stromal cells.</span></p>
<p style="top:334.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tissue Eng Part A. 2009;15(11):3401</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">15. doi:10.1089/ten.TEA.2008.0466.</span></p>
<p style="top:343.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">214. Jung Y, Chung Y-I, Kim SH, et al. In situ chondrogenic differentiation of human</span></p>
<p style="top:352.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adipose tissue-derived stem cells in a TGF-beta1 loaded fibrin-poly(lactide-</span></p>
<p style="top:361.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">caprolactone) nanoparticulate complex. Biomaterials. 2009;30(27):4657</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64.</span></p>
<p style="top:370.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/j.biomaterials.2009.05.034.</span></p>
<p style="top:379.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">215. Spadaccio C, Rainer A, Trombetta M, et al. Poly-L-lactic acid/hydroxyapatite</span></p>
<p style="top:388.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">electrospun nanocomposites induce chondrogenic differentiation of human</span></p>
<p style="top:397.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">MSC. Ann Biomed Eng. 2009;37(7):1376</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">89. doi:10.1007/s10439-009-9704-3.</span></p>
<p style="top:407.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">216. Seda Tigli R, Ghosh S, Laha MM, et al. Comparative chondrogenesis of</span></p>
<p style="top:416.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">human cell sources in 3D scaffolds. J Tissue Eng Regen Med. 2009;3(5):348</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">60.</span></p>
<p style="top:425.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1002/term.169.</span></p>
<p style="top:434.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">217. Heymer A, Bradica G, Eulert J, N&#xf6;th U. Multiphasic collagen fibre-PLA</span></p>
<p style="top:443.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">composites seeded with human mesenchymal stem cells for osteochondral</span></p>
<p style="top:452.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defect repair: an in vitro study. J Tissue Eng Regen Med. 2009;3(5):389</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">97.</span></p>
<p style="top:461.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1002/term.175.</span></p>
<p style="top:470.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">218. Pilgaard L, Lund P, Duroux M, et al. Effect of oxygen concentration, culture</span></p>
<p style="top:479.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">format and donor variability on in vitro chondrogenesis of human adipose</span></p>
<p style="top:488.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">tissue-derived stem cells. Regen Med. 2009;4(4):539</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">48. doi:10.2217/rme.09.28.</span></p>
<p style="top:497.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">219. Kim H-J, Im G-I. Combination of transforming growth factor-beta2 and bone</span></p>
<p style="top:506.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">morphogenetic protein 7 enhances chondrogenesis from adipose tissue-</span></p>
<p style="top:515.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived mesenchymal stem cells. Tissue Eng Part A. 2009;15(7):1543</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">51.</span></p>
<p style="top:524.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.tea.2008.0368.</span></p>
<p style="top:534.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">220. Cheng N-C, Estes BT, Awad HA, Guilak F. Chondrogenic differentiation of</span></p>
<p style="top:543.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adipose-derived adult stem cells by a porous scaffold derived from native</span></p>
<p style="top:552.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">articular cartilage extracellular matrix. Tissue Eng Part A. 2009;15(2):231</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41.</span></p>
<p style="top:561.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.tea.2008.0253.</span></p>
<p style="top:570.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">221. Babister JC, Tare RS, Green DW, Inglis S, Mann S, Oreffo ROC. Genetic</span></p>
<p style="top:579.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">manipulation of human mesenchymal progenitors to promote</span></p>
<p style="top:588.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chondrogenesis using</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313"> &#x201c;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bead-in-bead</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x201d;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> polysaccharide capsules. Biomaterials.</span></p>
<p style="top:597.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2008;29(1):58</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">65. doi:10.1016/j.biomaterials.2007.09.006.</span></p>
<p style="top:606.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">222. Miyamoto C, Matsumoto T, Sakimura K, Shindo H. Osteogenic protein-1</span></p>
<p style="top:615.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with transforming growth factor-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1: potent inducer of chondrogenesis of</span></p>
<p style="top:624.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">synovial mesenchymal stem cells in vitro. J Orthop Sci. 2007;12(6):555</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">61.</span></p>
<p style="top:633.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1007/s00776-007-1176-4.</span></p>
<p style="top:642.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">223. Mehlhorn AT, Schmal H, Kaiser S, et al. Mesenchymal stem cells maintain</span></p>
<p style="top:652.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">TGF-beta-mediated chondrogenic phenotype in alginate bead culture.</span></p>
<p style="top:661.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tissue Eng. 2006;12(6):1393</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">403. doi:10.1089/ten.2006.12.1393.</span></p>
<p style="top:670.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">224. Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic differentiation</span></p>
<p style="top:679.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of human adipose-derived adult stem cells by bone morphogenetic protein</span></p>
<p style="top:688.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">6. Arthritis Rheum. 2006;54(4):1222</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">32. doi:10.1002/art.21779.</span></p>
<p style="top:698.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">225. Zhang X, Mitsuru A, Igura K, et al. Mesenchymal progenitor cells derived</span></p>
<p style="top:707.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">from chorionic villi of human placenta for cartilage tissue engineering.</span></p>
<p style="top:716.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Biochem Biophys Res Commun. 2006;340(3):944</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">52. doi:10.1016/</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.bbrc.2005.12.091.</span></p>
<p style="top:89.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">226. Yokoyama A, Sekiya I, Miyazaki K, Ichinose S, Hata Y, Muneta T. In vitro</span></p>
<p style="top:98.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage formation of composites of synovium-derived mesenchymal stem</span></p>
<p style="top:107.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells with collagen gel. Cell Tissue Res. 2005;322(2):289</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">98. doi:10.1007/</span></p>
<p style="top:116.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">s00441-005-0010-6.</span></p>
<p style="top:125.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">227. Sekiya I, Larson BL, Vuoristo JT, Reger RL, Prockop DJ. Comparison of effect</span></p>
<p style="top:134.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of BMP-2, -4, and -6 on in vitro cartilage formation of human adult stem</span></p>
<p style="top:143.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells from bone marrow stroma. Cell Tissue Res. 2005;320(2):269</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">76.</span></p>
<p style="top:152.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1007/s00441-004-1075-3.</span></p>
<p style="top:162.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">228. Wickham MQ, Erickson GR, Gimble JM, Vail TP, Guilak F. Multipotent stromal</span></p>
<p style="top:171.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells derived from the infrapatellar fat pad of the knee. Clin Orthop Relat</span></p>
<p style="top:180.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Res. 2003;412:196</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">212. doi:10.1097/01.blo.0000072467.53786.ca.</span></p>
<p style="top:189.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">229. Dragoo JL, Samimi B, Zhu M, et al. Tissue-engineered cartilage and bone</span></p>
<p style="top:198.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">using stem cells from human infrapatellar fat pads. J Bone Joint Surg Br.</span></p>
<p style="top:207.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2003;85(5):740</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/</span></p>
<p style="top:216.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12892203. Accessed 22 June 2016.</span></p>
<p style="top:225.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">230. N&#xf6;th U, Tuli R, Osyczka AM, Danielson KG, Tuan RS. In vitro engineered</span></p>
<p style="top:234.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage constructs produced by press-coating biodegradable polymer with</span></p>
<p style="top:243.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">human mesenchymal stem cells. 2004. http://online.liebertpub.com/doi/abs/</span></p>
<p style="top:252.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">10.1089/107632702753503126. Accessed June 2016.</span></p>
<p style="top:262.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">231. Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, Guilak F.</span></p>
<p style="top:270.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chondrogenic potential of adipose tissue-derived stromal cells in vitro</span></p>
<p style="top:279.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">and in vivo. Biochem Biophys Res Commun. 2002;290(2):763</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.</span></p>
<p style="top:289.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1006/bbrc.2001.6270.</span></p>
<p style="top:298.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">232. Caterson EJ, Nesti LJ, Li WJ, et al. Three-dimensional cartilage formation by</span></p>
<p style="top:307.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow-derived cells seeded in polylactide/alginate amalgam. J</span></p>
<p style="top:316.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Biomed Mater Res. 2001;57(3):394</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">403. Available at: http://www.ncbi.nlm.</span></p>
<p style="top:325.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">nih.gov/pubmed/11523034. Accessed 22 June 2016.</span></p>
<p style="top:334.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">233. Ponticiello MS, Schinagl RM, Kadiyala S, Barry FP. Gelatin-based resorbable</span></p>
<p style="top:343.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">sponge as a carrier matrix for human mesenchymal stem cells in cartilage</span></p>
<p style="top:352.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">regeneration therapy. J Biomed Mater Res. 2000;52(2):246</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">55. Available at:</span></p>
<p style="top:361.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">http://www.ncbi.nlm.nih.gov/pubmed/10951362. Accessed 22 June 2016.</span></p>
<p style="top:370.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">234. Yoo JU, Barthel TS, Nishimura K, et al. The chondrogenic potential of human</span></p>
<p style="top:379.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone-marrow-derived mesenchymal progenitor cells. J Bone Joint Surg Am.</span></p>
<p style="top:388.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1998;80(12):1745</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">57. Available at: http://www.ncbi.nlm.nih.gov/pubmed/</span></p>
<p style="top:397.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9875932. Accessed 22 June 2016.</span></p>
<p style="top:407.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">235. Huang JI, Kazmi N, Durbhakula MM, Hering TM, Yoo JU, Johnstone B.</span></p>
<p style="top:416.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chondrogenic potential of progenitor cells derived from human bone</span></p>
<p style="top:425.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">marrow and adipose tissue: a patient-matched comparison. J Orthop Res.</span></p>
<p style="top:434.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2005;23(6):1383</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1016/j.orthres.2005.03.018.</span></p>
<p style="top:443.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">236. Chen W-C, Wei Y-H, Chu I-M, Yao C-L. Effect of chondroitin sulphate C</span></p>
<p style="top:452.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">on the in vitro and in vivo chondrogenesis of mesenchymal stem cells</span></p>
<p style="top:461.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in crosslinked type II collagen scaffolds. J Tissue Eng Regen Med.</span></p>
<p style="top:470.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;7(8):665</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">72. doi:10.1002/term.1463.</span></p>
<p style="top:479.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">237. Bornes TD, Jomha NM, Mulet-Sierra A, et al. Hypoxic culture of bone</span></p>
<p style="top:488.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">marrow-derived mesenchymal stromal stem cells differentially</span></p>
<p style="top:497.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">enhances in vitro chondrogenesis within cell-seeded collagen and</span></p>
<p style="top:506.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">hyaluronic acid porous scaffolds. Stem Cell Res Ther. 2015;6(1):84.</span></p>
<p style="top:515.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1186/s13287-015-0075-4.</span></p>
<p style="top:525.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">238. Benders KEM, Boot W, Cokelaere SM, et al. Multipotent stromal cells</span></p>
<p style="top:534.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">outperform chondrocytes on cartilage-derived matrix scaffolds. Cartilage.</span></p>
<p style="top:543.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2014;5(4):221</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">30. doi:10.1177/1947603514535245.</span></p>
<p style="top:552.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">239. Huang H, Zhang X, Hu X, et al. Directing chondrogenic differentiation of</span></p>
<p style="top:561.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells with a solid-supported chitosan thermogel for</span></p>
<p style="top:570.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage tissue engineering. Biomed Mater. 2014;9(3):35008. doi:10.1088/</span></p>
<p style="top:579.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1748-6041/9/3/035008.</span></p>
<p style="top:588.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">240. Lam J, Lu S, Meretoja VV, Tabata Y, Mikos AG, Kasper FK. Generation of</span></p>
<p style="top:597.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral tissue constructs with chondrogenically and</span></p>
<p style="top:606.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteogenically predifferentiated mesenchymal stem cells encapsulated</span></p>
<p style="top:615.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in bilayered hydrogels. Acta Biomater. 2014;10(3):1112</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">23. doi:10.1016/</span></p>
<p style="top:624.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.actbio.2013.11.020.</span></p>
<p style="top:633.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">241. Zhang L, Yuan T, Guo L, Zhang X. An in vitro study of collagen hydrogel</span></p>
<p style="top:642.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">to induce the chondrogenic differentiation of mesenchymal stem cells.</span></p>
<p style="top:651.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Biomed Mater Res Part A. 2012;100A(10):2717</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">25. doi:10.1002/jbm.a.34194.</span></p>
<p style="top:661.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">242. Xie X, Wang Y, Zhao C, et al. Comparative evaluation of MSCs from</span></p>
<p style="top:670.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow and adipose tissue seeded in PRP-derived scaffold for</span></p>
<p style="top:679.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage regeneration. Biomaterials. 2012;33(29):7008</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">18. doi:10.1016/</span></p>
<p style="top:688.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">j.biomaterials.2012.06.058.</span></p>
<p style="top:698.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">243. Giannoni P, Lazzarini E, Ceseracciu L, Barone AC, Quarto R, Scaglione S.</span></p>
<p style="top:707.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Design and characterization of a tissue-engineered bilayer scaffold for</span></p>
<p style="top:716.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral tissue repair. J Tissue Eng Regen Med. 2015;9(10):1182</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">92.</span></p>
<p style="top:725.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1002/term.1651.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 27 of 30</span></p>


<p style="top:89.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">244. Coburn JM, Gibson M, Monagle S, Patterson Z, Elisseeff JH. Bioinspired</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">nanofibers support chondrogenesis for articular cartilage repair. Proc Natl</span></p>
<p style="top:107.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Acad Sci U S A. 2012;109(25):10012</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. doi:10.1073/pnas.1121605109.</span></p>
<p style="top:116.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">245. Kim M, Erickson IE, Choudhury M, Pleshko N, Mauck RL. Transient exposure</span></p>
<p style="top:125.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">to TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">3 improves the functional chondrogenesis of MSC-laden hyaluronic</span></p>
<p style="top:134.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">acid hydrogels. J Mech Behav Biomed Mater. 2012;11:92</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">101. doi:10.1016/j.</span></p>
<p style="top:143.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">jmbbm.2012.03.006.</span></p>
<p style="top:153.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">246. Shafiee A, Soleimani M, Chamheidari GA, et al. Electrospun nanofiber-based</span></p>
<p style="top:162.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">regeneration of cartilage enhanced by mesenchymal stem cells. J Biomed</span></p>
<p style="top:171.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Mater Res A. 2011;99(3):467</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">78. doi:10.1002/jbm.a.33206.</span></p>
<p style="top:180.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">247. Meyer EG, Buckley CT, Thorpe SD, Kelly DJ. Low oxygen tension is a</span></p>
<p style="top:189.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">more potent promoter of chondrogenic differentiation than dynamic</span></p>
<p style="top:198.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">compression. J Biomech. 2010;43(13):2516</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">23. doi:10.1016/j.jbiomech.</span></p>
<p style="top:207.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010.05.020.</span></p>
<p style="top:216.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">248. Vinardell T, Thorpe SD, Buckley CT, Kelly DJ. Chondrogenesis and integration</span></p>
<p style="top:225.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of mesenchymal stem cells within an in vitro cartilage defect repair model.</span></p>
<p style="top:234.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ann Biomed Eng. 2009;37(12):2556</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">65. doi:10.1007/s10439-009-9791-1.</span></p>
<p style="top:243.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">249. Diao H, Wang J, Shen C, et al. Improved cartilage regeneration utilizing</span></p>
<p style="top:252.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells in TGF-beta1 gene-activated scaffolds. Tissue Eng</span></p>
<p style="top:261.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Part A. 2009;15(9):2687</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">98. doi:10.1089/ten.TEA.2008.0621.</span></p>
<p style="top:271.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">250. Eslaminejad MB, Taghiyar L, Falahi F. Co-culture of mesenchymal stem cells</span></p>
<p style="top:280.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with mature chondrocytes: producing cartilage construct for application in</span></p>
<p style="top:289.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage regeneration. Iran J Med Sci. 2015;34(4):251</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8.</span></p>
<p style="top:298.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">251. Schulz RM, Zscharnack M, Hanisch I, Geiling M, Hepp P, Bader A. Cartilage</span></p>
<p style="top:307.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">tissue engineering by collagen matrix associated bone marrow derived</span></p>
<p style="top:316.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells. Biomed Mater Eng. 2008;18(1 Suppl):S55</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">70.</span></p>
<p style="top:325.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/18334724. Accessed</span></p>
<p style="top:334.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">16 June 2016.</span></p>
<p style="top:343.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">252. Hannouche D, Terai H, Fuchs JR, et al. Engineering of implantable</span></p>
<p style="top:352.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilaginous structures from bone marrow-derived mesenchymal stem</span></p>
<p style="top:361.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells. Tissue Eng. 2007;13(1):87</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">99. doi:10.1089/ten.2006.0067.</span></p>
<p style="top:370.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">253. Hegewald AA, Ringe J, Bartel J, et al. Hyaluronic acid and autologous</span></p>
<p style="top:379.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">synovial fluid induce chondrogenic differentiation of equine mesenchymal</span></p>
<p style="top:388.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells: a preliminary study. Tissue Cell. 2004;36(6):431</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8. doi:10.1016/j.</span></p>
<p style="top:397.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">tice.2004.07.003.</span></p>
<p style="top:407.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">254. Worster AA, Brower-Toland BD, Fortier LA, Bent SJ, Williams J, Nixon AJ.</span></p>
<p style="top:416.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chondrocytic differentiation of mesenchymal stem cells sequentially</span></p>
<p style="top:425.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">exposed to transforming growth factor-beta1 in monolayer and insulin-like</span></p>
<p style="top:434.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">growth factor-I in a three-dimensional matrix. J Orthop Res. 2001;19(4):738</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">49.</span></p>
<p style="top:443.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1016/S0736-0266(00)00054-1.</span></p>
<p style="top:452.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">255. Angele P, Kujat R, Nerlich M, Yoo J, Goldberg V, Johnstone B. Engineering of</span></p>
<p style="top:461.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral tissue with bone marrow mesenchymal progenitor cells in a</span></p>
<p style="top:470.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derivatized hyaluronan-gelatin composite sponge. 2007. http://dx.doi.org/</span></p>
<p style="top:479.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">101089/ten19995545. Accessed June 2016.</span></p>
<p style="top:488.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">256. Ding X, Zhu M, Xu B, et al. Integrated trilayered silk fibroin scaffold for</span></p>
<p style="top:497.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral differentiation of adipose-derived stem cells. ACS Appl Mater</span></p>
<p style="top:506.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Interfaces. 2014;6(19):16696</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">705. doi:10.1021/am5036708.</span></p>
<p style="top:515.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">257. Lu C-H, Lin K-J, Chiu H-Y, et al. Improved chondrogenesis and</span></p>
<p style="top:524.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">engineered cartilage formation from TGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">3-expressing adipose-derived</span></p>
<p style="top:533.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells cultured in the rotating-shaft bioreactor. Tissue Eng Part A.</span></p>
<p style="top:542.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2012;18(19-20):2114</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">24. doi:10.1089/ten.TEA.2012.0010.</span></p>
<p style="top:552.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">258. Gong Z, Xiong H, Long X, et al. Use of synovium-derived stromal cells and</span></p>
<p style="top:561.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">chitosan/collagen type I scaffolds for cartilage tissue engineering. Biomed</span></p>
<p style="top:570.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Mater. 2010;5(5):55005. doi:10.1088/1748-6041/5/5/055005.</span></p>
<p style="top:579.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">259. Varshney RR, Zhou R, Hao J, et al. Chondrogenesis of synovium-derived</span></p>
<p style="top:588.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells in gene-transferred co-culture system. Biomaterials.</span></p>
<p style="top:597.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;31(26):6876</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">91. doi:10.1016/j.biomaterials.2010.05.038.</span></p>
<p style="top:606.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">260. Han Y, Wei Y, Wang S, Song Y. Cartilage regeneration using adipose-derived</span></p>
<p style="top:615.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells and the controlled-released hybrid microspheres. Joint Bone</span></p>
<p style="top:624.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Spine. 2010;77(1):27</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">31. doi:10.1016/j.jbspin.2009.05.013.</span></p>
<p style="top:633.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">261. Wei Y, Hu H, Wang H, Wu Y, Deng L, Qi J. Cartilage regeneration of</span></p>
<p style="top:642.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adipose-derived stem cells in a hybrid scaffold from fibrin-modified PLGA.</span></p>
<p style="top:652.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Cell Transplant. 2009;18(2):159</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">70. Available at: http://www.ncbi.nlm.nih.</span></p>
<p style="top:661.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">gov/pubmed/19499704. Accessed 22 June 2016.</span></p>
<p style="top:670.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">262. Han Y, Wei Y, Wang S, Song Y. Regenerative and technological section</span></p>
<p style="top:679.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">enhanced chondrogenesis of adipose-derived stem cells by the controlled</span></p>
<p style="top:688.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">release of transforming growth factor-</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:5.2pt;color:#131313">NL</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> 1 from hybrid microspheres.</span></p>
<p style="top:697.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Gerontology. 2009;55:592</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1159/000235547.</span></p>
<p style="top:707.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">263. Wei Y, Hu Y, Hao W, et al. A novel injectable scaffold for cartilage tissue</span></p>
<p style="top:716.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">engineering using adipose-derived adult stem cells. J Orthop Res.</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2008;26(1):27</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">33. doi:10.1002/jor.20468.</span></p>
<p style="top:89.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">264. Wei Y, Hu Y, Lv R, Li D. Regulation of adipose-derived adult stem cells</span></p>
<p style="top:98.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiating into chondrocytes with the use of rhBMP-2. Cytotherapy.</span></p>
<p style="top:107.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2006;8(6):570</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.1080/14653240600987690.</span></p>
<p style="top:116.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">265. An C, Cheng Y, Yuan Q, Li J. IGF-1 and BMP-2 induces differentiation of</span></p>
<p style="top:125.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">adipose-derived mesenchymal stem cells into chondrocytes-like cells. Ann</span></p>
<p style="top:134.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Biomed Eng. 2010;38(4):1647</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">54. doi:10.1007/s10439-009-9892-x.</span></p>
<p style="top:144.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">266. Lee CSD, Watkins E, Burnsed OA, Schwartz Z, Boyan BD. Tailoring adipose</span></p>
<p style="top:153.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cell trophic factor production with differentiation medium components</span></p>
<p style="top:162.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">to regenerate chondral defects. Tissue Eng Part A. 2013;19(11-12):1451</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64.</span></p>
<p style="top:171.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.TEA.2012.0233.</span></p>
<p style="top:180.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">267. Froelich K, Setiawan LE, Technau A, et al. Influence of different growth</span></p>
<p style="top:189.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">factors on chondrogenic differentiation of adipose-derived stem cells in</span></p>
<p style="top:198.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">polyurethane-fibrin composites. Int J Artif Organs. 2012;35(12):1047</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">60.</span></p>
<p style="top:207.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.5301/ijao.5000132.</span></p>
<p style="top:216.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">268. Buckley CT, Vinardell T, Thorpe SD, et al. Functional properties of</span></p>
<p style="top:225.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilaginous tissues engineered from infrapatellar fat pad-derived</span></p>
<p style="top:234.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells. J Biomech. 2010;43(5):920</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">6. doi:10.1016/j.</span></p>
<p style="top:243.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">jbiomech.2009.11.005.</span></p>
<p style="top:252.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">269. Feng G, Wan Y, Balian G, Laurencin CT, Li X. Adenovirus-mediated</span></p>
<p style="top:261.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">expression of growth and differentiation factor-5 promotes chondrogenesis</span></p>
<p style="top:270.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of adipose stem cells. Growth Factors. 2008;26(3):132</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">42. doi:10.1080/</span></p>
<p style="top:279.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">08977190802105917.</span></p>
<p style="top:289.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">270. Park Y, Sugimoto M, Watrin A, Chiquet M, Hunziker EB. BMP-2 induces the</span></p>
<p style="top:298.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">expression of chondrocyte-specific genes in bovine synovium-derived</span></p>
<p style="top:307.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">progenitor cells cultured in three-dimensional alginate hydrogel.</span></p>
<p style="top:316.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Osteoarthritis Cartilage. 2005;13(6):527</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">36. doi:10.1016/j.joca.2005.02.006.</span></p>
<p style="top:325.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">271. Steinert A, Weber M, Dimmler A, et al. Chondrogenic differentiation of</span></p>
<p style="top:334.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal progenitor cells encapsulated in ultrahigh-viscosity alginate.</span></p>
<p style="top:343.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Orthop Res. 2003;21(6):1090</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. doi:10.1016/S0736-0266(03)00100-1.</span></p>
<p style="top:352.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">272. Marquass B, Somerson JS, Hepp P, et al. A novel MSC-seeded triphasic</span></p>
<p style="top:361.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">construct for the repair of osteochondral defects. J Orthop Res.</span></p>
<p style="top:370.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;28(12):1586</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">99. doi:10.1002/jor.21173.</span></p>
<p style="top:380.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">273. Lee KBL, Hui JHP, Song IC, Ardany L, Lee EH. Injectable mesenchymal stem</span></p>
<p style="top:389.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cell therapy for large cartilage defects</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2014;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">a porcine model. Stem Cells.</span></p>
<p style="top:398.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2007;25(11):2964</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">71. doi:10.1634/stemcells.2006-0311.</span></p>
<p style="top:407.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">274. Zhou XZ, Leung VY, Dong QR, Cheung KM, Chan D, Lu WW. Mesenchymal</span></p>
<p style="top:416.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cell-based repair of articular cartilage with polyglycolic acid-</span></p>
<p style="top:425.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">hydroxyapatite biphasic scaffold. Int J Artif Organs. 2008;31(6):480</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9.</span></p>
<p style="top:434.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/18609500. Accessed 12</span></p>
<p style="top:443.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">June 2016.</span></p>
<p style="top:452.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">275. Shao X, Goh JCH, Hutmacher DW, Lee EH, Zigang G. Repair of large articular</span></p>
<p style="top:461.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral defects using hybrid scaffolds and bone marrow-derived</span></p>
<p style="top:470.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells in a rabbit model. Tissue Eng. 2006;12(6):1539</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">51.</span></p>
<p style="top:479.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.2006.12.1539.</span></p>
<p style="top:488.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">276. Zhang Y, Wang F, Chen J, Ning Z, Yang L. Bone marrow-derived</span></p>
<p style="top:497.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells versus bone marrow nucleated cells in the</span></p>
<p style="top:506.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">treatment of chondral defects. Int Orthop. 2012;36(5):1079</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">86. doi:10.1007/</span></p>
<p style="top:515.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">s00264-011-1362-z.</span></p>
<p style="top:525.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">277. Zhu S, Zhang B, Man C, Ma Y, Liu X, Hu J. Combined effects of</span></p>
<p style="top:534.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">connective tissue growth factor-modified bone marrow-derived</span></p>
<p style="top:543.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells and NaOH-treated PLGA scaffolds on repair</span></p>
<p style="top:552.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of articular cartilage defect in rabbits. Cell Transplant. 2013. doi:10.3727/</span></p>
<p style="top:561.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">096368913X6697790.</span></p>
<p style="top:571.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">278. Oshima Y, Watanabe N, Matsuda K, Takai S, Kawata M, Kubo T. Behavior of</span></p>
<p style="top:580.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplanted bone marrow-derived GFP mesenchymal cells in osteochondral</span></p>
<p style="top:589.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defect as a simulation of autologous transplantation. J Histochem Cytochem.</span></p>
<p style="top:598.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2005;53(2):207</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">16. doi:10.1369/jhc.4A6280.2005.</span></p>
<p style="top:607.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">279. Lim CT, Ren X, Afizah MH, et al. Repair of osteochondral defects with</span></p>
<p style="top:616.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">rehydrated freeze-dried oligo[poly(ethylene glycol) fumarate] hydrogels</span></p>
<p style="top:625.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">seeded with bone marrow mesenchymal stem cells in a porcine model.</span></p>
<p style="top:634.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tissue Eng Part A. 2013;19(15-16):1852</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">61. doi:10.1089/ten.TEA.2012.0621.</span></p>
<p style="top:643.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">280. Li T, Nina F, Xiaozuo T, Xiaopeng L, Zhuo W, Na L. Chondrogenic</span></p>
<p style="top:652.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiation of mesenchymal stem cells for repairing articular</span></p>
<p style="top:661.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage. J Clin Rehabil Tissue Eng Res. 2009;13(46):9041</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">4.</span></p>
<p style="top:671.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">281. Sato M, Uchida K, Nakajima H, et al. Direct transplantation of</span></p>
<p style="top:680.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cells into the knee joints of Hartley strain guinea</span></p>
<p style="top:689.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pigs with spontaneous osteoarthritis. Arthritis Res Ther. 2012;14(1):R31.</span></p>
<p style="top:698.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1186/ar3735.</span></p>
<p style="top:707.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">282. Ivkovic A, Pascher A, Hudetz D, et al. Articular cartilage repair by genetically</span></p>
<p style="top:716.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">modified bone marrow aspirate in sheep. Gene Ther. 2010;17(6):779</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">89.</span></p>
<p style="top:725.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1038/gt.2010.16.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 28 of 30</span></p>


<p style="top:89.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">283. Song F, Tang J, Geng R, et al. Comparison of the efficacy of bone marrow</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mononuclear cells and bone mesenchymal stem cells in the treatment of</span></p>
<p style="top:107.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteoarthritis in a sheep model. Int J Clin Exp Pathol. 2014;7(4):1415</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">26.</span></p>
<p style="top:116.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Available at: http://www.ncbi.nlm.nih.gov/pubmed/24817937. Accessed</span></p>
<p style="top:125.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12 June 2016.</span></p>
<p style="top:134.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">284. Ishihara K, Nakayama K, Akieda S, Matsuda S, Iwamoto Y. Simultaneous</span></p>
<p style="top:143.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">regeneration of full-thickness cartilage and subchondral bone defects in</span></p>
<p style="top:152.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">vivo using a three-dimensional scaffold-free autologous construct derived</span></p>
<p style="top:161.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">from high-density bone marrow-derived mesenchymal stem cells. J Orthop</span></p>
<p style="top:170.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Surg Res. 2014;9:98. doi:10.1186/s13018-014-0098-z.</span></p>
<p style="top:180.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">285. Wang W, Li B, Li Y, Jiang Y, Ouyang H, Gao C. In vivo restoration of</span></p>
<p style="top:189.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">full-thickness cartilage defects by poly(lactide-co-glycolide) sponges</span></p>
<p style="top:198.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">filled with fibrin gel, bone marrow mesenchymal stem cells and DNA</span></p>
<p style="top:207.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">complexes. Biomaterials. 2010;31(23):5953</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">65. doi:10.1016/j.biomaterials.</span></p>
<p style="top:216.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010.04.029.</span></p>
<p style="top:225.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">286. Xue D, Zheng Q, Zong C, et al. Osteochondral repair using porous</span></p>
<p style="top:234.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">poly(lactide-co-glycolide)/nano-hydroxyapatite hybrid scaffolds with</span></p>
<p style="top:243.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">undifferentiated mesenchymal stem cells in a rat model. J Biomed Mater</span></p>
<p style="top:252.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Res A. 2010;94(1):259</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">70. doi:10.1002/jbm.a.32691.</span></p>
<p style="top:261.6pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">287. Wayne JS, McDowell CL, Shields KJ, Tuan RS. In vivo response of polylactic</span></p>
<p style="top:270.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">acid-alginate scaffolds and bone marrow-derived cells for cartilage tissue</span></p>
<p style="top:279.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">engineering. Tissue Eng. 11(5-6):953-63. doi:10.1089/ten.2005.11.953.</span></p>
<p style="top:288.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">288. Bal BS, Rahaman MN, Jayabalan P, et al. In vivo outcomes of tissue-</span></p>
<p style="top:297.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">engineered osteochondral grafts. J Biomed Mater Res B Appl Biomater.</span></p>
<p style="top:306.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;93(1):164</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">74. doi:10.1002/jbm.b.31571.</span></p>
<p style="top:316.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">289. Qi Y, Du Y, Li W, Dai X, Zhao T, Yan W. Cartilage repair using mesenchymal</span></p>
<p style="top:325.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cell (MSC) sheet and MSCs-loaded bilayer PLGA scaffold in a rabbit</span></p>
<p style="top:334.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">model. Knee Surg Sports Traumatol Arthrosc. 2014;22(6):1424</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">33. doi:10.</span></p>
<p style="top:343.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1007/s00167-012-2256-3.</span></p>
<p style="top:352.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">290. Zhou G, Liu W, Cui L, Wang X, Liu T, Cao Y. Repair of porcine articular</span></p>
<p style="top:361.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">osteochondral defects in non-weightbearing areas with autologous bone marrow</span></p>
<p style="top:370.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stromal cells. Tissue Eng. 2006;12(11):3209</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">21. doi:10.1089/ten.2006.12.3209.</span></p>
<p style="top:379.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">291. Fan H, Hu Y, Qin L, Li X, Wu H, Lv R. Porous gelatin-chondroitin-hyaluronate</span></p>
<p style="top:388.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">tri-copolymer scaffold containing microspheres loaded with TGF-beta1 induces</span></p>
<p style="top:397.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">differentiation of mesenchymal stem cells in vivo for enhancing cartilage</span></p>
<p style="top:406.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">repair. J Biomed Mater Res A. 2006;77(4):785</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">94. doi:10.1002/jbm.a.30647.</span></p>
<p style="top:416.0pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">292. Fan H, Hu Y, Zhang C, et al. Cartilage regeneration using mesenchymal</span></p>
<p style="top:425.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells and a PLGA-gelatin/chondroitin/hyaluronate hybrid scaffold.</span></p>
<p style="top:434.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Biomaterials. 2006;27(26):4573</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">80. doi:10.1016/j.biomaterials.2006.04.013.</span></p>
<p style="top:443.3pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">293. Nathan S, De Das S, Thambyah A, Fen C, Goh J, Lee EH. Cell-based therapy</span></p>
<p style="top:452.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in the repair of osteochondral defects: a novel use for adipose tissue.</span></p>
<p style="top:461.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tissue Eng. 2003;9(4):733</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">44. doi:10.1089/107632703768247412.</span></p>
<p style="top:470.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">294. Diduch DR, Jordan LC, Mierisch CM, Balian G. Marrow stromal cells</span></p>
<p style="top:479.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">embedded in alginate for repair of osteochondral defects. Arthroscopy.</span></p>
<p style="top:488.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2000;16(6):571</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7. doi:10.1053/jars.2000.4827.</span></p>
<p style="top:497.8pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">295. Grigolo B, Lisignoli G, Desando G, et al. Osteoarthritis treated with mesenchymal</span></p>
<p style="top:506.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells on hyaluronan-based scaffold in rabbit. Tissue Eng Part C Methods.</span></p>
<p style="top:515.8pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2009;15(4):647</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">58. doi:10.1089/ten.TEC.2008.0569.</span></p>
<p style="top:525.1pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">296. Cui JH, Park SR, Park K, Choi BH, Min B-H. Preconditioning of mesenchymal</span></p>
<p style="top:534.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells with low-intensity ultrasound for cartilage formation in vivo.</span></p>
<p style="top:543.1pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tissue Eng. 2007;13(2):351</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">60. doi:10.1089/ten.2006.0080.</span></p>
<p style="top:553.4pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">297. L&#xf8;ken S, Jakobsen RB, Ar&#xf8;en A, et al. Bone marrow mesenchymal stem cells</span></p>
<p style="top:562.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in a hyaluronan scaffold for treatment of an osteochondral defect in a</span></p>
<p style="top:571.3pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">rabbit model. Knee Surg Sports Traumatol Arthrosc. 2008;16(10):896</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">903.</span></p>
<p style="top:580.4pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1007/s00167-008-0566-2.</span></p>
<p style="top:589.7pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">298. Tan W, Zha Z, Zhang J, Zheng L, Liang Y XJ. Animal-origin osteochondral</span></p>
<p style="top:598.7pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">scaffold combined with bone marrow mesenchymal stem cells/chondrocytes</span></p>
<p style="top:607.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">for repair of composite osteochondral defects in rabbit knee joints. J Clin</span></p>
<p style="top:616.6pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Rehabil Tissue Eng Res. 2011;15(12). doi:10.3969/j.issn.1673-8225.2011.12.043.</span></p>
<p style="top:625.9pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">299. Hu B, Ren J-L, Zhang J-R, Ma Q, Liu Y-P, Mao T-Q. Enhanced treatment of</span></p>
<p style="top:635.0pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">articular cartilage defect of the knee by intra-articular injection of Bcl-xL-</span></p>
<p style="top:643.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">engineered mesenchymal stem cells in rabbit model. J Tissue Eng Regen</span></p>
<p style="top:652.9pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Med. 2010;4(2):105</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">14. doi:10.1002/term.212.</span></p>
<p style="top:662.2pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">300. Xie J, Han Z, Naito M, et al. Articular cartilage tissue engineering based on a</span></p>
<p style="top:671.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mechano-active scaffold made of poly(L-lactide-co-epsilon-caprolactone): in</span></p>
<p style="top:680.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">vivo performance in adult rabbits. J Biomed Mater Res B Appl Biomater.</span></p>
<p style="top:689.2pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;94(1):80</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8. doi:10.1002/jbm.b.31627.</span></p>
<p style="top:698.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">301. Wakitani S, Goto T, Pineda SJ, et al. Mesenchymal cell-based repair of</span></p>
<p style="top:707.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">large, full-thickness defects of articular cartilage. J Bone Joint Surg Am.</span></p>
<p style="top:716.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1994;76(4):579</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">92. Available at: http://www.ncbi.nlm.nih.gov/pubmed/</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8150826. Accessed 12 June 2016.</span></p>
<p style="top:89.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">302. Jeong W-K, Oh S-H, Lee J-H, Im G-I. Repair of osteochondral defects</span></p>
<p style="top:98.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with a construct of mesenchymal stem cells and a polydioxanone/</span></p>
<p style="top:107.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">poly(vinyl alcohol) scaffold. Biotechnol Appl Biochem. 2008;49(Pt 2):155</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64.</span></p>
<p style="top:116.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1042/BA20070149.</span></p>
<p style="top:125.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">303. Im GI, Kim DY, Shin JH, Hyun CW, Cho WH. Repair of cartilage defect in</span></p>
<p style="top:134.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">the rabbit with cultured mesenchymal stem cells from bone marrow.</span></p>
<p style="top:143.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Bone Joint Surg Br. 2001;83(2):289</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">94. Available at: http://www.ncbi.nlm.nih.gov/</span></p>
<p style="top:152.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pubmed/11284583. Accessed 12 June 2016.</span></p>
<p style="top:162.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">304. Kayakabe M, Tsutsumi S, Watanabe H, Kato Y, Takagishi K. Transplantation of</span></p>
<p style="top:171.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous rabbit BM-derived mesenchymal stromal cells embedded in</span></p>
<p style="top:180.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">hyaluronic acid gel sponge into osteochondral defects of the knee.</span></p>
<p style="top:189.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Cytotherapy. 2006;8(4):343</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">53. doi:10.1080/14653240600845070.</span></p>
<p style="top:198.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">305. Tatebe M, Nakamura R, Kagami H, Okada K, Ueda M. Differentiation of</span></p>
<p style="top:207.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">transplanted mesenchymal stem cells in a large osteochondral defect in</span></p>
<p style="top:216.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">rabbit. Cytotherapy. 2005;7(6):520</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">30. doi:10.1080/14653240500361350.</span></p>
<p style="top:225.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">306. Yoshioka T, Mishima H, Sakai S, Uemura T. Long-term results of cartilage</span></p>
<p style="top:234.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">repair after allogeneic transplantation of cartilaginous aggregates formed</span></p>
<p style="top:243.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">from bone marrow-derived cells for large osteochondral defects in rabbit</span></p>
<p style="top:252.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">knees. Cartilage. 2013;4(4):339</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">44. doi:10.1177/1947603513494003.</span></p>
<p style="top:261.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">307. Liu P-F, Guo L, Zhao D-W, et al. Study of human acellular amniotic</span></p>
<p style="top:270.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">membrane loading bone marrow mesenchymal stem cells in repair of</span></p>
<p style="top:279.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">articular cartilage defect in rabbits. Genet Mol Res. 2014;13(3):7992</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8001.</span></p>
<p style="top:288.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.4238/2014.September.29.12.</span></p>
<p style="top:298.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">308. Jung M, Kaszap B, Red&#xf6;hl A, et al. Enhanced early tissue regeneration</span></p>
<p style="top:307.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">after matrix-assisted autologous mesenchymal stem cell transplantation</span></p>
<p style="top:316.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in full thickness chondral defects in a minipig model. Cell Transplant.</span></p>
<p style="top:325.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2009;18(8):923</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">32. doi:10.3727/096368909X471297.</span></p>
<p style="top:334.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">309. Chang C-H, Kuo T-F, Lin F-H, et al. Tissue engineering-based cartilage</span></p>
<p style="top:343.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">repair with mesenchymal stem cells in a porcine model. J Orthop Res.</span></p>
<p style="top:352.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2011;29(12):1874</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">80. doi:10.1002/jor.21461.</span></p>
<p style="top:361.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">310. Kamei G, Kobayashi T, Ohkawa S, et al. Articular cartilage repair with</span></p>
<p style="top:370.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">magnetic mesenchymal stem cells. Am J Sports Med. 2013;41(6):1255</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64.</span></p>
<p style="top:379.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1177/0363546513483270.</span></p>
<p style="top:389.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">311. Coleman RM, Schwartz Z, Boyan BD, Guldberg RE. The therapeutic effect of</span></p>
<p style="top:398.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow-derived stem cell implantation after epiphyseal plate injury</span></p>
<p style="top:407.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">is abrogated by chondrogenic predifferentiation. Tissue Eng Part A. 2013;</span></p>
<p style="top:416.0pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">19(3-4):475</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">83. doi:10.1089/ten.TEA.2012.0125.</span></p>
<p style="top:425.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">312. Dahlin RL, Kinard LA, Lam J, et al. Articular chondrocytes and mesenchymal</span></p>
<p style="top:434.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells seeded on biodegradable scaffolds for the repair of cartilage in a</span></p>
<p style="top:443.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">rat osteochondral defect model. Biomaterials. 2014;35(26):7460</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9. doi:10.</span></p>
<p style="top:452.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1016/j.biomaterials.2014.05.055.</span></p>
<p style="top:461.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">313. Marquass B, Schulz R, Hepp P, et al. Matrix-associated implantation of</span></p>
<p style="top:470.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">predifferentiated mesenchymal stem cells versus articular chondrocytes: in vivo</span></p>
<p style="top:479.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">results of cartilage repair after 1 year. Am J Sports Med. 2011;39(7):1401</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12.</span></p>
<p style="top:488.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1177/0363546511398646.</span></p>
<p style="top:497.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">314. Zscharnack M, Hepp P, Richter R, et al. Repair of chronic osteochondral</span></p>
<p style="top:506.8pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects using predifferentiated mesenchymal stem cells in an ovine model.</span></p>
<p style="top:515.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Am J Sports Med. 2010;38(9):1857</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">69. doi:10.1177/0363546510365296.</span></p>
<p style="top:525.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">315. Guo X, Wang C, Zhang Y, et al. Repair of large articular cartilage defects</span></p>
<p style="top:534.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with implants of autologous mesenchymal stem cells seeded into beta-</span></p>
<p style="top:543.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">tricalcium phosphate in a sheep model. Tissue Eng. 10(11-12):1818-29.</span></p>
<p style="top:552.1pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.2004.10.1818.</span></p>
<p style="top:562.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">316. Caminal M, Moll X, Codina D, et al. Transitory improvement of articular</span></p>
<p style="top:571.3pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cartilage characteristics after implantation of polylactide:polyglycolic acid</span></p>
<p style="top:580.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">(PLGA) scaffolds seeded with autologous mesenchymal stromal cells in</span></p>
<p style="top:589.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">a sheep model of critical-sized chondral defect. Biotechnol Lett.</span></p>
<p style="top:598.4pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2014;36(10):2143</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">53. doi:10.1007/s10529-014-1585-3.</span></p>
<p style="top:607.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">317. Wilke MM, Nydam DV, Nixon AJ. Enhanced early chondrogenesis in articular</span></p>
<p style="top:616.6pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects following arthroscopic mesenchymal stem cell implantation in an</span></p>
<p style="top:625.7pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">equine model. J Orthop Res. 2007;25(7):913</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">25. doi:10.1002/jor.20382.</span></p>
<p style="top:635.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">318. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a</span></p>
<p style="top:643.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">caprine model of osteoarthritis. Arthritis Rheum. 2003;48(12):3464</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">74.</span></p>
<p style="top:652.9pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1002/art.11365.</span></p>
<p style="top:662.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">319. Ma A, Jiang L, Song L, et al. Reconstruction of cartilage with clonal</span></p>
<p style="top:671.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">mesenchymal stem cell-acellular dermal matrix in cartilage defect model in</span></p>
<p style="top:680.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">nonhuman primates. Int Immunopharmacol. 2013;16(3):399</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">408. doi:10.1016/j.</span></p>
<p style="top:689.2pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">intimp.2013.02.005.</span></p>
<p style="top:698.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">320. Araki S, Imai S, Ishigaki H, et al. Improved quality of cartilage repair by bone</span></p>
<p style="top:707.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">marrow mesenchymal stem cells for treatment of an osteochondral defect</span></p>
<p style="top:716.5pt;left:319.8pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in a cynomolgus macaque model. Acta Orthop. 2015;86(1):119</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">26.</span></p>
<p style="top:725.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.3109/17453674.2014.958807.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 29 of 30</span></p>


<p style="top:89.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">321. Qi B, Yu A, Zhu S, Zhou M, Wu G. Chitosan/poly(vinyl alcohol) hydrogel</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">combined with Ad-hTGF-</span><span style="font-family:QjfqbvAdvTTb5929f4c+03,serif;font-size:7.3pt;color:#131313">&#x3b2;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1 transfected mesenchymal stem cells to repair</span></p>
<p style="top:107.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">rabbit articular cartilage defects. Exp Biol Med (Maywood). 2013;238(1):23</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">30.</span></p>
<p style="top:116.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1258/ebm.2012.012223.</span></p>
<p style="top:125.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">322. Qi Y, Zhao T, Xu K, Dai T, Yan W. The restoration of full-thickness cartilage</span></p>
<p style="top:134.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">defects with mesenchymal stem cells (MSCs) loaded and cross-linked</span></p>
<p style="top:143.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bilayer collagen scaffolds on rabbit model. Mol Biol Rep. 2012;39(2):1231</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:152.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1007/s11033-011-0853-8.</span></p>
<p style="top:161.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">323. Park JS, Woo DG, Yang HN, et al. Chondrogenesis of human mesenchymal</span></p>
<p style="top:170.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cells encapsulated in a hydrogel construct: neocartilage formation</span></p>
<p style="top:179.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in animal models as both mice and rabbits. J Biomed Mater Res A.</span></p>
<p style="top:188.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2010;92(3):988</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">96. doi:10.1002/jbm.a.32341.</span></p>
<p style="top:197.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">324. Liu Y, Shu XZ, Prestwich GD. Osteochondral defect repair with autologous</span></p>
<p style="top:206.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow-derived mesenchymal stem cells in an injectable, in situ,</span></p>
<p style="top:215.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cross-linked synthetic extracellular matrix. Tissue Eng. 2006;12(12):3405</span><span style="font-family:XjcjfhAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">16.</span></p>
<p style="top:224.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:DngfmgAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">doi:10.1089/ten.2006.12.3405.</span></p>
<p style="top:634.1pt;left:323.7pt;line-height:7.0pt"><span style="font-family:TyftflOpenSans,serif;font-size:7.0pt;color:#131313">&#x2022;</span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#131313">  </span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">We accept pre-submission inquiries</span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#131313"> </span></p>
<p style="top:646.1pt;left:323.7pt;line-height:7.0pt"><span style="font-family:TyftflOpenSans,serif;font-size:7.0pt;color:#131313">&#x2022;</span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#131313">  </span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">Our selector tool helps you to &#xfb01;nd the most relevant journal</span></p>
<p style="top:658.1pt;left:323.7pt;line-height:7.0pt"><span style="font-family:TyftflOpenSans,serif;font-size:7.0pt;color:#131313">&#x2022;  </span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">We provide round the clock customer support </span></p>
<p style="top:670.1pt;left:323.7pt;line-height:7.0pt"><span style="font-family:TyftflOpenSans,serif;font-size:7.0pt;color:#131313">&#x2022;  </span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">Convenient online submission</span></p>
<p style="top:682.1pt;left:323.7pt;line-height:7.0pt"><span style="font-family:TyftflOpenSans,serif;font-size:7.0pt;color:#131313">&#x2022;</span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#131313">  </span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">Thorough peer review</span></p>
<p style="top:694.1pt;left:323.7pt;line-height:7.0pt"><span style="font-family:TyftflOpenSans,serif;font-size:7.0pt;color:#131313">&#x2022;  </span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">Inclusion in PubMed and all major indexing services </span></p>
<p style="top:706.1pt;left:323.7pt;line-height:7.0pt"><span style="font-family:TyftflOpenSans,serif;font-size:7.0pt;color:#131313">&#x2022;</span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#131313">  </span><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">Maximum visibility for your research</span></p>
<p style="top:722.9pt;left:323.7pt;line-height:7.0pt"><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">Submit your manuscript at</span></p>
<p style="top:730.9pt;left:323.7pt;line-height:7.0pt"><span style="font-family:VnfnklOpenSans,serif;font-size:7.0pt;color:#292829">www.biomedcentral.com/submit</span></p>
<p style="top:602.9pt;left:318.4pt;line-height:11.0pt"><span style="font-family:XnxftlOregonLDOBook,serif;font-size:11.0pt;color:#131413">Submit your next manuscript to BioMed Central </span></p>
<p style="top:616.1pt;left:318.4pt;line-height:11.0pt"><span style="font-family:XnxftlOregonLDOBook,serif;font-size:11.0pt;color:#131413">and we will help you at every step:</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Goldberg</span><span style="font-family:BckfjrAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Journal of Orthopaedic Surgery and Research</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">  (2017) 12:39 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:KkxkcnAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 30 of 30</span></p>

</div>
